Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24954342,T1/2,"Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),h,1.9,2086,DB00328,Indomethacin
,24954342,"Css, muscle/Css","Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),,0.85,2087,DB00328,Indomethacin
,8477127,clearance (Cl),"For group 1, vancomycin clearance (Cl), volume of distribution (Vd), and half-life were (mean +/- 1 SD) 0.072 +/- 0.032 L/kg/h, 0.52 +/- 0.08 L/kg, and 5.6 +/- 1.6 hours, respectively.",Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477127/),[l] / [h·kg],0.072,2439,DB00328,Indomethacin
,8477127,volume of distribution (Vd),"For group 1, vancomycin clearance (Cl), volume of distribution (Vd), and half-life were (mean +/- 1 SD) 0.072 +/- 0.032 L/kg/h, 0.52 +/- 0.08 L/kg, and 5.6 +/- 1.6 hours, respectively.",Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477127/),[l] / [kg],0.52,2440,DB00328,Indomethacin
,8477127,half-life,"For group 1, vancomycin clearance (Cl), volume of distribution (Vd), and half-life were (mean +/- 1 SD) 0.072 +/- 0.032 L/kg/h, 0.52 +/- 0.08 L/kg, and 5.6 +/- 1.6 hours, respectively.",Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477127/),h,5.6,2441,DB00328,Indomethacin
,8477127,peak concentrations,"For both groups, loading doses provided 1-hour postinfusion peak concentrations of 25-35 mg/L in one of every two infants studied, whereas only three percent of initial maintenance doses were projected to provide desired peak and trough concentrations at steady-state.",Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477127/),[mg] / [l],25-35,2442,DB00328,Indomethacin
,8477127,peak,"For group 1, the mean daily dosage necessary to provide target peak (25-35 mg/L) and trough (5-10 mg/L) concentrations at steady-state was larger than that initially prescribed (29.6 +/- 13.1 vs. 22.2 +/- 4.7 mg/kg/d).",Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477127/),[mg] / [l],25-35,2443,DB00328,Indomethacin
,8477127,trough,"For group 1, the mean daily dosage necessary to provide target peak (25-35 mg/L) and trough (5-10 mg/L) concentrations at steady-state was larger than that initially prescribed (29.6 +/- 13.1 vs. 22.2 +/- 4.7 mg/kg/d).",Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477127/),,29,2444,DB00328,Indomethacin
,8477127,trough,"For group 1, the mean daily dosage necessary to provide target peak (25-35 mg/L) and trough (5-10 mg/L) concentrations at steady-state was larger than that initially prescribed (29.6 +/- 13.1 vs. 22.2 +/- 4.7 mg/kg/d).",Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477127/),,22,2445,DB00328,Indomethacin
,8477127,peak,"For group 2, the mean daily dosage required to achieve target peak and trough concentrations at steady-state was smaller than that initially prescribed (14.8 +/- 4.3 vs. 20.0 +/- 0.1 mg/kg/d) and was exactly half of that required for group 1.",Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477127/),,14,2446,DB00328,Indomethacin
,8477127,trough concentrations at steady-state,"For group 2, the mean daily dosage required to achieve target peak and trough concentrations at steady-state was smaller than that initially prescribed (14.8 +/- 4.3 vs. 20.0 +/- 0.1 mg/kg/d) and was exactly half of that required for group 1.",Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477127/),,14,2447,DB00328,Indomethacin
,8477127,trough concentrations at steady-state,"For group 2, the mean daily dosage required to achieve target peak and trough concentrations at steady-state was smaller than that initially prescribed (14.8 +/- 4.3 vs. 20.0 +/- 0.1 mg/kg/d) and was exactly half of that required for group 1.",Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477127/),,20.,2448,DB00328,Indomethacin
,7471606,plasma concentration,Mean (+/- SD) free clofibric acid plasma concentration in the four subjects over a dosage interval at steady state was 2.5 +/- 0.03 mg/1 before and 9.05 +/- 1.09 mg/1 after the probenecid.,Probenecid-clofibrate interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471606/),mg,2.5,4012,DB00328,Indomethacin
,7471606,plasma concentration,Mean (+/- SD) free clofibric acid plasma concentration in the four subjects over a dosage interval at steady state was 2.5 +/- 0.03 mg/1 before and 9.05 +/- 1.09 mg/1 after the probenecid.,Probenecid-clofibrate interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471606/),mg,9.05,4013,DB00328,Indomethacin
,7471606,plasma concentration,Probenecid reached an average plasma concentration of 71.3 mg/1.,Probenecid-clofibrate interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471606/),mg,71.3,4014,DB00328,Indomethacin
,8018454,EC50,"Using the sigmoidal Emax model the mean serum concentration of azapropazone inhibiting platelet TXB2 generation by 50% (EC50) was found to be 98.1 +/- 41.9 (s.d.) micrograms ml-1, a value 1000 times higher than that for rac-ketorolac.",Effects on platelet functions and pharmacokinetics of azapropazone and ketorolac tromethamine given as single parenteral doses. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018454/),[μg] / [ml],98.1,5123,DB00328,Indomethacin
,8373716,AUC,"The mean AUC value for the glucuronidated metabolite, GZDV, was reduced from 26.6 +/- 11.7 mumol l-1 h in the presence of placebo to 20.9 +/- 8.3 mumol l-1 h (95% C.I. of the difference 1.39-9.98; P < 0.05) following treatment with naproxen 250 mg twice daily for 3 days.",The effects of indomethacin and naproxen on zidovudine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373716/),[h·μM] / [l],26.6,5535,DB00328,Indomethacin
,8373716,AUC,"The mean AUC value for the glucuronidated metabolite, GZDV, was reduced from 26.6 +/- 11.7 mumol l-1 h in the presence of placebo to 20.9 +/- 8.3 mumol l-1 h (95% C.I. of the difference 1.39-9.98; P < 0.05) following treatment with naproxen 250 mg twice daily for 3 days.",The effects of indomethacin and naproxen on zidovudine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373716/),[h·μM] / [l],20.9,5536,DB00328,Indomethacin
,18474366,IC(50),Artepillin C also decreased the number of neutrophils during peritonitis (IC(50): 0.9 (0.5-1.4) mg/kg).,"Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[mg] / [kg],0.9,6319,DB00328,Indomethacin
,18474366,ID(50),"Treatment with Artepillin C decreased prostaglandin E(2) by 29+/-3% and 58+/-5% at 1 and 10 mg/kg, respectively, with a mean ID(50) of 8.5 (8.0-8.7) mg/kg).","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[mg] / [kg],8.5,6320,DB00328,Indomethacin
,18474366,IC(50),"Similarly, in in vitro models, Artepillin C (3, 10, or 100 microM) decreased nitric oxide production by RAW 264.7 cells with a mean IC(50) of 8.5 (7.8-9.2) microM.","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),μM,8.5,6321,DB00328,Indomethacin
,18474366,IC(50),"In HEK 293 cells, Artepillin C reduced NF-kappaB activity with a mean IC(50) of 26 (22-30) mug/ml), suggesting anti-inflammatory activity, particularly during acute inflammation.","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[μg] / [ml],26,6322,DB00328,Indomethacin
,18474366,maximal peaks,"Lastly, Artepillin C was absorbed after an oral dose (10 mg/kg) with maximal peaks found at 1 h (22 microg/ml).","Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474366/),[μg] / [ml],22,6323,DB00328,Indomethacin
,15739336,recovery,The mean recovery of indomethacin was 100.4%.,[Determination of plasma drug concentration and bioavailability of indomethacin controlled release capsule by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739336/),%,100.4,7113,DB00328,Indomethacin
,15739336,detectable limit,The detectable limit was 62.5 microg/L (S/N = 3:1).,[Determination of plasma drug concentration and bioavailability of indomethacin controlled release capsule by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739336/),[μg] / [l],62.5,7114,DB00328,Indomethacin
,15739336,S/N,The detectable limit was 62.5 microg/L (S/N = 3:1).,[Determination of plasma drug concentration and bioavailability of indomethacin controlled release capsule by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739336/),,3:1,7115,DB00328,Indomethacin
,3264245,terminal half-life,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),h,5.09,8082,DB00328,Indomethacin
,3264245,plasma clearance (CL,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[ml] / [kg·min],0.35,8083,DB00328,Indomethacin
,3264245,tissue distribution (Vss,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[l] / [kg],0.11,8084,DB00328,Indomethacin
,3264245,V beta,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[l] / [kg],0.17,8085,DB00328,Indomethacin
,3264245,peak levels,"Following i.m. and p.o. administration, peak levels of approximately 0.8 microgram/ml were rapidly attained (tmax = 0.8 and 0.9 h, respectively) and the systemic bioavailability was essentially complete.","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[μg] / [ml],0.8,8086,DB00328,Indomethacin
,3264245,tmax,"Following i.m. and p.o. administration, peak levels of approximately 0.8 microgram/ml were rapidly attained (tmax = 0.8 and 0.9 h, respectively) and the systemic bioavailability was essentially complete.","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),h,0.8,8087,DB00328,Indomethacin
,3264245,tmax,"Following i.m. and p.o. administration, peak levels of approximately 0.8 microgram/ml were rapidly attained (tmax = 0.8 and 0.9 h, respectively) and the systemic bioavailability was essentially complete.","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),h,0.9,8088,DB00328,Indomethacin
,1823871,half life,Plasma levels of apyramide quickly decreased and the mean (+/- SD) half life was 0.15 +/- 0.08 h.,Pharmacokinetics of an indomethacin pro-drug: apyramide after intravenous administration in dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823871/),h,0.15,8459,DB00328,Indomethacin
,1823871,area under curve,"For metabolic indomethacin, the mean (+/- SD) area under curve was 12.36 +/- 4.80 mg.h/l and the mean (+/- SD) half life of terminal phase was 16.71 +/- 9.46 h.",Pharmacokinetics of an indomethacin pro-drug: apyramide after intravenous administration in dog. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823871/),[h·mg] / [l],12.36,8460,DB00328,Indomethacin
,1823871,half life of terminal phase,"For metabolic indomethacin, the mean (+/- SD) area under curve was 12.36 +/- 4.80 mg.h/l and the mean (+/- SD) half life of terminal phase was 16.71 +/- 9.46 h.",Pharmacokinetics of an indomethacin pro-drug: apyramide after intravenous administration in dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823871/),h,16.71,8461,DB00328,Indomethacin
,19300040,clearance,"Estimated parameters were clearance [2.8 mL x min(-1) x (kg(0.75))(-1)], intercompartmental clearance (11.5 mL/min), volume of distribution of the central compartment (535 mL), and volume of distribution of the peripheral compartment (322 mL).",Population pharmacokinetics of ketorolac in neonates and young infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300040/),[ml] / [kg(0.75·min],2.8,8619,DB00328,Indomethacin
,19300040,intercompartmental clearance,"Estimated parameters were clearance [2.8 mL x min(-1) x (kg(0.75))(-1)], intercompartmental clearance (11.5 mL/min), volume of distribution of the central compartment (535 mL), and volume of distribution of the peripheral compartment (322 mL).",Population pharmacokinetics of ketorolac in neonates and young infants. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300040/),[ml] / [min],11.5,8620,DB00328,Indomethacin
,19300040,volume of distribution of the central compartment,"Estimated parameters were clearance [2.8 mL x min(-1) x (kg(0.75))(-1)], intercompartmental clearance (11.5 mL/min), volume of distribution of the central compartment (535 mL), and volume of distribution of the peripheral compartment (322 mL).",Population pharmacokinetics of ketorolac in neonates and young infants. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300040/),ml,535,8621,DB00328,Indomethacin
,19300040,volume of distribution of the peripheral compartment,"Estimated parameters were clearance [2.8 mL x min(-1) x (kg(0.75))(-1)], intercompartmental clearance (11.5 mL/min), volume of distribution of the central compartment (535 mL), and volume of distribution of the peripheral compartment (322 mL).",Population pharmacokinetics of ketorolac in neonates and young infants. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300040/),ml,322,8622,DB00328,Indomethacin
,2717521,AUC ratios,"The amount of PHK circulating in plasma was very low as judged by AUC ratios (PHK/K x 100) of 1.9 and 1.5% for the 30-mg po and im doses, respectively.",Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717521/),%,1.9,9597,DB00328,Indomethacin
,2717521,AUC ratios,"The amount of PHK circulating in plasma was very low as judged by AUC ratios (PHK/K x 100) of 1.9 and 1.5% for the 30-mg po and im doses, respectively.",Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717521/),%,1.5,9598,DB00328,Indomethacin
,2717521,plasma half-life,"The mean plasma half-life of K was remarkably consistent between po and im administration and was independent of dose, ranging from 5.21 to 5.56 hr.",Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717521/),h,5.21 to 5.56,9599,DB00328,Indomethacin
,6927543,half-life,Mean half-life in neonates less than 32 weeks gestation was 17.2 (0.8) vs. 12.5 (0.5) h for neonates greater than 32 weeks gestation.,Pharmacokinetics of oral and intravenous indomethacin in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6927543/),h,17.2,14069,DB00328,Indomethacin
,6927543,half-life,Mean half-life in neonates less than 32 weeks gestation was 17.2 (0.8) vs. 12.5 (0.5) h for neonates greater than 32 weeks gestation.,Pharmacokinetics of oral and intravenous indomethacin in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6927543/),h,12.5,14070,DB00328,Indomethacin
,6927543,Bioavailability,Bioavailability of the oral dosage based on AUC was 13% but no difference was observed in the plasma protein binding or distribution volume of drug as compared to adult values.,Pharmacokinetics of oral and intravenous indomethacin in preterm infants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6927543/),%,13,14071,DB00328,Indomethacin
,1577049,maximum serum concentration (Cmax),"Indomethacin was rapidly absorbed from the joint, giving a maximum serum concentration (Cmax) of 0.60 micrograms.",Pharmacokinetics of intraarticular indomethacin in patients with osteoarthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577049/),μg,0.60,16449,DB00328,Indomethacin
,1577049,systemic bioavailability (f),The systemic bioavailability (f) was 80% and the mean absorption time (MAT) was about 2 h.,Pharmacokinetics of intraarticular indomethacin in patients with osteoarthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577049/),%,80,16450,DB00328,Indomethacin
,1577049,mean absorption time (MAT),The systemic bioavailability (f) was 80% and the mean absorption time (MAT) was about 2 h.,Pharmacokinetics of intraarticular indomethacin in patients with osteoarthritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577049/),h,2,16451,DB00328,Indomethacin
,1577049,apparent terminal half-life,"The apparent terminal half-life and mean residence time (MRT) were 2.8 h and 4 h, respectively.",Pharmacokinetics of intraarticular indomethacin in patients with osteoarthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577049/),h,2.8,16452,DB00328,Indomethacin
,1577049,mean residence time (MRT),"The apparent terminal half-life and mean residence time (MRT) were 2.8 h and 4 h, respectively.",Pharmacokinetics of intraarticular indomethacin in patients with osteoarthritis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577049/),h,4,16453,DB00328,Indomethacin
,1577049,urinary recovery,The urinary recovery of total indomethacin (unchanged + glucuronides) was 24% of the dose and renal clearance (CLR) was estimated to be about 21 ml.min-1.,Pharmacokinetics of intraarticular indomethacin in patients with osteoarthritis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577049/),%,24,16454,DB00328,Indomethacin
,1577049,renal clearance (CLR),The urinary recovery of total indomethacin (unchanged + glucuronides) was 24% of the dose and renal clearance (CLR) was estimated to be about 21 ml.min-1.,Pharmacokinetics of intraarticular indomethacin in patients with osteoarthritis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577049/),[ml] / [min],21,16455,DB00328,Indomethacin
,7161704,elimination rate constant (beta) of beta phase,The elimination rate constant (beta) of beta phase was 0.138 +/- 0.015 h-1.,"Disposition, intestinal absorption and drug metabolizing enzyme activities after multiple doses of indomethacin in rat and effect of antacid and dicyclomine on the parameters. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161704/),1/[h],0.138,16601,DB00328,Indomethacin
,8801333,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 0.20, 0.18, and 0.82 microgram/mL for TD-A, TD-B, and TD-C, respectively.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),[μg] / [ml],0.20,17443,DB00328,Indomethacin
,8801333,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 0.20, 0.18, and 0.82 microgram/mL for TD-A, TD-B, and TD-C, respectively.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),[μg] / [ml],0.18,17444,DB00328,Indomethacin
,8801333,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 0.20, 0.18, and 0.82 microgram/mL for TD-A, TD-B, and TD-C, respectively.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),[μg] / [ml],0.82,17445,DB00328,Indomethacin
,8801333,terminal half-life,"The total AUC values for the concentration-time curves were TD-C > TD-A > TD-B, and the terminal half-life ranged from 6.6 to 9.7 h.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),h,6.6 to 9.7,17446,DB00328,Indomethacin
,3439372,maximal blood levels (cmax),"Mean maximal blood levels (cmax) were 1.51 +/- 0.19 (rheumatic patients with liver diseases), 1.85 +/- 0.33 (rheumatic patients without liver diseases) and 1.24 +/- 0.05 mumol/l (healthy volunteers).","[Acemetacin in patients with rheumatic disease with concomitant liver diseases. Pharmacokinetics, effectiveness and tolerance]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439372/),[μM] / [l],1.51,19049,DB00328,Indomethacin
,3439372,maximal blood levels (cmax),"Mean maximal blood levels (cmax) were 1.51 +/- 0.19 (rheumatic patients with liver diseases), 1.85 +/- 0.33 (rheumatic patients without liver diseases) and 1.24 +/- 0.05 mumol/l (healthy volunteers).","[Acemetacin in patients with rheumatic disease with concomitant liver diseases. Pharmacokinetics, effectiveness and tolerance]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439372/),[μM] / [l],1.85,19050,DB00328,Indomethacin
,3439372,maximal blood levels (cmax),"Mean maximal blood levels (cmax) were 1.51 +/- 0.19 (rheumatic patients with liver diseases), 1.85 +/- 0.33 (rheumatic patients without liver diseases) and 1.24 +/- 0.05 mumol/l (healthy volunteers).","[Acemetacin in patients with rheumatic disease with concomitant liver diseases. Pharmacokinetics, effectiveness and tolerance]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439372/),[μM] / [l],1.24,19051,DB00328,Indomethacin
,3439372,Elimination half lives,"Elimination half lives are 4.63 +/- 2.25, 4.52 +/- 2.81 and 4.03 hours.","[Acemetacin in patients with rheumatic disease with concomitant liver diseases. Pharmacokinetics, effectiveness and tolerance]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439372/),h,4.63,19052,DB00328,Indomethacin
,3439372,Elimination half lives,"Elimination half lives are 4.63 +/- 2.25, 4.52 +/- 2.81 and 4.03 hours.","[Acemetacin in patients with rheumatic disease with concomitant liver diseases. Pharmacokinetics, effectiveness and tolerance]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439372/),h,4.52,19053,DB00328,Indomethacin
,3439372,Elimination half lives,"Elimination half lives are 4.63 +/- 2.25, 4.52 +/- 2.81 and 4.03 hours.","[Acemetacin in patients with rheumatic disease with concomitant liver diseases. Pharmacokinetics, effectiveness and tolerance]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439372/),h,4.03,19054,DB00328,Indomethacin
,3439372,AUC-,AUC-values were in the same range for rheumatic patients with liver diseases (11.62 +/- 5.56) and volunteers after Rantudil forte (14.30 +/- 8.79) or Rantudil retard (12.52 +/- 5.90 mumol.l-1.h).,"[Acemetacin in patients with rheumatic disease with concomitant liver diseases. Pharmacokinetics, effectiveness and tolerance]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439372/),[h·μM] / [l],11.62,19055,DB00328,Indomethacin
,3439372,AUC-,AUC-values were in the same range for rheumatic patients with liver diseases (11.62 +/- 5.56) and volunteers after Rantudil forte (14.30 +/- 8.79) or Rantudil retard (12.52 +/- 5.90 mumol.l-1.h).,"[Acemetacin in patients with rheumatic disease with concomitant liver diseases. Pharmacokinetics, effectiveness and tolerance]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439372/),[h·μM] / [l],14.30,19056,DB00328,Indomethacin
,3439372,AUC-,AUC-values were in the same range for rheumatic patients with liver diseases (11.62 +/- 5.56) and volunteers after Rantudil forte (14.30 +/- 8.79) or Rantudil retard (12.52 +/- 5.90 mumol.l-1.h).,"[Acemetacin in patients with rheumatic disease with concomitant liver diseases. Pharmacokinetics, effectiveness and tolerance]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439372/),[h·μM] / [l],12.52,19057,DB00328,Indomethacin
,24938850,clearance (CL),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),[l] / [h],0.089,19891,DB00328,Indomethacin
,24938850,central volume of distribution (Vc ),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),l,0.908,19892,DB00328,Indomethacin
,24938850,intercompartmental clearance (Q),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),[l] / [h],0.157,19893,DB00328,Indomethacin
,24938850,peripheral volume of distribution (Vp ),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),l,0.560,19894,DB00328,Indomethacin
,17269145,relative drug exposure (r(e)),The time-averaged relative drug exposure (r(e)) of the drug in paw for the folate-PEG conjugates ranged from 1.81 to 2.37.,Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17269145/),,1.81 to 2.37,20100,DB00328,Indomethacin
,17269145,overall drug targeting efficiency (T(e)),The overall drug targeting efficiency (T(e)) was highest for folate-PEG conjugate (3.44) when compared to native dendrimer (1.72).,Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17269145/),,3.44,20101,DB00328,Indomethacin
,17269145,overall drug targeting efficiency (T(e)),The overall drug targeting efficiency (T(e)) was highest for folate-PEG conjugate (3.44) when compared to native dendrimer (1.72).,Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17269145/),,1.72,20102,DB00328,Indomethacin
,15556544,total run time,The total run time was 18 min and the extraction recovery was 77% for MPA and 84% for MPAG.,Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),min,18,20477,DB00328,Indomethacin
,15556544,extraction recovery,The total run time was 18 min and the extraction recovery was 77% for MPA and 84% for MPAG.,Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),%,77,20478,DB00328,Indomethacin
,15556544,extraction recovery,The total run time was 18 min and the extraction recovery was 77% for MPA and 84% for MPAG.,Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),%,84,20479,DB00328,Indomethacin
,15556544,flow rate,Analytical column was the same as the HPLC-UV method and the mobile phase was a gradient composition of methanol:0.05% formic acid with a flow rate of 0.6 ml/min for the first 3 min and 0.7 ml for the last 4 min.,Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),[ml] / [min],0.6,20480,DB00328,Indomethacin
,15556544,flow rate,Analytical column was the same as the HPLC-UV method and the mobile phase was a gradient composition of methanol:0.05% formic acid with a flow rate of 0.6 ml/min for the first 3 min and 0.7 ml for the last 4 min.,Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),ml,0.7,20481,DB00328,Indomethacin
,15556544,m/z,"Mass transitions in negative ionization mode for MPA and the internal standard, indomethacin were m/z: 319-->190.9 and m/z: 356-->312.2, respectively.",Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),,319,20482,DB00328,Indomethacin
,15556544,m/z,"Mass transitions in negative ionization mode for MPA and the internal standard, indomethacin were m/z: 319-->190.9 and m/z: 356-->312.2, respectively.",Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),,190.9,20483,DB00328,Indomethacin
,15556544,m/z,"Mass transitions in negative ionization mode for MPA and the internal standard, indomethacin were m/z: 319-->190.9 and m/z: 356-->312.2, respectively.",Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),,356,20484,DB00328,Indomethacin
,15556544,m/z,"Mass transitions in negative ionization mode for MPA and the internal standard, indomethacin were m/z: 319-->190.9 and m/z: 356-->312.2, respectively.",Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),,312.2,20485,DB00328,Indomethacin
,20450581,peak time,"The pharmacokinetic test of IDM-AM-3 showed that absorption was delayed significantly (P < 0.01), peak time [(11.35 + or - 2.45) h], elimination half-life [(16.74 + or - 4.04) h] and mean residence time [(22.27 + or - 0.52) h] were significantly prolonged (P < 0.01), as well as peak serum concentrations [(9.69 + or - 2.40) mg/L] and AUC(0-t) [(236.7 + or - 13.1) mg x L(-1) x h] were decreased markedly (P < 0.01) as compared with those of IDM regarding to portal vein.",[Synthesis of colon-specific prodrug of indomethacin and its inhibitory effect on liver metastasis from colon cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450581/),h,11.35,20515,DB00328,Indomethacin
,20450581,elimination half-life,"The pharmacokinetic test of IDM-AM-3 showed that absorption was delayed significantly (P < 0.01), peak time [(11.35 + or - 2.45) h], elimination half-life [(16.74 + or - 4.04) h] and mean residence time [(22.27 + or - 0.52) h] were significantly prolonged (P < 0.01), as well as peak serum concentrations [(9.69 + or - 2.40) mg/L] and AUC(0-t) [(236.7 + or - 13.1) mg x L(-1) x h] were decreased markedly (P < 0.01) as compared with those of IDM regarding to portal vein.",[Synthesis of colon-specific prodrug of indomethacin and its inhibitory effect on liver metastasis from colon cancer]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450581/),h,16.74,20516,DB00328,Indomethacin
,20450581,mean residence time,"The pharmacokinetic test of IDM-AM-3 showed that absorption was delayed significantly (P < 0.01), peak time [(11.35 + or - 2.45) h], elimination half-life [(16.74 + or - 4.04) h] and mean residence time [(22.27 + or - 0.52) h] were significantly prolonged (P < 0.01), as well as peak serum concentrations [(9.69 + or - 2.40) mg/L] and AUC(0-t) [(236.7 + or - 13.1) mg x L(-1) x h] were decreased markedly (P < 0.01) as compared with those of IDM regarding to portal vein.",[Synthesis of colon-specific prodrug of indomethacin and its inhibitory effect on liver metastasis from colon cancer]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450581/),h,22.27,20517,DB00328,Indomethacin
,20450581,peak serum concentrations,"The pharmacokinetic test of IDM-AM-3 showed that absorption was delayed significantly (P < 0.01), peak time [(11.35 + or - 2.45) h], elimination half-life [(16.74 + or - 4.04) h] and mean residence time [(22.27 + or - 0.52) h] were significantly prolonged (P < 0.01), as well as peak serum concentrations [(9.69 + or - 2.40) mg/L] and AUC(0-t) [(236.7 + or - 13.1) mg x L(-1) x h] were decreased markedly (P < 0.01) as compared with those of IDM regarding to portal vein.",[Synthesis of colon-specific prodrug of indomethacin and its inhibitory effect on liver metastasis from colon cancer]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450581/),[mg] / [l],9.69,20518,DB00328,Indomethacin
,20450581,AUC(0-t),"The pharmacokinetic test of IDM-AM-3 showed that absorption was delayed significantly (P < 0.01), peak time [(11.35 + or - 2.45) h], elimination half-life [(16.74 + or - 4.04) h] and mean residence time [(22.27 + or - 0.52) h] were significantly prolonged (P < 0.01), as well as peak serum concentrations [(9.69 + or - 2.40) mg/L] and AUC(0-t) [(236.7 + or - 13.1) mg x L(-1) x h] were decreased markedly (P < 0.01) as compared with those of IDM regarding to portal vein.",[Synthesis of colon-specific prodrug of indomethacin and its inhibitory effect on liver metastasis from colon cancer]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450581/),[h·mg] / [l],236.7,20519,DB00328,Indomethacin
,8148223,clearance,The mean +/- s.d. clearance of (S)-ketorolac (45.9 +/- 10.1 ml h-1 kg-1) exceeded (P = 0.0032) that of the (R)-enantiomer (19.0 +/- 5.0 ml h-1 kg-1).,The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[ml] / [h·kg],45.9,20885,DB00328,Indomethacin
,8148223,clearance,The mean +/- s.d. clearance of (S)-ketorolac (45.9 +/- 10.1 ml h-1 kg-1) exceeded (P = 0.0032) that of the (R)-enantiomer (19.0 +/- 5.0 ml h-1 kg-1).,The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[ml] / [h·kg],19.0,20886,DB00328,Indomethacin
,8148223,AUC ratio,The mean +/- s.d. AUC ratio for (S)-ketorolac:(R)-ketorolac (0.442 +/- 0.043) was significantly different from unity (P = 0.0001).,The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),,0.442,20887,DB00328,Indomethacin
,8148223,steady-state volume of distribution,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[l] / [kg],0.135,20888,DB00328,Indomethacin
,8148223,steady-state volume of distribution,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[l] / [kg],0.075,20889,DB00328,Indomethacin
,8148223,half-lives,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),h,2.35,20890,DB00328,Indomethacin
,8148223,half-lives,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),h,3.62,20891,DB00328,Indomethacin
,688724,AUC,"There was an increase in the mean AUC of indomethacin in plasma from 2,553 +/- 213 hr ng/ml to 4,181 +/- 384 hr ng/ml when probenecid was given, but there was no change in the plasma half-life of indomethacin.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[h·ng] / [ml],"2,553",21057,DB00328,Indomethacin
,688724,AUC,"There was an increase in the mean AUC of indomethacin in plasma from 2,553 +/- 213 hr ng/ml to 4,181 +/- 384 hr ng/ml when probenecid was given, but there was no change in the plasma half-life of indomethacin.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[h·ng] / [ml],"4,181",21058,DB00328,Indomethacin
,688724,plasma clearance,"There was a reduction in the mean plasma clearance of indomethacin from 174 +/- 21 ml/kg/hr to 107 +/- 14 ml/kg/hr when probenecid was added to the indomethacin therapy and a decrease in the apparent volume of distribution from 0,927 +/- 0.16 L/kg to 0.613 +/- 0.13 L/kg.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[ml] / [h·kg],174,21059,DB00328,Indomethacin
,688724,plasma clearance,"There was a reduction in the mean plasma clearance of indomethacin from 174 +/- 21 ml/kg/hr to 107 +/- 14 ml/kg/hr when probenecid was added to the indomethacin therapy and a decrease in the apparent volume of distribution from 0,927 +/- 0.16 L/kg to 0.613 +/- 0.13 L/kg.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[ml] / [h·kg],107,21060,DB00328,Indomethacin
,688724,apparent volume of distribution,"There was a reduction in the mean plasma clearance of indomethacin from 174 +/- 21 ml/kg/hr to 107 +/- 14 ml/kg/hr when probenecid was added to the indomethacin therapy and a decrease in the apparent volume of distribution from 0,927 +/- 0.16 L/kg to 0.613 +/- 0.13 L/kg.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[l] / [kg],"0,927",21061,DB00328,Indomethacin
,688724,apparent volume of distribution,"There was a reduction in the mean plasma clearance of indomethacin from 174 +/- 21 ml/kg/hr to 107 +/- 14 ml/kg/hr when probenecid was added to the indomethacin therapy and a decrease in the apparent volume of distribution from 0,927 +/- 0.16 L/kg to 0.613 +/- 0.13 L/kg.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[l] / [kg],0.613,21062,DB00328,Indomethacin
,688724,urinary excretion,"There was no change in the amount of free indomethacin excreted in the urine during probenecid therapy but there was a reduction in the urinary excretion of free plus glucuronide conjugate of indomethacin from 8,967 +/- 867 microgram/day to 4,760 +/- 674 microgram/day, with a fall in the mean renal clearance of indomethacin glucuronide from 271 +/- 48 ml/min to 126 +/- 57.0 ml/min.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[μg] / [d],"8,967",21063,DB00328,Indomethacin
,688724,urinary excretion,"There was no change in the amount of free indomethacin excreted in the urine during probenecid therapy but there was a reduction in the urinary excretion of free plus glucuronide conjugate of indomethacin from 8,967 +/- 867 microgram/day to 4,760 +/- 674 microgram/day, with a fall in the mean renal clearance of indomethacin glucuronide from 271 +/- 48 ml/min to 126 +/- 57.0 ml/min.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[μg] / [d],"4,760",21064,DB00328,Indomethacin
,688724,renal clearance,"There was no change in the amount of free indomethacin excreted in the urine during probenecid therapy but there was a reduction in the urinary excretion of free plus glucuronide conjugate of indomethacin from 8,967 +/- 867 microgram/day to 4,760 +/- 674 microgram/day, with a fall in the mean renal clearance of indomethacin glucuronide from 271 +/- 48 ml/min to 126 +/- 57.0 ml/min.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[ml] / [min],271,21065,DB00328,Indomethacin
,688724,renal clearance,"There was no change in the amount of free indomethacin excreted in the urine during probenecid therapy but there was a reduction in the urinary excretion of free plus glucuronide conjugate of indomethacin from 8,967 +/- 867 microgram/day to 4,760 +/- 674 microgram/day, with a fall in the mean renal clearance of indomethacin glucuronide from 271 +/- 48 ml/min to 126 +/- 57.0 ml/min.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[ml] / [min],126,21066,DB00328,Indomethacin
,15987831,area under concentration-time curve (AUC)(brain)/AUC(plasma) ratio,The mean area under concentration-time curve (AUC)(brain)/AUC(plasma) ratio of unbound pemetrexed was 0.078 +/- 0.038 in the i.v. bolus study.,Distribution of the novel antifolate pemetrexed to the brain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987831/),,0.078,22824,DB00328,Indomethacin
,15987831,steady-state brain-to-plasma unbound concentration ratio,The pemetrexed steady-state brain-to-plasma unbound concentration ratio after i.v. infusion was 0.106 +/- 0.054.,Distribution of the novel antifolate pemetrexed to the brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987831/),,0.106,22825,DB00328,Indomethacin
,448576,plasma half-life,The plasma half-life of indomethacin ranged from 11 to 20 hours.,Disposition of indomethacin in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/448576/),h,11 to 20,23676,DB00328,Indomethacin
,448576,Peak levels,Peak levels were achieved within four hours and ranged from 0.027 to 0.310 microgram/ml.,Disposition of indomethacin in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/448576/),[μg] / [ml],0.027 to 0.310,23677,DB00328,Indomethacin
,7441434,half-life of elimination,"The mean half-life of elimination (20.7 +/- 8 hours) was three times longer, and the mean clearance rate (13 +/0 9.5 ml/kg/hour) was seven times less than that reported in adults.",Pharmacokinetics of intravenously administered indomethacin in premature infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7441434/),h,20.7,24705,DB00328,Indomethacin
,7441434,clearance rate,"The mean half-life of elimination (20.7 +/- 8 hours) was three times longer, and the mean clearance rate (13 +/0 9.5 ml/kg/hour) was seven times less than that reported in adults.",Pharmacokinetics of intravenously administered indomethacin in premature infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7441434/),[ml] / [h·kg],13,24706,DB00328,Indomethacin
,31182538,area under the concentration-time curve from 0 to 24 h [AUC0-24],"The derived vancomycin pharmacokinetic model was subsequently used to propose dose adjustments that yield effective vancomycin exposure (i.e., area under the concentration-time curve from 0 to 24 h [AUC0-24] between 300 to 550 mg·h/liter, with a probability of <0.1 of subtherapeutic exposure) in preterm neonates with patent ductus arteriosus.",Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31182538/),[h·mg] / [l],300 to 550,27592,DB00328,Indomethacin
,7117089,peak indomethacin plasma concentrations,"PDA closures occurred in 4 infants when peak indomethacin plasma concentrations were 0.71-1.10 micrograms/ml, mean 0.93 +/- 0.16 microgram/ml.",Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117089/),[μg] / [ml],0.71-1.10,28201,DB00328,Indomethacin
,7117089,peak indomethacin plasma concentrations,"PDA closures occurred in 4 infants when peak indomethacin plasma concentrations were 0.71-1.10 micrograms/ml, mean 0.93 +/- 0.16 microgram/ml.",Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117089/),[μg] / [ml],0.93,28202,DB00328,Indomethacin
,7117089,peak concentrations,"With partial or no PDA response to oral treatment, the peak concentrations were 0.20-0.69 microgram/ml, mean 0.57 +/- 0.08 microgram/ml, p less than 0.01.",Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117089/),[μg] / [ml],0.20-0.69,28203,DB00328,Indomethacin
,7117089,peak concentrations,"With partial or no PDA response to oral treatment, the peak concentrations were 0.20-0.69 microgram/ml, mean 0.57 +/- 0.08 microgram/ml, p less than 0.01.",Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117089/),[μg] / [ml],0.57,28204,DB00328,Indomethacin
greater,7117089,peak concentrations,All patients with peak concentrations greater than 0.50 microgram/ml had transient oliguria.,Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117089/),[μg] / [ml],0.50,28205,DB00328,Indomethacin
,3435706,half life,"RhTNF was cleared from plasma with a half life of approximately 20 minutes but non-linear pharmacokinetics lymphoma, improvements in their tumours were recorded.",Tumour necrosis factor in man: clinical and biological observations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435706/),min,20,30553,DB00328,Indomethacin
,7996395,Cmax,"Y-23023 was rapidly absorbed, producing a mean Cmax (1.13 micrograms mL-1) of M1 after 1 h in plasma.","Pharmacokinetic behaviour in polymorphonuclear leucocytes of N,N-dimethylcarbamoylmethyl alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]- pyridine-7-acetate (Y-23023), a new prodrug type of anti-inflammatory agent, and indomethacin after oral administrations in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996395/),[μg] / [ml],1.13,31012,DB00328,Indomethacin
,7996395,Cmax,"Indomethacin was less rapidly absorbed, producing a mean Cmax (3.38 micrograms mL-1) after 3 h in plasma.","Pharmacokinetic behaviour in polymorphonuclear leucocytes of N,N-dimethylcarbamoylmethyl alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]- pyridine-7-acetate (Y-23023), a new prodrug type of anti-inflammatory agent, and indomethacin after oral administrations in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996395/),[μg] / [ml],3.38,31013,DB00328,Indomethacin
,7996395,AUC,"The mean AUC of M1 and indomethacin in plasma were 5.45 micrograms h mL-1 and 22.49 micrograms h mL-1, respectively.","Pharmacokinetic behaviour in polymorphonuclear leucocytes of N,N-dimethylcarbamoylmethyl alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]- pyridine-7-acetate (Y-23023), a new prodrug type of anti-inflammatory agent, and indomethacin after oral administrations in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996395/),[h·μg] / [ml],5.45,31014,DB00328,Indomethacin
,7996395,AUC,"The mean AUC of M1 and indomethacin in plasma were 5.45 micrograms h mL-1 and 22.49 micrograms h mL-1, respectively.","Pharmacokinetic behaviour in polymorphonuclear leucocytes of N,N-dimethylcarbamoylmethyl alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]- pyridine-7-acetate (Y-23023), a new prodrug type of anti-inflammatory agent, and indomethacin after oral administrations in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996395/),[h·μg] / [ml],22.49,31015,DB00328,Indomethacin
,7996395,tmax,"The mean tmax, Cmax and AUC of M1 in PMNs were 1 h, 11.1 ng (41 pmol)/10(8) cells and 58.6 ng (164 pmol) h/10(8) cells, respectively.","Pharmacokinetic behaviour in polymorphonuclear leucocytes of N,N-dimethylcarbamoylmethyl alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]- pyridine-7-acetate (Y-23023), a new prodrug type of anti-inflammatory agent, and indomethacin after oral administrations in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996395/),h,1,31016,DB00328,Indomethacin
,7996395,Cmax,"The mean tmax, Cmax and AUC of M1 in PMNs were 1 h, 11.1 ng (41 pmol)/10(8) cells and 58.6 ng (164 pmol) h/10(8) cells, respectively.","Pharmacokinetic behaviour in polymorphonuclear leucocytes of N,N-dimethylcarbamoylmethyl alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]- pyridine-7-acetate (Y-23023), a new prodrug type of anti-inflammatory agent, and indomethacin after oral administrations in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996395/),ng,11.1,31017,DB00328,Indomethacin
,7996395,AUC,"The mean tmax, Cmax and AUC of M1 in PMNs were 1 h, 11.1 ng (41 pmol)/10(8) cells and 58.6 ng (164 pmol) h/10(8) cells, respectively.","Pharmacokinetic behaviour in polymorphonuclear leucocytes of N,N-dimethylcarbamoylmethyl alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]- pyridine-7-acetate (Y-23023), a new prodrug type of anti-inflammatory agent, and indomethacin after oral administrations in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996395/),ng,58.6,31018,DB00328,Indomethacin
,6970498,detection limit,"As an example, the practical detection limit for naproxen in plasma was about 0.2 microgram ml-1.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[μg] / [ml],0.2,31759,DB00328,Indomethacin
,6970498,Vc,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.038,31760,DB00328,Indomethacin
,6970498,Vdss,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.138,31761,DB00328,Indomethacin
,6970498,t 1/2 (beta,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,21.3,31762,DB00328,Indomethacin
,6970498,t 1/2 (alpha),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.99,31763,DB00328,Indomethacin
,6970498,t 1/2 (ka),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.67,31764,DB00328,Indomethacin
,8494579,plasma levels,"The mean indomethacin plasma levels of 19 female patients were 7 ng/ml, in the vein tissue of the application side 280 ng/g and at the opposite side 80 ng/g.",[Transcutaneous absorption of non-steroidal antirheumatics. Clinical study under a new model for investigation of pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494579/),,7,32370,DB00328,Indomethacin
,1981545,steady-state plasma concentration,Indomethacin was administered as iv bolus injection and iv infusion to yield a steady-state plasma concentration of approximately 1 microgram/ml.,Effects of sodium salicylate on elimination kinetics of indomethacin and bile production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981545/),[μg] / [ml],1,32541,DB00328,Indomethacin
,11195429,absolute bioavailability,A nasal spray formulation of ketorolac tromethamine showed the highest absorption with an absolute bioavailability of 91%.,Development and evaluation of nasal formulations of ketorolac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11195429/),%,91,32893,DB00328,Indomethacin
,11195429,absolute bioavailability,The absolute bioavailability of a solution of ketorolac acid was 70%.,Development and evaluation of nasal formulations of ketorolac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11195429/),%,70,32894,DB00328,Indomethacin
,11195429,absolute bioavailability,"Interestingly, the absolute bioavailability of ketorolac tromethamine from a powder formulation is only 38%, indicating that the drug may not be totally released from the polymer matrix before it is removed from nasal epithelium by mucociliary clearance.",Development and evaluation of nasal formulations of ketorolac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11195429/),%,38,32895,DB00328,Indomethacin
,3569930,maximum concentration (Cmax),A maximum concentration (Cmax) of 4.28 +/- (SE) 0.43 micrograms/ml was reached after 1.85 +/- 0.22 h.,Pharmacokinetics of a sustained-release product of indomethacin in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3569930/),[μg] / [ml],4.28,35106,DB00328,Indomethacin
,3569930,area under the plasma concentration versus time curve (AUC),The area under the plasma concentration versus time curve (AUC) was 22.83 +/- 2.70 micrograms ml-1 h and the plasma elimination half-life was 4.34 +/- 0.64 h.,Pharmacokinetics of a sustained-release product of indomethacin in the elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3569930/),[h·μg] / [ml],22.83,35107,DB00328,Indomethacin
,3569930,plasma elimination half-life,The area under the plasma concentration versus time curve (AUC) was 22.83 +/- 2.70 micrograms ml-1 h and the plasma elimination half-life was 4.34 +/- 0.64 h.,Pharmacokinetics of a sustained-release product of indomethacin in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3569930/),h,4.34,35108,DB00328,Indomethacin
,3569930,maximum concentration,The maximum concentration of Indo in the red blood cells was 0.123 +/- 0.013 microgram/ml and was obtained at 1.95 +/- 0.14 h after drug administration.,Pharmacokinetics of a sustained-release product of indomethacin in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3569930/),[μg] / [ml],0.123,35109,DB00328,Indomethacin
>,22334358,recoveries,The recoveries from spiked control samples were >75% for MFX and >79% for KTC.,Development and validation of liquid chromatography-mass spectrometric method for simultaneous determination of moxifloxacin and ketorolac in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22334358/),%,75,35960,DB00328,Indomethacin
>,22334358,recoveries,The recoveries from spiked control samples were >75% for MFX and >79% for KTC.,Development and validation of liquid chromatography-mass spectrometric method for simultaneous determination of moxifloxacin and ketorolac in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22334358/),%,79,35961,DB00328,Indomethacin
,7194675,u,"For the 75 mg single dose urinary recoveries of the main metabolites, DMA-glucuronide and desbenzoyldesmethylmetacinamide (DBDMA)-glucuronide are 22.9% and 9.2%, respectively.",[Pharmacokinetics and biotransformation of oxametacine in healthy volunteers (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194675/),%,22.9,38137,DB00328,Indomethacin
,7194675,u,"For the 75 mg single dose urinary recoveries of the main metabolites, DMA-glucuronide and desbenzoyldesmethylmetacinamide (DBDMA)-glucuronide are 22.9% and 9.2%, respectively.",[Pharmacokinetics and biotransformation of oxametacine in healthy volunteers (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194675/),%,9.2,38138,DB00328,Indomethacin
,7194675,rinary recoveries,"For the 75 mg single dose urinary recoveries of the main metabolites, DMA-glucuronide and desbenzoyldesmethylmetacinamide (DBDMA)-glucuronide are 22.9% and 9.2%, respectively.",[Pharmacokinetics and biotransformation of oxametacine in healthy volunteers (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194675/),%,22.9,38139,DB00328,Indomethacin
,7194675,rinary recoveries,"For the 75 mg single dose urinary recoveries of the main metabolites, DMA-glucuronide and desbenzoyldesmethylmetacinamide (DBDMA)-glucuronide are 22.9% and 9.2%, respectively.",[Pharmacokinetics and biotransformation of oxametacine in healthy volunteers (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194675/),%,9.2,38140,DB00328,Indomethacin
,7194675,total recovery,"The total recovery was found to be 97.55% of the dose, this being made up of 48.49% renal and 49.06% fecal excretion.",[Pharmacokinetics and biotransformation of oxametacine in healthy volunteers (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194675/),%,97.55,38141,DB00328,Indomethacin
,7194675,total recovery,"The total recovery was found to be 97.55% of the dose, this being made up of 48.49% renal and 49.06% fecal excretion.",[Pharmacokinetics and biotransformation of oxametacine in healthy volunteers (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194675/),%,48.49,38142,DB00328,Indomethacin
,7194675,total recovery,"The total recovery was found to be 97.55% of the dose, this being made up of 48.49% renal and 49.06% fecal excretion.",[Pharmacokinetics and biotransformation of oxametacine in healthy volunteers (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194675/),%,49.06,38143,DB00328,Indomethacin
,10079499,AUC S/R,"After the racemate, R-KT was predominant in plasma (AUC S/R, 0.45).",Stereospecific pharmacokinetics and toxicodynamics of ketorolac after oral administration of the racemate and optically pure enantiomers to the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079499/),,0.45,40282,DB00328,Indomethacin
,8504626,Total clearance,Total clearance of indomethacin after a single oral dose of 50mg was 0.8 ml/min/kg in elderly individuals (mean 79.5 +/- 1.3 years) compared with 1.4 ml/min/kg in younger individuals (mean 36.9 +/- 3.0 years).,Pharmacokinetics of indomethacin in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504626/),[ml] / [kg·min],0.8,42167,DB00328,Indomethacin
,8504626,Total clearance,Total clearance of indomethacin after a single oral dose of 50mg was 0.8 ml/min/kg in elderly individuals (mean 79.5 +/- 1.3 years) compared with 1.4 ml/min/kg in younger individuals (mean 36.9 +/- 3.0 years).,Pharmacokinetics of indomethacin in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504626/),[ml] / [kg·min],1.4,42168,DB00328,Indomethacin
,8504626,apparent elimination rate constant,The apparent elimination rate constant averaged 0.23 h-1 in the aged and 0.32 h-1 in the young people.,Pharmacokinetics of indomethacin in the elderly. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504626/),1/[h],0.23,42169,DB00328,Indomethacin
,8504626,apparent elimination rate constant,The apparent elimination rate constant averaged 0.23 h-1 in the aged and 0.32 h-1 in the young people.,Pharmacokinetics of indomethacin in the elderly. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504626/),1/[h],0.32,42170,DB00328,Indomethacin
,8504626,Oral bioavailability,Oral bioavailability was close to 1 in the young but 0.77 in the elderly.,Pharmacokinetics of indomethacin in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504626/),,1,42171,DB00328,Indomethacin
,8504626,Oral bioavailability,Oral bioavailability was close to 1 in the young but 0.77 in the elderly.,Pharmacokinetics of indomethacin in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504626/),,0.77,42172,DB00328,Indomethacin
less,7346745,bioavailability,"Oral absorption of indomethacin was prolonged and bioavailability, based on area under the curve (AUC), was less than 20%.",A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7346745/),%,20,42527,DB00328,Indomethacin
,7346745,volume of distribution,The mean volume of distribution for indomethacin was 0.36 l/kg and showed only a small variation between subjects.,A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7346745/),[l] / [kg],0.36,42528,DB00328,Indomethacin
,7346745,elimination half-life,The drug elimination half-life ranged from 10-25 hours and demonstrated a significant correlation with gestational age.,A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7346745/),h,10-25,42529,DB00328,Indomethacin
,23199134,drug release,"From the in vitro dissolution study, optimized formulation F3 showed negligible drug release (6.75 ± 0.49%) in the initial lag period followed by slow release (97.47 ± 0.93%) for 24 h which clearly indicates that the drug is delivered to the colon.","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),%,6.75,42663,DB00328,Indomethacin
,23199134,peak plasma concentration (C(max)),"From the pharmacokinetic evaluation, the immediate-release tablets producing peak plasma concentration (C(max)) was 4482.74 ng/ml at 2 h T(max) and colon-targeted tablets showed C(max) = 3562.67 ng/ml at 10 h T(max).","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),[ng] / [ml],4482.74,42664,DB00328,Indomethacin
,23199134,C(max),"From the pharmacokinetic evaluation, the immediate-release tablets producing peak plasma concentration (C(max)) was 4482.74 ng/ml at 2 h T(max) and colon-targeted tablets showed C(max) = 3562.67 ng/ml at 10 h T(max).","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),[ng] / [ml],3562.67,42665,DB00328,Indomethacin
,23199134,T(max),"From the pharmacokinetic evaluation, the immediate-release tablets producing peak plasma concentration (C(max)) was 4482.74 ng/ml at 2 h T(max) and colon-targeted tablets showed C(max) = 3562.67 ng/ml at 10 h T(max).","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),,10,42666,DB00328,Indomethacin
,23199134,area under the curve,"The area under the curve for the immediate-release and compression-coated tablets was 10595.14 and 18796.70 ng h/ml and the mean resident time was 3.82 and 10.75 h, respectively.","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),[h·ng] / [ml],10595.14,42667,DB00328,Indomethacin
,23199134,area under the curve,"The area under the curve for the immediate-release and compression-coated tablets was 10595.14 and 18796.70 ng h/ml and the mean resident time was 3.82 and 10.75 h, respectively.","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),[h·ng] / [ml],18796.70,42668,DB00328,Indomethacin
,23199134,resident time,"The area under the curve for the immediate-release and compression-coated tablets was 10595.14 and 18796.70 ng h/ml and the mean resident time was 3.82 and 10.75 h, respectively.","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),h,3.82,42669,DB00328,Indomethacin
,23199134,resident time,"The area under the curve for the immediate-release and compression-coated tablets was 10595.14 and 18796.70 ng h/ml and the mean resident time was 3.82 and 10.75 h, respectively.","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),h,10.75,42670,DB00328,Indomethacin
,7779142,"Css,max","The Css,max of nimodipine was increased after the combined administration of nimodipine (30 mg t.i.d.) and indometacin (25 mg b.i.d.) as compared with those after nimodipine monotherapy: 24.2 +/- 14.7 micrograms/l vs. 19.7 +/- 10.3 micrograms/l.",Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779142/),[μg] / [l],24.2,42868,DB00328,Indomethacin
,7779142,"Css,max","The Css,max of nimodipine was increased after the combined administration of nimodipine (30 mg t.i.d.) and indometacin (25 mg b.i.d.) as compared with those after nimodipine monotherapy: 24.2 +/- 14.7 micrograms/l vs. 19.7 +/- 10.3 micrograms/l.",Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779142/),[μg] / [l],19.7,42869,DB00328,Indomethacin
,7779142,AUCss,Nimodipine AUCss slightly increased under indometacin co-medication from 57.9 +/- 27.5 micrograms.,Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779142/),μg,57.9,42870,DB00328,Indomethacin
,7779142,relative bioavailability,"h.l-1, resulting in a mean relative bioavailability of nimodipine of 111% with a 90%-confidence interval of 96-128% for the combined medication.",Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779142/),%,111,42871,DB00328,Indomethacin
,6539116,half-lives,"The average half-lives of sulindac, sulindac sulfide and sulfone were 1.7 -4.2 h, 15.3-16.1 h and 16.6-19.6 h, respectively.",Pharmacokinetics of graded oral doses of sulindac in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539116/),h,1.7 -4.2,43622,DB00328,Indomethacin
,6539116,half-lives,"The average half-lives of sulindac, sulindac sulfide and sulfone were 1.7 -4.2 h, 15.3-16.1 h and 16.6-19.6 h, respectively.",Pharmacokinetics of graded oral doses of sulindac in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539116/),h,15.3-16.1,43623,DB00328,Indomethacin
,6539116,half-lives,"The average half-lives of sulindac, sulindac sulfide and sulfone were 1.7 -4.2 h, 15.3-16.1 h and 16.6-19.6 h, respectively.",Pharmacokinetics of graded oral doses of sulindac in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539116/),h,16.6-19.6,43624,DB00328,Indomethacin
,23059909,flow rate,"Chromatographic separation was achieved with 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 0.60 mL/min on an Atlantis dC18 column with a total run time 3.0 min.",Development and validation of a liquid chromatography-tandem mass spectrometry method for quantitation of indomethacin in rat plasma and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23059909/),[ml] / [min],0.60,44747,DB00328,Indomethacin
,23059909,total run time,"Chromatographic separation was achieved with 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 0.60 mL/min on an Atlantis dC18 column with a total run time 3.0 min.",Development and validation of a liquid chromatography-tandem mass spectrometry method for quantitation of indomethacin in rat plasma and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23059909/),min,3.0,44748,DB00328,Indomethacin
,2273487,elimination half-life,The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03).,Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),h,1.7,45863,DB00328,Indomethacin
,2273487,elimination half-life,The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03).,Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),h,1.2,45864,DB00328,Indomethacin
,2273487,apparent MTX clearance (CI),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[l] / [h],10.6,45865,DB00328,Indomethacin
,2273487,apparent MTX clearance (CI),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[l] / [h],13.1,45866,DB00328,Indomethacin
,2273487,area under the serum MTX concentration-time curve (Auc),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[μM] / [h·l],2.1,45867,DB00328,Indomethacin
,2273487,area under the serum MTX concentration-time curve (Auc),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[μM] / [h·l],1.5,45868,DB00328,Indomethacin
,2273487,apparent volume of distribution (Vd),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),l,23.0,45869,DB00328,Indomethacin
,2273487,apparent volume of distribution (Vd),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),l,21.9,45870,DB00328,Indomethacin
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,33.7,52863,DB00328,Indomethacin
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,55.9,52864,DB00328,Indomethacin
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,64.6,52865,DB00328,Indomethacin
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,49.4,52866,DB00328,Indomethacin
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,65.1,52867,DB00328,Indomethacin
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,80.3,52868,DB00328,Indomethacin
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,16.2,52869,DB00328,Indomethacin
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,45.2,52870,DB00328,Indomethacin
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,86.6,52871,DB00328,Indomethacin
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,46.2,52872,DB00328,Indomethacin
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,58.4,52873,DB00328,Indomethacin
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,92.6,52874,DB00328,Indomethacin
,3141302,Maximum plasma levels,Maximum plasma levels of 17.5 micrograms/ml were observed after 2.5 h.,Transsynovial kinetics of indoprofen in patients with rheumatoid arthritis and cyclooxygenase-inhibition in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141302/),[μg] / [ml],17.5,52950,DB00328,Indomethacin
,3141302,Peak synovial fluid concentrations,Peak synovial fluid concentrations amounted to 8.1 micrograms/ml 4 h following the last dose.,Transsynovial kinetics of indoprofen in patients with rheumatoid arthritis and cyclooxygenase-inhibition in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141302/),[μg] / [ml],8.1,52951,DB00328,Indomethacin
,3141302,Elimination,Elimination from synovial fluid occurred at 10.6 h compared to 9.3 h from plasma.,Transsynovial kinetics of indoprofen in patients with rheumatoid arthritis and cyclooxygenase-inhibition in vitro. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141302/),h,10,52952,DB00328,Indomethacin
,3141302,Elimination,Elimination from synovial fluid occurred at 10.6 h compared to 9.3 h from plasma.,Transsynovial kinetics of indoprofen in patients with rheumatoid arthritis and cyclooxygenase-inhibition in vitro. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141302/),h,9.3,52953,DB00328,Indomethacin
,17988844,n,Obvious increase in overall release rate was observed at sodium chloride level of 0.9% with an n value of 1.20 and a T0.1 of 3.4h.,"Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),,1.20,53549,DB00328,Indomethacin
,17988844,T0.1,Obvious increase in overall release rate was observed at sodium chloride level of 0.9% with an n value of 1.20 and a T0.1 of 3.4h.,"Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),h,3.4,53550,DB00328,Indomethacin
,17988844,Tmax/Cmax,"Pharmacokinetic study in dogs gave Tmax/Cmax of 4h/604 ng/ml and 3h/1662 ng/ml for HPMC/pectin/calcium and HPMC/pectin tablet, respectively.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),-1·h,4,53551,DB00328,Indomethacin
,17988844,Tmax/Cmax,"Pharmacokinetic study in dogs gave Tmax/Cmax of 4h/604 ng/ml and 3h/1662 ng/ml for HPMC/pectin/calcium and HPMC/pectin tablet, respectively.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),[ng] / [ml],604,53552,DB00328,Indomethacin
,17988844,Tmax/Cmax,"Pharmacokinetic study in dogs gave Tmax/Cmax of 4h/604 ng/ml and 3h/1662 ng/ml for HPMC/pectin/calcium and HPMC/pectin tablet, respectively.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),-1·h,3,53553,DB00328,Indomethacin
,17988844,Tmax/Cmax,"Pharmacokinetic study in dogs gave Tmax/Cmax of 4h/604 ng/ml and 3h/1662 ng/ml for HPMC/pectin/calcium and HPMC/pectin tablet, respectively.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),[ng] / [ml],1662,53554,DB00328,Indomethacin
,17988844,MRT,"The plasma indomethacin level of the calcium-containing tablet was maintained at a much lower level for 3h with a MRT of 7.13 h, longer than 3.97 and 5.61 h for indomethacin crude drug and HPMC/pectin tablet, confirming delayed absorption.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),h,7.13,53555,DB00328,Indomethacin
,17988844,MRT,"The plasma indomethacin level of the calcium-containing tablet was maintained at a much lower level for 3h with a MRT of 7.13 h, longer than 3.97 and 5.61 h for indomethacin crude drug and HPMC/pectin tablet, confirming delayed absorption.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),h,longer,53556,DB00328,Indomethacin
,17988844,MRT,"The plasma indomethacin level of the calcium-containing tablet was maintained at a much lower level for 3h with a MRT of 7.13 h, longer than 3.97 and 5.61 h for indomethacin crude drug and HPMC/pectin tablet, confirming delayed absorption.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),h,3.97,53557,DB00328,Indomethacin
,17988844,MRT,"The plasma indomethacin level of the calcium-containing tablet was maintained at a much lower level for 3h with a MRT of 7.13 h, longer than 3.97 and 5.61 h for indomethacin crude drug and HPMC/pectin tablet, confirming delayed absorption.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),h,5.61,53558,DB00328,Indomethacin
,15120451,oral bioavailability,"The present work was aimed to study the effect of concomitant administration of Trikatu on the pharmacokinetics and pharmacodynamics of diclofenac sodium, a frequently prescribed non-steroidal anti-inflammatory drug, having a poor oral bioavailability (54 +/- 2%).","Pharmacokinetic and pharmacodynamic studies on interaction of ""Trikatu"" with diclofenac sodium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120451/),%,54,55916,DB00328,Indomethacin
,3694433,lag time,"IND and IND-Ca were readily absorbed with a short lag time from IND-Ca ointment (1% as IND, 0.14 g/cm2, 3.0 x 1.2 cm area) containing Azone.",Prediction of plasma concentration profile during single and repeated skin applications of indomethacin and its calcium salt ointments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694433/),%,1,58145,DB00328,Indomethacin
,3694433,lag time,"IND and IND-Ca were readily absorbed with a short lag time from IND-Ca ointment (1% as IND, 0.14 g/cm2, 3.0 x 1.2 cm area) containing Azone.",Prediction of plasma concentration profile during single and repeated skin applications of indomethacin and its calcium salt ointments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694433/),,0,58146,DB00328,Indomethacin
,8592665,AUC S/R,"In both humans and rats, the pharmacokinetics of racemic KT were stereoselective with the R enantiomer being predominant (AUC S/R: humans, 0.26; Rats: 0.45).",The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592665/),,0.26,58983,DB00328,Indomethacin
,8592665,AUC S/R,"In both humans and rats, the pharmacokinetics of racemic KT were stereoselective with the R enantiomer being predominant (AUC S/R: humans, 0.26; Rats: 0.45).",The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592665/),,0.45,58984,DB00328,Indomethacin
,8592665,unbound S/R,This is likely due to more extensive plasma protein binding of S than its antipode (unbound S/R: 1.35).,The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592665/),,1.35,58985,DB00328,Indomethacin
,8415407,pKa's,Potentiometrically determined pKa's for prodrugs were in the range of 6.89 to 8.62 at 25 degrees C.,Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8415407/),,6.89 to 8.62,60436,DB00328,Indomethacin
,8415407,half-lives,"The esters were generally found to be hydrolyzed rapidly in rat plasma at 37 degrees C, the half-lives being in the range of 1.2-31.0 min.",Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8415407/),min,1.2-31.0,60437,DB00328,Indomethacin
,8749226,half-life,"Then, concentrations decayed with a half-life of about 6 h.",Pharmacokinetics of oral ketorolac in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8749226/),h,6,60902,DB00328,Indomethacin
,17192497,tmax,"The i.n. ketorolac was rapidly and well absorbed (median tmax, 0.50-0.75 hours), and the half-life was approximately 5 to 6 hours, values that were similar to those following i.m. administration.",Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192497/),h,0.50-0.75,61122,DB00328,Indomethacin
,17192497,half-life,"The i.n. ketorolac was rapidly and well absorbed (median tmax, 0.50-0.75 hours), and the half-life was approximately 5 to 6 hours, values that were similar to those following i.m. administration.",Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192497/),h,5 to 6,61123,DB00328,Indomethacin
,17192497,Relative bioavailability,Relative bioavailability of i.n. compared to i.m. administration at the same doses was approximately 67% to 75%.,Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192497/),%,67,61124,DB00328,Indomethacin
,17192497,Relative bioavailability,Relative bioavailability of i.n. compared to i.m. administration at the same doses was approximately 67% to 75%.,Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192497/),%,75,61125,DB00328,Indomethacin
,21088943,detection limit,"The concentration of ibuprofen in blood plasma was analysed by HPLC, following solid-phase extraction and using indometacin as internal standard (detection limit, 0.05 microg/ml).",In vivo assessment of parenteral formulations of oligo(3-hydroxybutyric Acid) conjugates with the model compound Ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088943/),[μg] / [ml],0.05,61366,DB00328,Indomethacin
,21088943,relative bioavailability,"In comparison to the non-conjugated drug in oily solution, the relative bioavailability of ibuprofen conjugates from oily solution, and o/w emulsion was reduced to 17% and 10%, respectively.",In vivo assessment of parenteral formulations of oligo(3-hydroxybutyric Acid) conjugates with the model compound Ibuprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088943/),%,17,61367,DB00328,Indomethacin
,21088943,relative bioavailability,"In comparison to the non-conjugated drug in oily solution, the relative bioavailability of ibuprofen conjugates from oily solution, and o/w emulsion was reduced to 17% and 10%, respectively.",In vivo assessment of parenteral formulations of oligo(3-hydroxybutyric Acid) conjugates with the model compound Ibuprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088943/),%,10,61368,DB00328,Indomethacin
,11426885,MRT,"Pharmacokinetics parameters (mean +/- s.d.) such as the mean residence time (MRT, h), the steady-state volume of distribution (Vdss, l), the terminal half-time (t 1/2, h) and the plasma clearance (CL, l/h) of IMC in each groups (control vs. DMEP70) were determined; MRT (16.97 +/- 4.83 vs. 28.69 +/- 11.28, p < 0.01); Vdss (14.26 +/- 4.86 vs. 20.37 +/- 12.04, p < 0.05); t 1/2 (15.12 +/- 4.77 vs. 23.1 +/- 8.24, p < 0.01); CL (0.84 +/- 0.27 vs. 0.71 +/- 0.41).",Indomethacin-loaded methoxy poly(ethylene glycol)/ poly(epsilon-caprolactone) diblock copolymeric nanosphere: pharmacokinetic characteristics of indomethacin in the normal Sprague-Dawley rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11426885/),,16.97,61912,DB00328,Indomethacin
,11426885,MRT,"Pharmacokinetics parameters (mean +/- s.d.) such as the mean residence time (MRT, h), the steady-state volume of distribution (Vdss, l), the terminal half-time (t 1/2, h) and the plasma clearance (CL, l/h) of IMC in each groups (control vs. DMEP70) were determined; MRT (16.97 +/- 4.83 vs. 28.69 +/- 11.28, p < 0.01); Vdss (14.26 +/- 4.86 vs. 20.37 +/- 12.04, p < 0.05); t 1/2 (15.12 +/- 4.77 vs. 23.1 +/- 8.24, p < 0.01); CL (0.84 +/- 0.27 vs. 0.71 +/- 0.41).",Indomethacin-loaded methoxy poly(ethylene glycol)/ poly(epsilon-caprolactone) diblock copolymeric nanosphere: pharmacokinetic characteristics of indomethacin in the normal Sprague-Dawley rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11426885/),,28.69,61913,DB00328,Indomethacin
,11426885,Vdss,"Pharmacokinetics parameters (mean +/- s.d.) such as the mean residence time (MRT, h), the steady-state volume of distribution (Vdss, l), the terminal half-time (t 1/2, h) and the plasma clearance (CL, l/h) of IMC in each groups (control vs. DMEP70) were determined; MRT (16.97 +/- 4.83 vs. 28.69 +/- 11.28, p < 0.01); Vdss (14.26 +/- 4.86 vs. 20.37 +/- 12.04, p < 0.05); t 1/2 (15.12 +/- 4.77 vs. 23.1 +/- 8.24, p < 0.01); CL (0.84 +/- 0.27 vs. 0.71 +/- 0.41).",Indomethacin-loaded methoxy poly(ethylene glycol)/ poly(epsilon-caprolactone) diblock copolymeric nanosphere: pharmacokinetic characteristics of indomethacin in the normal Sprague-Dawley rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11426885/),,14.26,61914,DB00328,Indomethacin
,11426885,Vdss,"Pharmacokinetics parameters (mean +/- s.d.) such as the mean residence time (MRT, h), the steady-state volume of distribution (Vdss, l), the terminal half-time (t 1/2, h) and the plasma clearance (CL, l/h) of IMC in each groups (control vs. DMEP70) were determined; MRT (16.97 +/- 4.83 vs. 28.69 +/- 11.28, p < 0.01); Vdss (14.26 +/- 4.86 vs. 20.37 +/- 12.04, p < 0.05); t 1/2 (15.12 +/- 4.77 vs. 23.1 +/- 8.24, p < 0.01); CL (0.84 +/- 0.27 vs. 0.71 +/- 0.41).",Indomethacin-loaded methoxy poly(ethylene glycol)/ poly(epsilon-caprolactone) diblock copolymeric nanosphere: pharmacokinetic characteristics of indomethacin in the normal Sprague-Dawley rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11426885/),,20.37,61915,DB00328,Indomethacin
,11426885,t 1/2,"Pharmacokinetics parameters (mean +/- s.d.) such as the mean residence time (MRT, h), the steady-state volume of distribution (Vdss, l), the terminal half-time (t 1/2, h) and the plasma clearance (CL, l/h) of IMC in each groups (control vs. DMEP70) were determined; MRT (16.97 +/- 4.83 vs. 28.69 +/- 11.28, p < 0.01); Vdss (14.26 +/- 4.86 vs. 20.37 +/- 12.04, p < 0.05); t 1/2 (15.12 +/- 4.77 vs. 23.1 +/- 8.24, p < 0.01); CL (0.84 +/- 0.27 vs. 0.71 +/- 0.41).",Indomethacin-loaded methoxy poly(ethylene glycol)/ poly(epsilon-caprolactone) diblock copolymeric nanosphere: pharmacokinetic characteristics of indomethacin in the normal Sprague-Dawley rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11426885/),,15.12,61916,DB00328,Indomethacin
,11426885,t 1/2,"Pharmacokinetics parameters (mean +/- s.d.) such as the mean residence time (MRT, h), the steady-state volume of distribution (Vdss, l), the terminal half-time (t 1/2, h) and the plasma clearance (CL, l/h) of IMC in each groups (control vs. DMEP70) were determined; MRT (16.97 +/- 4.83 vs. 28.69 +/- 11.28, p < 0.01); Vdss (14.26 +/- 4.86 vs. 20.37 +/- 12.04, p < 0.05); t 1/2 (15.12 +/- 4.77 vs. 23.1 +/- 8.24, p < 0.01); CL (0.84 +/- 0.27 vs. 0.71 +/- 0.41).",Indomethacin-loaded methoxy poly(ethylene glycol)/ poly(epsilon-caprolactone) diblock copolymeric nanosphere: pharmacokinetic characteristics of indomethacin in the normal Sprague-Dawley rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11426885/),,23.1,61917,DB00328,Indomethacin
,11426885,CL,"Pharmacokinetics parameters (mean +/- s.d.) such as the mean residence time (MRT, h), the steady-state volume of distribution (Vdss, l), the terminal half-time (t 1/2, h) and the plasma clearance (CL, l/h) of IMC in each groups (control vs. DMEP70) were determined; MRT (16.97 +/- 4.83 vs. 28.69 +/- 11.28, p < 0.01); Vdss (14.26 +/- 4.86 vs. 20.37 +/- 12.04, p < 0.05); t 1/2 (15.12 +/- 4.77 vs. 23.1 +/- 8.24, p < 0.01); CL (0.84 +/- 0.27 vs. 0.71 +/- 0.41).",Indomethacin-loaded methoxy poly(ethylene glycol)/ poly(epsilon-caprolactone) diblock copolymeric nanosphere: pharmacokinetic characteristics of indomethacin in the normal Sprague-Dawley rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11426885/),,0.84,61918,DB00328,Indomethacin
,11426885,CL,"Pharmacokinetics parameters (mean +/- s.d.) such as the mean residence time (MRT, h), the steady-state volume of distribution (Vdss, l), the terminal half-time (t 1/2, h) and the plasma clearance (CL, l/h) of IMC in each groups (control vs. DMEP70) were determined; MRT (16.97 +/- 4.83 vs. 28.69 +/- 11.28, p < 0.01); Vdss (14.26 +/- 4.86 vs. 20.37 +/- 12.04, p < 0.05); t 1/2 (15.12 +/- 4.77 vs. 23.1 +/- 8.24, p < 0.01); CL (0.84 +/- 0.27 vs. 0.71 +/- 0.41).",Indomethacin-loaded methoxy poly(ethylene glycol)/ poly(epsilon-caprolactone) diblock copolymeric nanosphere: pharmacokinetic characteristics of indomethacin in the normal Sprague-Dawley rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11426885/),,0.71,61919,DB00328,Indomethacin
,1888622,plasma elimination half-life,"After dosing to steady state (7 days), the mean plasma elimination half-life for acemetacin was 1.1 h and 1.0 h, and for indomethacin 7.1 h and 7.2 h in the young and elderly groups respectively.",The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888622/),h,1.1,63669,DB00328,Indomethacin
,1888622,plasma elimination half-life,"After dosing to steady state (7 days), the mean plasma elimination half-life for acemetacin was 1.1 h and 1.0 h, and for indomethacin 7.1 h and 7.2 h in the young and elderly groups respectively.",The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888622/),h,1.0,63670,DB00328,Indomethacin
,1888622,plasma elimination half-life,"After dosing to steady state (7 days), the mean plasma elimination half-life for acemetacin was 1.1 h and 1.0 h, and for indomethacin 7.1 h and 7.2 h in the young and elderly groups respectively.",The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888622/),h,7.1,63671,DB00328,Indomethacin
,1888622,plasma elimination half-life,"After dosing to steady state (7 days), the mean plasma elimination half-life for acemetacin was 1.1 h and 1.0 h, and for indomethacin 7.1 h and 7.2 h in the young and elderly groups respectively.",The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888622/),h,7.2,63672,DB00328,Indomethacin
,7597909,peak concentration (Cmax),"kg-1 solution was 0.08 h, approached that after i.v. route the peak concentration (Cmax) following ina was 20.0 mg.L-1, 2.4 times higher than po dosing.",Absorption of indomethacin from nasal cavity in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7597909/),[mg] / [l],20.0,65103,DB00328,Indomethacin
,33153182,ED30,"According to the isobolographic analysis, the experimental and theoretical ED30 values were similar for methyleugenol plus diclofenac, suggesting an additive effect, but significantly different for methyleugenol plus ketorolac (3.6 ± 0.5 vs. 7.7 ± 0.6 mg/kg, respectively), indicating a probable synergistic interaction.",Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33153182/),[mg] / [kg],3.6,65584,DB00328,Indomethacin
,33153182,ED30,"According to the isobolographic analysis, the experimental and theoretical ED30 values were similar for methyleugenol plus diclofenac, suggesting an additive effect, but significantly different for methyleugenol plus ketorolac (3.6 ± 0.5 vs. 7.7 ± 0.6 mg/kg, respectively), indicating a probable synergistic interaction.",Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33153182/),[mg] / [kg],7.7,65585,DB00328,Indomethacin
,6644592,flow rate,Lactated Ringer's solution was administered intravenously throughout both treatments at a flow rate of 2 ml/min to avoid fluid and electrolyte depletion.,Determinants of bumetanide response in the dog: effect of indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644592/),[ml] / [min],2,65963,DB00328,Indomethacin
,3761139,bioavailability,The bioavailability of IND after application of ointments was 9.1-27.8% for the gel base and 4.5-6.3% for the white petrolatum base.,Absorption of indomethacin and its calcium salt through rat skin: effect of penetration enhancers and relationship between in vivo and in vitro penetration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761139/),%,9.1-27.8,66338,DB00328,Indomethacin
,3761139,bioavailability,The bioavailability of IND after application of ointments was 9.1-27.8% for the gel base and 4.5-6.3% for the white petrolatum base.,Absorption of indomethacin and its calcium salt through rat skin: effect of penetration enhancers and relationship between in vivo and in vitro penetration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761139/),%,4.5-6.3,66339,DB00328,Indomethacin
,2376240,elimination half-life,It has an intermediate elimination half-life of 17 h which does not depend on age or sex.,The pharmacokinetics of pirazolac in human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376240/),h,17,66914,DB00328,Indomethacin
,2717517,bioavailability,"Oral administration of the gel formulation did not result in any gastric ulceration and improved the bioavailability of indomethacin to 115.5%, compared with 68.2% for the suspension.",Influence of indomethacin amphoteric gel on gastric ulcerogenicity and absorption of indomethacin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717517/),%,115.5,66980,DB00328,Indomethacin
,2717517,bioavailability,"Oral administration of the gel formulation did not result in any gastric ulceration and improved the bioavailability of indomethacin to 115.5%, compared with 68.2% for the suspension.",Influence of indomethacin amphoteric gel on gastric ulcerogenicity and absorption of indomethacin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717517/),%,68.2,66981,DB00328,Indomethacin
,22467894,clearance (CL/F),"Population parameter estimates (between subject variability) were clearance (CL/F) 2.05 L/h (60.5%), volume of distribution (V/F) 15.2 L (32.4%), absorption half-life (t(1/2)abs) 0.173 hour (25.0%).",The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22467894/),[l] / [h],2.05,67574,DB00328,Indomethacin
,22467894,volume of distribution (V/F),"Population parameter estimates (between subject variability) were clearance (CL/F) 2.05 L/h (60.5%), volume of distribution (V/F) 15.2 L (32.4%), absorption half-life (t(1/2)abs) 0.173 hour (25.0%).",The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22467894/),l,15.2,67575,DB00328,Indomethacin
,22467894,absorption half-life (t(1/2)abs),"Population parameter estimates (between subject variability) were clearance (CL/F) 2.05 L/h (60.5%), volume of distribution (V/F) 15.2 L (32.4%), absorption half-life (t(1/2)abs) 0.173 hour (25.0%).",The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22467894/),h,0.173,67576,DB00328,Indomethacin
,22467894,Time to peak concentration (Tmax),Time to peak concentration (Tmax) was 52 minutes (SD 6 minutes).,The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22467894/),min,52,67577,DB00328,Indomethacin
,23791718,permeation,"Iontophoretic permeation of KT from a 2% hydroxymethyl cellulose gel was comparable to that from an aqueous solution with equivalent drug loading (584.59±114.67 and 462.05±66.56μg/cm(2), respectively).",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],584.59,67787,DB00328,Indomethacin
,23791718,permeation,"Iontophoretic permeation of KT from a 2% hydroxymethyl cellulose gel was comparable to that from an aqueous solution with equivalent drug loading (584.59±114.67 and 462.05±66.56μg/cm(2), respectively).",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],462.05,67788,DB00328,Indomethacin
,23791718,Cumulative permeation,"Cumulative permeation (462.05±66.56 and 416.28±95.71μg/cm(2)) and steady state flux (106.72±11.70 and 94.28±15.47μg/cm(2)h), across porcine and human skin, were statistically equivalent confirming the validity of the model.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],462.05,67789,DB00328,Indomethacin
,23791718,Cumulative permeation,"Cumulative permeation (462.05±66.56 and 416.28±95.71μg/cm(2)) and steady state flux (106.72±11.70 and 94.28±15.47μg/cm(2)h), across porcine and human skin, were statistically equivalent confirming the validity of the model.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],416.28,67790,DB00328,Indomethacin
,23791718,steady state flux,"Cumulative permeation (462.05±66.56 and 416.28±95.71μg/cm(2)) and steady state flux (106.72±11.70 and 94.28±15.47μg/cm(2)h), across porcine and human skin, were statistically equivalent confirming the validity of the model.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2)h],106.72,67791,DB00328,Indomethacin
,23791718,steady state flux,"Cumulative permeation (462.05±66.56 and 416.28±95.71μg/cm(2)) and steady state flux (106.72±11.70 and 94.28±15.47μg/cm(2)h), across porcine and human skin, were statistically equivalent confirming the validity of the model.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2)h],94.28,67792,DB00328,Indomethacin
,23791718,KT,"Iontophoretic administration for 30min was superior to passive topical delivery for 1h and resulted in statistically significant increases in KT levels in the skin (91.04±15.48 vs. 20.16±8.58μg/cm(2)), in the biceps femoris at the treatment site (TM; 6.74±3.80 vs.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],91.04,67793,DB00328,Indomethacin
,23791718,KT,"Iontophoretic administration for 30min was superior to passive topical delivery for 1h and resulted in statistically significant increases in KT levels in the skin (91.04±15.48 vs. 20.16±8.58μg/cm(2)), in the biceps femoris at the treatment site (TM; 6.74±3.80 vs.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],20.16,67794,DB00328,Indomethacin
,23791718,KT,"Iontophoretic administration for 30min was superior to passive topical delivery for 1h and resulted in statistically significant increases in KT levels in the skin (91.04±15.48 vs. 20.16±8.58μg/cm(2)), in the biceps femoris at the treatment site (TM; 6.74±3.80 vs.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),,6.74,67795,DB00328,Indomethacin
,23791718,ratio,"In addition to increasing bioavailability, iontophoretic administration of KT showed clear selectivity for local delivery to the biceps femoris at the treatment site - the TM:NTM ratio was 5.26±1.45, and the TM:P and NTM:P ratios were 0.75±0.32 and 0.14±0.04, respectively.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),,5,67796,DB00328,Indomethacin
,24471938,lag time,The lag time varied between 3 h and 7 h depending on the amount of calcium chloride and the coating weight.,An in situ crosslinked compression coat comprised of pectin and calcium chloride for colon-specific delivery of indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24471938/),h,3,68935,DB00328,Indomethacin
,24471938,lag time,The lag time varied between 3 h and 7 h depending on the amount of calcium chloride and the coating weight.,An in situ crosslinked compression coat comprised of pectin and calcium chloride for colon-specific delivery of indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24471938/),h,7,68936,DB00328,Indomethacin
,6664824,apparent pH,The organic solvent was evaporated and the residue dissolved in a water-methanol (2 + 3) phosphate buffer mixture with an apparent pH of 6.8.,Plasma indomethacin assay by reversed-phase ion pair high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664824/),,6.8,71370,DB00328,Indomethacin
,6664824,analytical recovery,"At a 2.0 mg X l-1 concentration of indomethacin in plasma the analytical recovery was 82.9 +/- 3.4% (n = 7), the intra-day variability (CV) was 3.6% (n = 7) and the inter-day variability (CV) was 11.0% (n = 7).",Plasma indomethacin assay by reversed-phase ion pair high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664824/),%,82.9,71371,DB00328,Indomethacin
,21233498,clearance,"Estimated individual parameters were clearance 1.49 ± 1.12 mL/min/kg, Vss (volume of distribution at steady state) 0.31 ± 0.11 L/kg, and half-life of 236 ± 169 minutes.",Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[ml] / [kg·min],1.49,74618,DB00328,Indomethacin
,21233498,Vss (volume of distribution at steady state),"Estimated individual parameters were clearance 1.49 ± 1.12 mL/min/kg, Vss (volume of distribution at steady state) 0.31 ± 0.11 L/kg, and half-life of 236 ± 169 minutes.",Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[l] / [kg],0.31,74619,DB00328,Indomethacin
,21233498,half-life,"Estimated individual parameters were clearance 1.49 ± 1.12 mL/min/kg, Vss (volume of distribution at steady state) 0.31 ± 0.11 L/kg, and half-life of 236 ± 169 minutes.",Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),min,236,74620,DB00328,Indomethacin
,21233498,clearance,Estimated population pharmacokinetic parameters were clearance 1.52 mL/min/kg and Vss 0.29 L/kg.,Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[ml] / [kg·min],1.52,74621,DB00328,Indomethacin
,21233498,Vss,Estimated population pharmacokinetic parameters were clearance 1.52 mL/min/kg and Vss 0.29 L/kg.,Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[l] / [kg],0.29,74622,DB00328,Indomethacin
,3598886,ocular bioavailability,The ocular bioavailability of ketorolac was 4% in anesthetized rabbits and was determined by comparing drug concentrations in the aqueous humor after topical application with those obtained after intracameral injection of an equivalent dose of 0.25 mg of ketorolac tromethamine per eye.,Ocular bioavailability and tissue distribution of [14C]ketorolac tromethamine in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598886/),%,4,75893,DB00328,Indomethacin
,2775449,oral bioavailability,"Following intragastric administration, the oral bioavailability of indomethacin in solution was 90%--indicating complete absorption of this drug from the gastrointestinal tract of the rat.",Pharmacokinetic evaluation of indomethacin nanocapsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775449/),%,90,76501,DB00328,Indomethacin
,30159654,steady-state apparent oral clearance (CL/Fss),"For subjects with the *1/*2 genotype, the mean steady-state apparent oral clearance (CL/Fss) of indomethacin was 13.5 ± 7.7 L/h (n = 4) and the mean metabolic ratio (AUCDMI/AUCindomethacin) was 0.291 ± 0.133.",Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30159654/),[l] / [h],13.5,76749,DB00328,Indomethacin
,30159654,metabolic ratio (AUCDMI/AUCindomethacin),"For subjects with the *1/*2 genotype, the mean steady-state apparent oral clearance (CL/Fss) of indomethacin was 13.5 ± 7.7 L/h (n = 4) and the mean metabolic ratio (AUCDMI/AUCindomethacin) was 0.291 ± 0.133.",Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30159654/),,0.291,76750,DB00328,Indomethacin
,30159654,CL/Fss,This subject had a metabolic ratio of 0.390 and a CL/Fss of indomethacin (24.3 L/h) that was nearly double the wild-type clearance.,Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30159654/),[l] / [h],24.3,76751,DB00328,Indomethacin
,7104182,peak concentration,Plasma concentrations of indomethacin were significantly higher during indomethacin retard therapy with a peak concentration of 2500 +/- 25 ng ml-1 during indomethacin retard therapy (mean +/- s.d.) and 1900 +/- 200 ng ml during conventional oral therapy.,A clinical and pharmacokinetic study of indomethacin in standard and slow release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104182/),[ng] / [ml],2500,76773,DB00328,Indomethacin
,7104182,peak concentration,Plasma concentrations of indomethacin were significantly higher during indomethacin retard therapy with a peak concentration of 2500 +/- 25 ng ml-1 during indomethacin retard therapy (mean +/- s.d.) and 1900 +/- 200 ng ml during conventional oral therapy.,A clinical and pharmacokinetic study of indomethacin in standard and slow release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104182/),ml·ng,1900,76774,DB00328,Indomethacin
,9457380,attained maximum levels (Cmax,"The in vivo IMC release from the cement increased and attained maximum levels (Cmax of 2% and 5% drug-loaded cements was 0.27 and 3.37 micrograms/ml, respectively) at Tmax, 3 and 0.5 d, respectively, upon subcutaneous (s.c.) administration in rats.",The in vitro and in vivo indomethacin release from self-setting bioactive glass bone cement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9457380/),[μg] / [ml],0.27,77124,DB00328,Indomethacin
,9457380,attained maximum levels (Cmax,"The in vivo IMC release from the cement increased and attained maximum levels (Cmax of 2% and 5% drug-loaded cements was 0.27 and 3.37 micrograms/ml, respectively) at Tmax, 3 and 0.5 d, respectively, upon subcutaneous (s.c.) administration in rats.",The in vitro and in vivo indomethacin release from self-setting bioactive glass bone cement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9457380/),[μg] / [ml],3.37,77125,DB00328,Indomethacin
,9457380,Tmax,"The in vivo IMC release from the cement increased and attained maximum levels (Cmax of 2% and 5% drug-loaded cements was 0.27 and 3.37 micrograms/ml, respectively) at Tmax, 3 and 0.5 d, respectively, upon subcutaneous (s.c.) administration in rats.",The in vitro and in vivo indomethacin release from self-setting bioactive glass bone cement. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9457380/),d,3,77126,DB00328,Indomethacin
,9457380,Tmax,"The in vivo IMC release from the cement increased and attained maximum levels (Cmax of 2% and 5% drug-loaded cements was 0.27 and 3.37 micrograms/ml, respectively) at Tmax, 3 and 0.5 d, respectively, upon subcutaneous (s.c.) administration in rats.",The in vitro and in vivo indomethacin release from self-setting bioactive glass bone cement. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9457380/),d,0.5,77127,DB00328,Indomethacin
,15285335,Css(max),"Based on pharmacodynamic/pharmacokinetic correlation in the animal studies, Css(max) and Css(min) of 51.39 and 30.0 microg/mL, respectively, were determined and considered as performance markers for pharmacokinetic evaluation of test formulations.",In vitro-in vivo characterization of release modifying agents for parenteral sustained-release ketorolac formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285335/),[μg] / [ml],51.39,77145,DB00328,Indomethacin
,15285335,Css(min),"Based on pharmacodynamic/pharmacokinetic correlation in the animal studies, Css(max) and Css(min) of 51.39 and 30.0 microg/mL, respectively, were determined and considered as performance markers for pharmacokinetic evaluation of test formulations.",In vitro-in vivo characterization of release modifying agents for parenteral sustained-release ketorolac formulation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285335/),[μg] / [ml],30.0,77146,DB00328,Indomethacin
,1804863,area under the indomethacin plasma concentration curve AUC 0-alpha,The mean area under the indomethacin plasma concentration curve AUC 0-alpha was 10.4 +/- 4.21 micrograms/mL x hr and did not change during combined paracetamol treatment (11.0 +/- 3.24 micrograms/mL x hr NS).,Lack of effect of paracetamol on the pharmacokinetics of indomethacin and paracetamol in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804863/),[μg] / [h·ml],10.4,77546,DB00328,Indomethacin
,1804863,area under the indomethacin plasma concentration curve AUC 0-alpha,The mean area under the indomethacin plasma concentration curve AUC 0-alpha was 10.4 +/- 4.21 micrograms/mL x hr and did not change during combined paracetamol treatment (11.0 +/- 3.24 micrograms/mL x hr NS).,Lack of effect of paracetamol on the pharmacokinetics of indomethacin and paracetamol in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804863/),[μg] / [h·ml],11.0,77547,DB00328,Indomethacin
,9731954,volumes of distribution at steady state (Vd(ss)),"The mean (+/- SD) volumes of distribution at steady state (Vd(ss)) were 4.10 +/- 1.40 and 4.21 +/- 1.93 L/kg and the mean clearance values (ClB) were 0.17 +/- 0.06 and 0.22 +/- 0.12 L/h x kg for i.v. and i.m. routes, respectively.",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),[l] / [kg],4.10,79688,DB00328,Indomethacin
,9731954,volumes of distribution at steady state (Vd(ss)),"The mean (+/- SD) volumes of distribution at steady state (Vd(ss)) were 4.10 +/- 1.40 and 4.21 +/- 1.93 L/kg and the mean clearance values (ClB) were 0.17 +/- 0.06 and 0.22 +/- 0.12 L/h x kg for i.v. and i.m. routes, respectively.",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),[l] / [kg],4.21,79689,DB00328,Indomethacin
,9731954,clearance,"The mean (+/- SD) volumes of distribution at steady state (Vd(ss)) were 4.10 +/- 1.40 and 4.21 +/- 1.93 L/kg and the mean clearance values (ClB) were 0.17 +/- 0.06 and 0.22 +/- 0.12 L/h x kg for i.v. and i.m. routes, respectively.",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),[l] / [h·kg],0.17,79690,DB00328,Indomethacin
,9731954,clearance,"The mean (+/- SD) volumes of distribution at steady state (Vd(ss)) were 4.10 +/- 1.40 and 4.21 +/- 1.93 L/kg and the mean clearance values (ClB) were 0.17 +/- 0.06 and 0.22 +/- 0.12 L/h x kg for i.v. and i.m. routes, respectively.",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),[l] / [h·kg],0.22,79691,DB00328,Indomethacin
,9731954,t1/2beta,"The elimination phase half-lives did not show any significant difference between routes of injection (t1/2beta = 17.4 +/- 4.6 and 21.25 +/- 4.44 h, i.v. and i.m. respectively).",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),h,17.4,79692,DB00328,Indomethacin
,9731954,t1/2beta,"The elimination phase half-lives did not show any significant difference between routes of injection (t1/2beta = 17.4 +/- 4.6 and 21.25 +/- 4.44 h, i.v. and i.m. respectively).",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),h,21.25,79693,DB00328,Indomethacin
,9731954,plasma maximum concentration (Cmax,"After i.m. administration, plasma maximum concentration (Cmax = 1.10 +/- 0.68 microg/mL) was reached 10 min after dosing; the absorption phase was fast (Kab = 26 +/- 18 h(-1)) and short (t1/2ab = 2.33 +/- 1.51 min) and the mean bioavailability was 91.0 +/- 32.8%, although there was considerable interanimal variation.",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),[μg] / [ml],1.10,79694,DB00328,Indomethacin
,9731954,Kab,"After i.m. administration, plasma maximum concentration (Cmax = 1.10 +/- 0.68 microg/mL) was reached 10 min after dosing; the absorption phase was fast (Kab = 26 +/- 18 h(-1)) and short (t1/2ab = 2.33 +/- 1.51 min) and the mean bioavailability was 91.0 +/- 32.8%, although there was considerable interanimal variation.",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),1/[h],26,79695,DB00328,Indomethacin
,9731954,t1/2ab,"After i.m. administration, plasma maximum concentration (Cmax = 1.10 +/- 0.68 microg/mL) was reached 10 min after dosing; the absorption phase was fast (Kab = 26 +/- 18 h(-1)) and short (t1/2ab = 2.33 +/- 1.51 min) and the mean bioavailability was 91.0 +/- 32.8%, although there was considerable interanimal variation.",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),min,2.33,79696,DB00328,Indomethacin
,9731954,bioavailability,"After i.m. administration, plasma maximum concentration (Cmax = 1.10 +/- 0.68 microg/mL) was reached 10 min after dosing; the absorption phase was fast (Kab = 26 +/- 18 h(-1)) and short (t1/2ab = 2.33 +/- 1.51 min) and the mean bioavailability was 91.0 +/- 32.8%, although there was considerable interanimal variation.",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),%,91.0,79697,DB00328,Indomethacin
higher,9731954,bioavailability,"In some individuals, bioavailability was higher than 100%.",Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731954/),%,100,79698,DB00328,Indomethacin
,2229205,flow rate,"The mobile phase consisted of ethanol:water:glacial acetic acid (65:34:1, v/v) pumped isocratically at a flow rate of 1.3 ml/min.",High-performance liquid chromatographic analysis of indomethacin in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229205/),[ml] / [min],1.3,80117,DB00328,Indomethacin
,2229205,absolute recoveries,"Quantification was achieved by the measurement of the peak area ratio, and the absolute recoveries ranged from 94 to 97%.",High-performance liquid chromatographic analysis of indomethacin in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229205/),%,94 to 97,80118,DB00328,Indomethacin
,21992030,area under the curves (AUCs),"In IAGU rats, the area under the curves (AUCs) of AACA were significantly smaller after both the intravenous (551 versus 1270 μg min ml⁻¹) and oral (397 versus 562 μg min ml⁻¹) administration of ZAC than controls, possible due to the significantly faster CL(R) of AACA.",ε-Acetamidocaproic acid pharmacokinetics in rats with gastric ulcer or small bowel inflammation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21992030/),min·ml⁻¹·μg,551,81094,DB00328,Indomethacin
,21992030,area under the curves (AUCs),"In IAGU rats, the area under the curves (AUCs) of AACA were significantly smaller after both the intravenous (551 versus 1270 μg min ml⁻¹) and oral (397 versus 562 μg min ml⁻¹) administration of ZAC than controls, possible due to the significantly faster CL(R) of AACA.",ε-Acetamidocaproic acid pharmacokinetics in rats with gastric ulcer or small bowel inflammation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21992030/),min·ml⁻¹·μg,1270,81095,DB00328,Indomethacin
,21992030,area under the curves (AUCs),"In IAGU rats, the area under the curves (AUCs) of AACA were significantly smaller after both the intravenous (551 versus 1270 μg min ml⁻¹) and oral (397 versus 562 μg min ml⁻¹) administration of ZAC than controls, possible due to the significantly faster CL(R) of AACA.",ε-Acetamidocaproic acid pharmacokinetics in rats with gastric ulcer or small bowel inflammation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21992030/),min·ml⁻¹·μg,397,81096,DB00328,Indomethacin
,21992030,area under the curves (AUCs),"In IAGU rats, the area under the curves (AUCs) of AACA were significantly smaller after both the intravenous (551 versus 1270 μg min ml⁻¹) and oral (397 versus 562 μg min ml⁻¹) administration of ZAC than controls, possible due to the significantly faster CL(R) of AACA.",ε-Acetamidocaproic acid pharmacokinetics in rats with gastric ulcer or small bowel inflammation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21992030/),min·ml⁻¹·μg,562,81097,DB00328,Indomethacin
,23338686,maximum concentration (Cmax,"Regarding its pharmacokinetics in mice, after a single intraperitoneal injection of PTI, its plasma levels reached the maximum concentration (Cmax = 46 μM) at 2h (Tmax) and became undetectable at 4h.","The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338686/),μM,46,81883,DB00328,Indomethacin
,23338686,plasma Cmax,"Indomethacin is the major metabolite of PTI, with plasma Cmax = 378 μM and Tmax = 2.5h; it became undetectable 24h postadministration.","The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338686/),μM,378,81884,DB00328,Indomethacin
,23338686,Tmax,"Indomethacin is the major metabolite of PTI, with plasma Cmax = 378 μM and Tmax = 2.5h; it became undetectable 24h postadministration.","The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338686/),h,2.5,81885,DB00328,Indomethacin
,7161340,detection limit,The assay is quantitative down to 0.25 microgram ml-1 from a 200-microliters aliquot of plasma with a detection limit of 0.1 microgram ml-1 and a recovery of approximately 90%.,High-performance liquid chromatographic assay of indomethacin and its application in pharmacokinetics in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161340/),[μg] / [ml],0.1,82634,DB00328,Indomethacin
,7161340,recovery,The assay is quantitative down to 0.25 microgram ml-1 from a 200-microliters aliquot of plasma with a detection limit of 0.1 microgram ml-1 and a recovery of approximately 90%.,High-performance liquid chromatographic assay of indomethacin and its application in pharmacokinetics in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161340/),%,90,82635,DB00328,Indomethacin
,11812682,volume of distribution at steady state,"Body weight-normalized pharmacokinetic variables did not differ among the age groups and were similar to those reported for adults, including a volume of distribution at steady state of 113 +/- 33 mL/kg (mean +/- SD) and an elimination clearance of 0.57 +/- 0.17 mL x min(-1) x kg(-1).",Age-stratified pharmacokinetics of ketorolac tromethamine in pediatric surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812682/),[ml] / [kg],113,85033,DB00328,Indomethacin
,11812682,elimination clearance,"Body weight-normalized pharmacokinetic variables did not differ among the age groups and were similar to those reported for adults, including a volume of distribution at steady state of 113 +/- 33 mL/kg (mean +/- SD) and an elimination clearance of 0.57 +/- 0.17 mL x min(-1) x kg(-1).",Age-stratified pharmacokinetics of ketorolac tromethamine in pediatric surgical patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812682/),[ml] / [kg·min],0.57,85034,DB00328,Indomethacin
,428423,half-life,"The half-life of TXA2 in blood was 30-47 sec, a similar value to that found in aqueous solutions at 37 degrees C. PGH2 was also converted in blood to other product(s) which contracted RSS and RC, relaxed RbCA and RbMA but had little effect on RbA.",Biotransformation and cardiovascular effects of arachidonic acid in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428423/),s,30-47,85811,DB00328,Indomethacin
,6856668,Binding,Binding to human serum albumin (14 X 10(-5) mol/l) was significantly lower for esterified indomethacin than for nonesterified.,Binding of indomethacin ester with tropic acid to human serum albumin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6856668/),[mol] / [l],14 X 10(-5),86903,DB00328,Indomethacin
,6856668,association constant,"The tropic ester of indomethacin has an association constant for the primary binding sites of 2.16 X 10(5) l/mol, and while the association constant for indomethacin is 8.15 X 10(5) l/mol.",Binding of indomethacin ester with tropic acid to human serum albumin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6856668/),[l] / [mol],2.16 X 10(5),86904,DB00328,Indomethacin
,6856668,association constant,"The tropic ester of indomethacin has an association constant for the primary binding sites of 2.16 X 10(5) l/mol, and while the association constant for indomethacin is 8.15 X 10(5) l/mol.",Binding of indomethacin ester with tropic acid to human serum albumin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6856668/),[l] / [mol],8.15 X 10(5),86905,DB00328,Indomethacin
,9112830,AUC,"The in-vivo study showed that the oral administration of Riopan 1 h after administration of Indocid capsules to fed dogs resulted in a significant (p < 0.05) reduction in plasma concentrations of indomethacin, a non-significant (p > 0.05) change in Cmax, significantly (p < 0.05) shorter Tmax and significantly reduced AUC where it decreased from 15.06 +/- 5.65 to 9.52 +/- 3.69 micrograms h/ml resulted in a relative bioavailability of 63.21% after Riopan administration.",Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112830/),,15.06,87500,DB00328,Indomethacin
,9112830,AUC,"The in-vivo study showed that the oral administration of Riopan 1 h after administration of Indocid capsules to fed dogs resulted in a significant (p < 0.05) reduction in plasma concentrations of indomethacin, a non-significant (p > 0.05) change in Cmax, significantly (p < 0.05) shorter Tmax and significantly reduced AUC where it decreased from 15.06 +/- 5.65 to 9.52 +/- 3.69 micrograms h/ml resulted in a relative bioavailability of 63.21% after Riopan administration.",Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112830/),,9.52,87501,DB00328,Indomethacin
,9112830,relative bioavailability,"The in-vivo study showed that the oral administration of Riopan 1 h after administration of Indocid capsules to fed dogs resulted in a significant (p < 0.05) reduction in plasma concentrations of indomethacin, a non-significant (p > 0.05) change in Cmax, significantly (p < 0.05) shorter Tmax and significantly reduced AUC where it decreased from 15.06 +/- 5.65 to 9.52 +/- 3.69 micrograms h/ml resulted in a relative bioavailability of 63.21% after Riopan administration.",Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112830/),%,63.21,87502,DB00328,Indomethacin
,7139063,overall bioavailability,"Results indicate that the sustained release test formulation exhibited more prolonged and uniform absorption rate, yielded more sustained plasma levels after ingestion, and showed an overall bioavailability of 0.93 (95 per cent C.I. = 0.82, 1.04) relative to three 25 mg doses of the conventional capsules.",Effect of sustained release on the pharmacokinetic profile of indomethacin in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139063/),,0.93,89215,DB00328,Indomethacin
,17365283,Tmax,"The Tmax and Tlag of Eudragit FS30D-coated pellets were postponed to about 2.5 and 1 h, respectively.",In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of indomethacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365283/),h,2.5,90118,DB00328,Indomethacin
,17365283,Tlag,"The Tmax and Tlag of Eudragit FS30D-coated pellets were postponed to about 2.5 and 1 h, respectively.",In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365283/),h,1,90119,DB00328,Indomethacin
,17365283,Tlag,"After a further guar gum coating, Tlag was further postponed to about 2.8 h, about 2 h of additional lag time on the basis of Eudragit FS30D coating.",In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365283/),h,2.8,90120,DB00328,Indomethacin
,17365283,Tlag,"After a further guar gum coating, Tlag was further postponed to about 2.8 h, about 2 h of additional lag time on the basis of Eudragit FS30D coating.",In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365283/),h,2,90121,DB00328,Indomethacin
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,0.31,94872,DB00328,Indomethacin
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,2.2,94873,DB00328,Indomethacin
,17920584,ID(50),"In an adjuvant-induced arthritic model in rats, CS-706 suppressed foot swelling prophylactically with an ID(50) of 0.10 mg/kg/day, and decreased foot swelling in the established arthritis therapeutically in a dose range of 0.040 to 1.0 mg/kg/day.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),[mg] / [d·kg],0.10,94874,DB00328,Indomethacin
,18426955,uptake clearance,"Indomethacin, however, was shown to have a higher uptake clearance (599 +/- 101 microl/min/10(6) cells) than atorvastatin (375 +/- 45 microl/min/10(6) cells) and cerivastatin (413 +/- 47 microl/min/10(6) cells).","Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18426955/),[min·μl] / [10(6)·cells],599,95659,DB00328,Indomethacin
,18426955,uptake clearance,"Indomethacin, however, was shown to have a higher uptake clearance (599 +/- 101 microl/min/10(6) cells) than atorvastatin (375 +/- 45 microl/min/10(6) cells) and cerivastatin (413 +/- 47 microl/min/10(6) cells).","Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18426955/),[min·μl] / [10(6)·cells],375,95660,DB00328,Indomethacin
,18426955,uptake clearance,"Indomethacin, however, was shown to have a higher uptake clearance (599 +/- 101 microl/min/10(6) cells) than atorvastatin (375 +/- 45 microl/min/10(6) cells) and cerivastatin (413 +/- 47 microl/min/10(6) cells).","Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18426955/),[min·μl] / [10(6],413,95661,DB00328,Indomethacin
,18426955,passive permeability,The high passive permeability of indomethacin (237 +/- 63 microl/min/10(6) cells) clearly negated the effect of the active transport on the overall disposition.,"Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18426955/),[μl] / [10·min],237,95662,DB00328,Indomethacin
,23143939,C(max),"Mean (±SD) plasma ketorolac C(max) was 10 % higher (2,028.8 ± 1,069.5 and 1,840.1 ± 995.9 ng/mL) and mean (±SD) terminal elimination half-life (t(½β)) was 37 % longer (4.52 ± 1.14 and 3.31 ± 0.96 h) in the ≥65-years age group than in the <65-years group, respectively.",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),[ng] / [ml],"2,028.8",95694,DB00328,Indomethacin
,23143939,C(max),"Mean (±SD) plasma ketorolac C(max) was 10 % higher (2,028.8 ± 1,069.5 and 1,840.1 ± 995.9 ng/mL) and mean (±SD) terminal elimination half-life (t(½β)) was 37 % longer (4.52 ± 1.14 and 3.31 ± 0.96 h) in the ≥65-years age group than in the <65-years group, respectively.",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),[ng] / [ml],"1,840.1",95695,DB00328,Indomethacin
,23143939,terminal elimination half-life (t(½β)),"Mean (±SD) plasma ketorolac C(max) was 10 % higher (2,028.8 ± 1,069.5 and 1,840.1 ± 995.9 ng/mL) and mean (±SD) terminal elimination half-life (t(½β)) was 37 % longer (4.52 ± 1.14 and 3.31 ± 0.96 h) in the ≥65-years age group than in the <65-years group, respectively.",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),h,4.52,95696,DB00328,Indomethacin
,23143939,terminal elimination half-life (t(½β)),"Mean (±SD) plasma ketorolac C(max) was 10 % higher (2,028.8 ± 1,069.5 and 1,840.1 ± 995.9 ng/mL) and mean (±SD) terminal elimination half-life (t(½β)) was 37 % longer (4.52 ± 1.14 and 3.31 ± 0.96 h) in the ≥65-years age group than in the <65-years group, respectively.",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),h,3.31,95697,DB00328,Indomethacin
,23143939,area under the plasma concentration-time curve from time zero to infinity (AUC(∞)),"Mean (±SD) plasma ketorolac area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) was 28 % higher in older subjects than in younger subjects (8,794.8 ± 4,129.4 and 6,890.8 ± 3,448.5 ng · h/mL, respectively).",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),[h·ng] / [ml],"8,794.8",95698,DB00328,Indomethacin
,23143939,area under the plasma concentration-time curve from time zero to infinity (AUC(∞)),"Mean (±SD) plasma ketorolac area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) was 28 % higher in older subjects than in younger subjects (8,794.8 ± 4,129.4 and 6,890.8 ± 3,448.5 ng · h/mL, respectively).",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),[h·ng] / [ml],"6,890.8",95699,DB00328,Indomethacin
,23143939,),"Mean (±SD) residence time was 36 % higher in the ≥65-years age group than in the <65-years group (6.02 ± 1.50 and 4.44 ± 1.06 h, respectively) (p = 0.003).",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),h,6.02,95700,DB00328,Indomethacin
,23143939,residence time,"Mean (±SD) residence time was 36 % higher in the ≥65-years age group than in the <65-years group (6.02 ± 1.50 and 4.44 ± 1.06 h, respectively) (p = 0.003).",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),h,6.02,95701,DB00328,Indomethacin
,23143939,residence time,"Mean (±SD) residence time was 36 % higher in the ≥65-years age group than in the <65-years group (6.02 ± 1.50 and 4.44 ± 1.06 h, respectively) (p = 0.003).",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),h,4.44,95702,DB00328,Indomethacin
,19857147,peak gentamicin plasma concentration,Protocol success was defined as a peak gentamicin plasma concentration of 7-10 mg/L and a trough concentration less than 2 mg/L.,"Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857147/),[mg] / [l],7-10,95991,DB00328,Indomethacin
less,19857147,trough concentration,Protocol success was defined as a peak gentamicin plasma concentration of 7-10 mg/L and a trough concentration less than 2 mg/L.,"Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857147/),[mg] / [l],2,95992,DB00328,Indomethacin
,19857147,peak,"Mean gentamicin peak and trough concentrations were 9.38 mg/L (95% confidence interval [CI] 9.24-9.52 mg/L) and 1.00 mg/L (95% CI 0.96-1.04 mg/L), respectively.","Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857147/),[mg] / [l],9.38,95993,DB00328,Indomethacin
,19857147,trough concentrations,"Mean gentamicin peak and trough concentrations were 9.38 mg/L (95% confidence interval [CI] 9.24-9.52 mg/L) and 1.00 mg/L (95% CI 0.96-1.04 mg/L), respectively.","Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857147/),[mg] / [l],1.00,95994,DB00328,Indomethacin
,19857147,apparent volume of distribution,"The mean gentamicin apparent volume of distribution and half-life were 0.48 L/kg (95% CI 0.47-0.49 L/kg) and 8.31 hours (95% CI 8.09-8.52 hrs), respectively.","Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857147/),[l] / [kg],0.48,95995,DB00328,Indomethacin
,19857147,half-life,"The mean gentamicin apparent volume of distribution and half-life were 0.48 L/kg (95% CI 0.47-0.49 L/kg) and 8.31 hours (95% CI 8.09-8.52 hrs), respectively.","Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857147/),h,8.31,95996,DB00328,Indomethacin
,23780501,cumulative percent drug release,"RESULTS & DISCUSSIONS: From the in vitro drug release studies, in case of optimized formulation, the cumulative percent drug release in 15 min (Q15) was found to be 94.34±1.68 where as the conventional tablets showed 28.78±0.82 in 15 min.",Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),,94.34,100306,DB00328,Indomethacin
,23780501,cumulative percent drug release,"RESULTS & DISCUSSIONS: From the in vitro drug release studies, in case of optimized formulation, the cumulative percent drug release in 15 min (Q15) was found to be 94.34±1.68 where as the conventional tablets showed 28.78±0.82 in 15 min.",Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),,28.78,100307,DB00328,Indomethacin
,23780501,initial dissolution rate,The initial dissolution rate and dissolution efficiency of optimized formulation was 6.29%/min and 53.43 but it was 1.92%/min and 14.03 in conventional tablets.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[%] / [min],6.29,100308,DB00328,Indomethacin
,23780501,initial dissolution rate,The initial dissolution rate and dissolution efficiency of optimized formulation was 6.29%/min and 53.43 but it was 1.92%/min and 14.03 in conventional tablets.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[%] / [min],1.92,100309,DB00328,Indomethacin
,23780501,dissolution efficiency,The initial dissolution rate and dissolution efficiency of optimized formulation was 6.29%/min and 53.43 but it was 1.92%/min and 14.03 in conventional tablets.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),,53.43,100310,DB00328,Indomethacin
,23780501,dissolution efficiency,The initial dissolution rate and dissolution efficiency of optimized formulation was 6.29%/min and 53.43 but it was 1.92%/min and 14.03 in conventional tablets.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),,14.03,100311,DB00328,Indomethacin
,23780501,peak plasma concentration (Cmax),"From the in vivo pharmacokinetic evaluation, the optimized formulation showed peak plasma concentration (Cmax) as 1 248.39 ng/ml at 1 h Tmax, but they were found to be 988.22 ng/ml at 2 h Tmax, in case of conventional tablets.",Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[ng] / [ml],1 248.39,100312,DB00328,Indomethacin
,23780501,Tmax,"From the in vivo pharmacokinetic evaluation, the optimized formulation showed peak plasma concentration (Cmax) as 1 248.39 ng/ml at 1 h Tmax, but they were found to be 988.22 ng/ml at 2 h Tmax, in case of conventional tablets.",Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[ng] / [ml],988.22,100313,DB00328,Indomethacin
,23780501,Tmax,"From the in vivo pharmacokinetic evaluation, the optimized formulation showed peak plasma concentration (Cmax) as 1 248.39 ng/ml at 1 h Tmax, but they were found to be 988.22 ng/ml at 2 h Tmax, in case of conventional tablets.",Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),,2,100314,DB00328,Indomethacin
,23780501,area under the curve,The area under the curve for the optimized and conventional tablets was 3 890.68 and 3 173.07 ng-h/ml.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[ng-h] / [ml],3 890.68,100315,DB00328,Indomethacin
,23780501,area under the curve,The area under the curve for the optimized and conventional tablets was 3 890.68 and 3 173.07 ng-h/ml.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[ng-h] / [ml],3 173.07,100316,DB00328,Indomethacin
,22059858,T(max),"Retinal T(max) was 30 min and 120 min in the IND-HPMC-treated group and the IND-CD-treated group, respectively.",Ocular pharmacokinetics profile of different indomethacin topical formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),min,30,100451,DB00328,Indomethacin
,22059858,T(max),"Retinal T(max) was 30 min and 120 min in the IND-HPMC-treated group and the IND-CD-treated group, respectively.",Ocular pharmacokinetics profile of different indomethacin topical formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),min,120,100452,DB00328,Indomethacin
,22059858,AUC(0-240),"Higher levels of indomethacin were found in retina after IND-HPMC administration compared to IND-CD (AUC(0-240) 272.9 ng/g per min vs. AUC(0-240) 73.5 ng/g/min, respectively; P<0.01).",Ocular pharmacokinetics profile of different indomethacin topical formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [g·min],272.9,100453,DB00328,Indomethacin
,22059858,AUC(0-240),"Higher levels of indomethacin were found in retina after IND-HPMC administration compared to IND-CD (AUC(0-240) 272.9 ng/g per min vs. AUC(0-240) 73.5 ng/g/min, respectively; P<0.01).",Ocular pharmacokinetics profile of different indomethacin topical formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [g·min],73.5,100454,DB00328,Indomethacin
,22059858,AUC(0-240),"Also in the aqueous and vitreous, the drug levels were statistically higher (P<0.01) in the IND-HPMC group in comparison with the IND-CD group (AUC(0-240) 2039 ng/mL per min vs. AUC(0-240) 427.3 ng/mL per min, AUC(0-240) 53.8 ng/mL per min vs. AUC(0-240) 12.5 ng/mL per min, respectively).",Ocular pharmacokinetics profile of different indomethacin topical formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [min·ml],2039,100455,DB00328,Indomethacin
,22059858,AUC(0-240),"Also in the aqueous and vitreous, the drug levels were statistically higher (P<0.01) in the IND-HPMC group in comparison with the IND-CD group (AUC(0-240) 2039 ng/mL per min vs. AUC(0-240) 427.3 ng/mL per min, AUC(0-240) 53.8 ng/mL per min vs. AUC(0-240) 12.5 ng/mL per min, respectively).",Ocular pharmacokinetics profile of different indomethacin topical formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [min·ml],427.3,100456,DB00328,Indomethacin
,22059858,AUC(0-240),"Also in the aqueous and vitreous, the drug levels were statistically higher (P<0.01) in the IND-HPMC group in comparison with the IND-CD group (AUC(0-240) 2039 ng/mL per min vs. AUC(0-240) 427.3 ng/mL per min, AUC(0-240) 53.8 ng/mL per min vs. AUC(0-240) 12.5 ng/mL per min, respectively).",Ocular pharmacokinetics profile of different indomethacin topical formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [min·ml],53.8,100457,DB00328,Indomethacin
,22059858,AUC(0-240),"Also in the aqueous and vitreous, the drug levels were statistically higher (P<0.01) in the IND-HPMC group in comparison with the IND-CD group (AUC(0-240) 2039 ng/mL per min vs. AUC(0-240) 427.3 ng/mL per min, AUC(0-240) 53.8 ng/mL per min vs. AUC(0-240) 12.5 ng/mL per min, respectively).",Ocular pharmacokinetics profile of different indomethacin topical formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [min·ml],12.5,100458,DB00328,Indomethacin
,22059858,C(max),The highest drug levels in the ocular tissues were found following IND-HPMC administration compared with IND-CD (retina: C(max) 73.7±6.4 ng/g vs. 25.5±1.73 ng/g; aqueous: C(max) 952±6.8 ng/mL vs. 163±4.1 ng/mL; vitreous C(max) 31±3.5 ng/mL vs. 6.37±3.6 ng/mL).,Ocular pharmacokinetics profile of different indomethacin topical formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [g],73.7,100459,DB00328,Indomethacin
,22059858,C(max),The highest drug levels in the ocular tissues were found following IND-HPMC administration compared with IND-CD (retina: C(max) 73.7±6.4 ng/g vs. 25.5±1.73 ng/g; aqueous: C(max) 952±6.8 ng/mL vs. 163±4.1 ng/mL; vitreous C(max) 31±3.5 ng/mL vs. 6.37±3.6 ng/mL).,Ocular pharmacokinetics profile of different indomethacin topical formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [g],25.5,100460,DB00328,Indomethacin
,22059858,C(max),The highest drug levels in the ocular tissues were found following IND-HPMC administration compared with IND-CD (retina: C(max) 73.7±6.4 ng/g vs. 25.5±1.73 ng/g; aqueous: C(max) 952±6.8 ng/mL vs. 163±4.1 ng/mL; vitreous C(max) 31±3.5 ng/mL vs. 6.37±3.6 ng/mL).,Ocular pharmacokinetics profile of different indomethacin topical formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [ml],952,100461,DB00328,Indomethacin
,22059858,C(max),The highest drug levels in the ocular tissues were found following IND-HPMC administration compared with IND-CD (retina: C(max) 73.7±6.4 ng/g vs. 25.5±1.73 ng/g; aqueous: C(max) 952±6.8 ng/mL vs. 163±4.1 ng/mL; vitreous C(max) 31±3.5 ng/mL vs. 6.37±3.6 ng/mL).,Ocular pharmacokinetics profile of different indomethacin topical formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [ml],163,100462,DB00328,Indomethacin
,22059858,C(max),The highest drug levels in the ocular tissues were found following IND-HPMC administration compared with IND-CD (retina: C(max) 73.7±6.4 ng/g vs. 25.5±1.73 ng/g; aqueous: C(max) 952±6.8 ng/mL vs. 163±4.1 ng/mL; vitreous C(max) 31±3.5 ng/mL vs. 6.37±3.6 ng/mL).,Ocular pharmacokinetics profile of different indomethacin topical formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [ml],31,100463,DB00328,Indomethacin
,22059858,C(max),The highest drug levels in the ocular tissues were found following IND-HPMC administration compared with IND-CD (retina: C(max) 73.7±6.4 ng/g vs. 25.5±1.73 ng/g; aqueous: C(max) 952±6.8 ng/mL vs. 163±4.1 ng/mL; vitreous C(max) 31±3.5 ng/mL vs. 6.37±3.6 ng/mL).,Ocular pharmacokinetics profile of different indomethacin topical formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22059858/),[ng] / [ml],6.37,100464,DB00328,Indomethacin
,1180089,Plasma-I,Plasma-I-concentrations of 13-14 mug/ml reduced renal venous plasma PGE-concentration significantly from 216 to 85 pg/ml within 45 min.,Indomethacin blockade of renal PGE-synthesis: effect on total renal and tubular function and plasma renin concentration in hydropenic rats and on their response to isotonic saline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1180089/),[μg] / [ml],13-14,100821,DB00328,Indomethacin
,7194676,elimination half-life t 1/2 (beta),"The elimination half-life t 1/2 (beta) for the total sum of the oxametacin metabolites was 11.5 (h) and 9.9 (h) after 2 x 75 mg and 3 x 75 mg/d, resp., thus being comparable.",[Pharmacokinetics of oxametacin in healthy volunteers following multiple administration (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194676/),h,11.5,100907,DB00328,Indomethacin
,7194676,elimination half-life t 1/2 (beta),"The elimination half-life t 1/2 (beta) for the total sum of the oxametacin metabolites was 11.5 (h) and 9.9 (h) after 2 x 75 mg and 3 x 75 mg/d, resp., thus being comparable.",[Pharmacokinetics of oxametacin in healthy volunteers following multiple administration (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194676/),h,9.9,100908,DB00328,Indomethacin
,10505957,maximum plasma concentrations,"Average maximum plasma concentrations of PBZ (16.43 microg/ml) and OPBZ (2.37 microg/ml) were attained at 0.76 and 7.17 h, respectively.",Disposition and tolerance of suxibuzone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),[μg] / [ml],16.43,100983,DB00328,Indomethacin
,10505957,maximum plasma concentrations,"Average maximum plasma concentrations of PBZ (16.43 microg/ml) and OPBZ (2.37 microg/ml) were attained at 0.76 and 7.17 h, respectively.",Disposition and tolerance of suxibuzone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),[μg] / [ml],2.37,100984,DB00328,Indomethacin
,10505957,mean residence time (MRT),The mean residence time (MRT) of PBZ was 6.96 h in plasma.,Disposition and tolerance of suxibuzone in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),h,6.96,100985,DB00328,Indomethacin
,10505957,MRT,"Oxyphenbutazone plasma concentrations were below those reached by phenylbutazone during the first 12 h after suxibuzone administration, even though its values were detectable for at least 24 h (MRT = 10.65 h).",Disposition and tolerance of suxibuzone in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),h,10.65,100986,DB00328,Indomethacin
,10505957,Synovial fluid concentrations,Synovial fluid concentrations of PBZ and OPBZ were 2.87+/-0.37 microg/ml and 0.97+/-0.08 microg/ml at 9 h after suxibuzone administration and exceeded IC50 of PGE2 for at least this time.,Disposition and tolerance of suxibuzone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),[μg] / [ml],2.87,100987,DB00328,Indomethacin
,10505957,Synovial fluid concentrations,Synovial fluid concentrations of PBZ and OPBZ were 2.87+/-0.37 microg/ml and 0.97+/-0.08 microg/ml at 9 h after suxibuzone administration and exceeded IC50 of PGE2 for at least this time.,Disposition and tolerance of suxibuzone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),[μg] / [ml],0.97,100988,DB00328,Indomethacin
,1458761,Cmax,"The absorption of ketorolac is rapid, Cmax being attained between 20 to 60 min.",Clinical pharmacokinetics of ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),min,20 to 60,102714,DB00328,Indomethacin
,1458761,oral bioavailability,Its oral bioavailability is estimated to range from 80 to 100%.,Clinical pharmacokinetics of ketorolac tromethamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),%,80 to 100,102715,DB00328,Indomethacin
,1458761,volume of distribution,The drug is extensively bound (> 99%) to plasma proteins and has a volume of distribution (0.1 to 0.3 L/kg) comparable with those of other NSAIDs.,Clinical pharmacokinetics of ketorolac tromethamine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),[l] / [kg],0.1 to 0.3,102716,DB00328,Indomethacin
,1458761,elimination half-life,The elimination half-life is between 4 and 6h and is moderate in comparison with other NSAIDs.,Clinical pharmacokinetics of ketorolac tromethamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),h,4 and 6,102717,DB00328,Indomethacin
,21199130,central volume of distribution,"The population estimates of the R (+) isomer were (%CV): central volume of distribution 1130 (10%) ml, peripheral volume of distribution 626 (25%) ml, and clearance from the central compartment 7.40 (8%) ml·min(-1).",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),ml,1130,104745,DB00328,Indomethacin
,21199130,peripheral volume of distribution,"The population estimates of the R (+) isomer were (%CV): central volume of distribution 1130 (10%) ml, peripheral volume of distribution 626 (25%) ml, and clearance from the central compartment 7.40 (8%) ml·min(-1).",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),ml,626,104746,DB00328,Indomethacin
,21199130,clearance from the central compartment,"The population estimates of the R (+) isomer were (%CV): central volume of distribution 1130 (10%) ml, peripheral volume of distribution 626 (25%) ml, and clearance from the central compartment 7.40 (8%) ml·min(-1).",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),[ml] / [min],7.40,104747,DB00328,Indomethacin
,21199130,elimination half-lives,"Typical elimination half-lives were 191 and 33 min, respectively.",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),min,191,104748,DB00328,Indomethacin
,21199130,elimination half-lives,"Typical elimination half-lives were 191 and 33 min, respectively.",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),min,33,104749,DB00328,Indomethacin
,22901775,Clearance,"Clearance in Group IP was higher compared to Groups LP and C (2.11 vs. 1.43 and 1.07 L/h·m(2) respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[h·l] / [m(2],2.11,104935,DB00328,Indomethacin
,22901775,Clearance,"Clearance in Group IP was higher compared to Groups LP and C (2.11 vs. 1.43 and 1.07 L/h·m(2) respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[h·l] / [m(2],1.43,104936,DB00328,Indomethacin
,22901775,Clearance,"Clearance in Group IP was higher compared to Groups LP and C (2.11 vs. 1.43 and 1.07 L/h·m(2) respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[h·l] / [m(2],1.07,104937,DB00328,Indomethacin
,22901775,Volume of distribution,"Volume of distribution was also increased in Group IP compared to Groups LP and C (0.24 vs. 0.16 and 0.17 L/kg respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[l] / [kg],0.24,104938,DB00328,Indomethacin
,22901775,Volume of distribution,"Volume of distribution was also increased in Group IP compared to Groups LP and C (0.24 vs. 0.16 and 0.17 L/kg respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[l] / [kg],0.16,104939,DB00328,Indomethacin
,22901775,Volume of distribution,"Volume of distribution was also increased in Group IP compared to Groups LP and C (0.24 vs. 0.16 and 0.17 L/kg respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[l] / [kg],0.17,104940,DB00328,Indomethacin
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,249,106087,DB00328,Indomethacin
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,950,106088,DB00328,Indomethacin
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,834,106089,DB00328,Indomethacin
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,286,106090,DB00328,Indomethacin
,21380569,V (d),"The predicted V (d) value (21.92 L) is close to the reported value (17.5 L), whereas the CL was predicted by simple allometric approach or with standard correction factors viz., MLP, brain weight, CF1 and CF2.","Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21380569/),l,21.92,106888,DB00328,Indomethacin
,21380569,V (d),"The predicted V (d) value (21.92 L) is close to the reported value (17.5 L), whereas the CL was predicted by simple allometric approach or with standard correction factors viz., MLP, brain weight, CF1 and CF2.","Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21380569/),l,17.5,106889,DB00328,Indomethacin
,26431339,steady-state apparent clearance (CL/Fss) ratio,"In addition, the predicted steady-state apparent clearance (CL/Fss) ratio was almost similar to the observed value (0.46 vs. 0.42).",Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26431339/),,0.46,107006,DB00328,Indomethacin
,26431339,steady-state apparent clearance (CL/Fss) ratio,"In addition, the predicted steady-state apparent clearance (CL/Fss) ratio was almost similar to the observed value (0.46 vs. 0.42).",Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26431339/),,0.42,107007,DB00328,Indomethacin
,30393871,half-life (T1/2 ),"Using this approach, we identified a long half-life (T1/2 ) of 9.78 hr and a volume of distribution (Vss ) of 0.26 L/kg.",Pharmacokinetics of ketorolac in wild Eastern box turtles (Terrapene carolina carolina) after single intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30393871/),h,9.78,108171,DB00328,Indomethacin
,30393871,volume of distribution (Vss ),"Using this approach, we identified a long half-life (T1/2 ) of 9.78 hr and a volume of distribution (Vss ) of 0.26 L/kg.",Pharmacokinetics of ketorolac in wild Eastern box turtles (Terrapene carolina carolina) after single intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30393871/),[l] / [kg],0.26,108172,DB00328,Indomethacin
,6739184,urine output,This phenomenon correlated well with decreased urine output (from 86 +/- 34 ml to 43 +/- 24 per 24 hour) (P less than 0.001) following indomethacin.,Effects of indomethacin on digoxin pharmacokinetics in preterm infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6739184/),ml,86,108613,DB00328,Indomethacin
,6739184,urine output,This phenomenon correlated well with decreased urine output (from 86 +/- 34 ml to 43 +/- 24 per 24 hour) (P less than 0.001) following indomethacin.,Effects of indomethacin on digoxin pharmacokinetics in preterm infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6739184/),1/[24·h],43,108614,DB00328,Indomethacin
,6739184,half-life,Digoxin half-life was significantly prolonged (mean 97 +/- 17 hour) following indomethacin therapy as compared with an age matched control group (mean half-life 43 +/- 19 hour) (P less than 0.05).,Effects of indomethacin on digoxin pharmacokinetics in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6739184/),h,97,108615,DB00328,Indomethacin
,6739184,half-life,Digoxin half-life was significantly prolonged (mean 97 +/- 17 hour) following indomethacin therapy as compared with an age matched control group (mean half-life 43 +/- 19 hour) (P less than 0.05).,Effects of indomethacin on digoxin pharmacokinetics in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6739184/),h,43,108616,DB00328,Indomethacin
,19203570,run time,"Chromatography was performed isocratically with a run time of 8.0 min and the retention time observed for diclofenac and IS was 6.0 and 7.0 min, respectively.",A simple high-performance liquid chromatographic method for the determination of diclofenac in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203570/),min,8.0,108772,DB00328,Indomethacin
,19203570,retention time,"Chromatography was performed isocratically with a run time of 8.0 min and the retention time observed for diclofenac and IS was 6.0 and 7.0 min, respectively.",A simple high-performance liquid chromatographic method for the determination of diclofenac in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203570/),min,6.0,108773,DB00328,Indomethacin
,19203570,retention time,"Chromatography was performed isocratically with a run time of 8.0 min and the retention time observed for diclofenac and IS was 6.0 and 7.0 min, respectively.",A simple high-performance liquid chromatographic method for the determination of diclofenac in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203570/),min,7.0,108774,DB00328,Indomethacin
,19203570,recovery,The mean recovery of diclofenac ranged from 88.76 to 99.14% and the limit of quantification was 50 ng/ml.,A simple high-performance liquid chromatographic method for the determination of diclofenac in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203570/),%,88.76 to 99.14,108775,DB00328,Indomethacin
,16813969,plasma half-life,"The drug has prolonged elimination (plasma half-life = ca 23 hours), suggesting that once daily dosing is appropriate.",Systematic review: intravenous Ibuprofen in preterm newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16813969/),h,23,111519,DB00328,Indomethacin
,9187531,maximum daily dosage,"The maximum daily dosage is 90mg, and the maximum duration of treatment is 48 hours.",Ketorolac for postoperative pain management in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9187531/),,90,112027,DB00328,Indomethacin
,30472732,withdrawal time,The estimated withdrawal time based on the limit of detection was 342 h.,Concentrations of indomethacin and its metabolite desmethylindomethacin in plasma and urine after repeated indomethacin topical application to Thoroughbreds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472732/),h,342,112504,DB00328,Indomethacin
low,24827888,IC50,RGC has demonstrated a strong inhibitory effect on LDL oxidation with IC50 as low as 8.0 μg/ml.,A novel red grape cells complex: health effects and bioavailability of natural resveratrol. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827888/),[μg] / [ml],8.0,114646,DB00328,Indomethacin
,25088343,%,"The %PDA closed by ibuprofen (n=24) and indomethacin (n=24) is 77.7±14.1 and 77.3±11.0, respectively.",Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25088343/),,77.7,115576,DB00328,Indomethacin
,25088343,%,"The %PDA closed by ibuprofen (n=24) and indomethacin (n=24) is 77.7±14.1 and 77.3±11.0, respectively.",Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25088343/),,77.3,115577,DB00328,Indomethacin
,24493205,area under the plasma concentration versus time curve at steady state (AUCss),"The mean area under the plasma concentration versus time curve at steady state (AUCss) was 1.91 ± 0.53 μg·h/mL, mean peak plasma concentration (C max) was 1.02 ± 0.49 μg/mL, and mean time to reach C max (t max) was 1.3 ± 0.7 h.",Pharmacokinetics of indomethacin in pregnancy. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24493205/),[h·μg] / [ml],1.91,115994,DB00328,Indomethacin
,24493205,peak plasma concentration (C max),"The mean area under the plasma concentration versus time curve at steady state (AUCss) was 1.91 ± 0.53 μg·h/mL, mean peak plasma concentration (C max) was 1.02 ± 0.49 μg/mL, and mean time to reach C max (t max) was 1.3 ± 0.7 h.",Pharmacokinetics of indomethacin in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24493205/),[μg] / [ml],1.02,115995,DB00328,Indomethacin
,24493205,time to reach C max (t max),"The mean area under the plasma concentration versus time curve at steady state (AUCss) was 1.91 ± 0.53 μg·h/mL, mean peak plasma concentration (C max) was 1.02 ± 0.49 μg/mL, and mean time to reach C max (t max) was 1.3 ± 0.7 h.",Pharmacokinetics of indomethacin in pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24493205/),h,1.3,115996,DB00328,Indomethacin
,24493205,apparent clearance at steady state,"The mean apparent clearance at steady state was 14.5 ± 5.5 L/h, which is higher than the apparent clearance reported in the literature for non-pregnant subjects.",Pharmacokinetics of indomethacin in pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24493205/),[l] / [h],14.5,115997,DB00328,Indomethacin
,24493205,f,Indomethacin crosses the placenta; the mean fetal/maternal ratio from five sets of cord blood samples collected at delivery was 4.0 ± 1.1.,Pharmacokinetics of indomethacin in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24493205/),,4.0,115998,DB00328,Indomethacin
,9356198,maximal effect,"The maximal effect lasted 12 and 36 h following 10 and 20 mg kg-1 doses, respectively.",Toxicokinetics of indomethacin-induced intestinal permeability in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356198/),h,12,116211,DB00328,Indomethacin
,9356198,maximal effect,"The maximal effect lasted 12 and 36 h following 10 and 20 mg kg-1 doses, respectively.",Toxicokinetics of indomethacin-induced intestinal permeability in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356198/),h,36,116212,DB00328,Indomethacin
,17627676,half-life,"Indomethacin is the principal metabolite of DP-155 in rat serum and, after DP-155 oral administration, the half-life of the metabolite was 22 and 93 h in serum and brain, respectively, compared to 10 and 24 h following indomethacin administration.","DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17627676/),h,22,116561,DB00328,Indomethacin
,17627676,half-life,"Indomethacin is the principal metabolite of DP-155 in rat serum and, after DP-155 oral administration, the half-life of the metabolite was 22 and 93 h in serum and brain, respectively, compared to 10 and 24 h following indomethacin administration.","DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17627676/),h,93,116562,DB00328,Indomethacin
,17627676,half-life,"Indomethacin is the principal metabolite of DP-155 in rat serum and, after DP-155 oral administration, the half-life of the metabolite was 22 and 93 h in serum and brain, respectively, compared to 10 and 24 h following indomethacin administration.","DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17627676/),h,10,116563,DB00328,Indomethacin
,17627676,half-life,"Indomethacin is the principal metabolite of DP-155 in rat serum and, after DP-155 oral administration, the half-life of the metabolite was 22 and 93 h in serum and brain, respectively, compared to 10 and 24 h following indomethacin administration.","DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17627676/),h,24,116564,DB00328,Indomethacin
,1658024,detection limit,The detection limit of both compounds was 0.1 microgram/ml in rat plasma.,High-performance liquid chromatographic determination of 18 alpha-glycyrrhetinic acid and 18 beta-glycyrrhetinic acid in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1658024/),[μg] / [ml],0.1,116830,DB00328,Indomethacin
,8529330,total body clearance,"The total body clearance, volume of distribution, and elimination serum half-life of ceftazidime (mean +/- SD) were 55.7 +/- 34.4 ml/hr (37.3 +/- 11.9 ml/hr/kg), 496 +/- 228 ml (350 +/- 96 ml/kg), and 6.95 +/- 2.32 hours, respectively.",Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529330/),[ml] / [h],55.7,117697,DB00328,Indomethacin
,8529330,volume of distribution,"The total body clearance, volume of distribution, and elimination serum half-life of ceftazidime (mean +/- SD) were 55.7 +/- 34.4 ml/hr (37.3 +/- 11.9 ml/hr/kg), 496 +/- 228 ml (350 +/- 96 ml/kg), and 6.95 +/- 2.32 hours, respectively.",Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529330/),[ml] / [h·kg],37.3,117698,DB00328,Indomethacin
,8529330,volume of distribution,"The total body clearance, volume of distribution, and elimination serum half-life of ceftazidime (mean +/- SD) were 55.7 +/- 34.4 ml/hr (37.3 +/- 11.9 ml/hr/kg), 496 +/- 228 ml (350 +/- 96 ml/kg), and 6.95 +/- 2.32 hours, respectively.",Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529330/),ml,496,117699,DB00328,Indomethacin
,8529330,elimination serum half-life,"The total body clearance, volume of distribution, and elimination serum half-life of ceftazidime (mean +/- SD) were 55.7 +/- 34.4 ml/hr (37.3 +/- 11.9 ml/hr/kg), 496 +/- 228 ml (350 +/- 96 ml/kg), and 6.95 +/- 2.32 hours, respectively.",Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529330/),[ml] / [kg],350,117700,DB00328,Indomethacin
,8529330,elimination serum half-life,"The total body clearance, volume of distribution, and elimination serum half-life of ceftazidime (mean +/- SD) were 55.7 +/- 34.4 ml/hr (37.3 +/- 11.9 ml/hr/kg), 496 +/- 228 ml (350 +/- 96 ml/kg), and 6.95 +/- 2.32 hours, respectively.",Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529330/),h,6.95,117701,DB00328,Indomethacin
,8529330,peak,The mean +/- SD peak and trough levels were 114.9 +/- 39.4 and 33.9 +/- 17.8 mg/L.,Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529330/),[mg] / [l],114.9,117702,DB00328,Indomethacin
,8529330,trough levels,The mean +/- SD peak and trough levels were 114.9 +/- 39.4 and 33.9 +/- 17.8 mg/L.,Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529330/),[mg] / [l],33.9,117703,DB00328,Indomethacin
above,8529330,serum trough level,All infants had a serum trough level above 5 mg/L.,Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529330/),[mg] / [l],5,117704,DB00328,Indomethacin
,2658392,lesions score,In the corresponding acemetacin-series the lesions score was 1.6 +/- 0.1 (+/- SEM).,"[Ranitidine ameliorates acemetacin and indomethacin-induced changes of the gastroduodenal mucosa, without modifying the pharmacokinetic behavior of both antirheumatic drugs]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658392/),,1.6,118178,DB00328,Indomethacin
,4090993,bioavailability,"The bioavailability after the two rectal forms was found to be almost the same, about 80%.",Bioavailability of indomethacin after intramuscular injection and rectal administration of solution and suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090993/),%,80,118448,DB00328,Indomethacin
,25523103,end tidal isoflurane concentration,"During surgery, mean end tidal isoflurane concentration was 1.63 (SD 0.24)% and normocapnia and spontaneous ventilation were maintained in all animals.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),%,1.63,119249,DB00328,Indomethacin
,25523103,distribution,"The distribution and elimination half-lives were 0.09 (SD 0.06) and 4.14 (SD 1.18) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),h,0.09,119250,DB00328,Indomethacin
,25523103,elimination half-lives,"The distribution and elimination half-lives were 0.09 (SD 0.06) and 4.14 (SD 1.18) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),h,4.14,119251,DB00328,Indomethacin
,25523103,body clearance,The body clearance was 56.8 (SD 33.1) mL/h/kg.,Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),[ml] / [h·kg],56.8,119252,DB00328,Indomethacin
,25523103,volume of distribution at steady-state,"The volume of distribution at steady-state and the mean residence time were 323.9 (SD 115.7) mL/kg and 6.47 (SD 2.86) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),[ml] / [kg],323.9,119253,DB00328,Indomethacin
,25523103,mean residence time,"The volume of distribution at steady-state and the mean residence time were 323.9 (SD 115.7) mL/kg and 6.47 (SD 2.86) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),h,6.47,119254,DB00328,Indomethacin
,16390350,volume of distribution (V),The population parameter estimate for volume of distribution (V) was 40.2 l per 70 kg.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·kg],40.2,120128,DB00328,Indomethacin
,16390350,Clearance (CL),Clearance (CL) increased from 0.486 l h(-1) per 70 kg at 24 weeks PCA to 0.940 l h(-1) per 70 kg by 30 weeks PCA.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·h·kg],0.486,120129,DB00328,Indomethacin
,16390350,Clearance (CL),Clearance (CL) increased from 0.486 l h(-1) per 70 kg at 24 weeks PCA to 0.940 l h(-1) per 70 kg by 30 weeks PCA.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·h·kg],0.940,120130,DB00328,Indomethacin
,15327584,clearance (CL),"The final population parameter estimates of clearance (CL) and volume of distribution (V) (standardized to the median weight of 1.17 kg) were 0.00711 l h(-1) and 0.266 l, respectively.",Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15327584/),[l] / [h],0.00711,120459,DB00328,Indomethacin
,15327584,volume of distribution (V),"The final population parameter estimates of clearance (CL) and volume of distribution (V) (standardized to the median weight of 1.17 kg) were 0.00711 l h(-1) and 0.266 l, respectively.",Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15327584/),l,0.266,120460,DB00328,Indomethacin
>,15327584,24 h plasma concentration,The population estimates can be used to determine typical values of CL and V allowing the prediction of individualized doses of indometacin that should increase the probability of achieving a 24 h plasma concentration > or = 0.4 mg l(-1).,Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15327584/),[mg] / [l],0.4,120461,DB00328,Indomethacin
,1712269,terminal half-life,"In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.",Clinical pharmacology of cilazapril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712269/),h,30 to 50,120675,DB00328,Indomethacin
,2591467,renal clearance,High dose diflunisal (1500 mg/day) decreased the renal clearance of indomethacin from 21.9 to 1.8 ml/min (92%) and reduced the renal excretion of both unchanged (63%) and conjugated (82%) indomethacin.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[ml] / [min],21.9,121315,DB00328,Indomethacin
,2591467,renal clearance,High dose diflunisal (1500 mg/day) decreased the renal clearance of indomethacin from 21.9 to 1.8 ml/min (92%) and reduced the renal excretion of both unchanged (63%) and conjugated (82%) indomethacin.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[ml] / [min],1.8,121316,DB00328,Indomethacin
,2591467,apparent total body clearance,"The apparent total body clearance (0.12 l/h/kg), apparent volume of distribution (0.98 l/kg), and volume of distribution at steady state (0.80 l/kg) were decreased by 47%, 35% and 30%.","Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[l] / [h·kg],0.12,121317,DB00328,Indomethacin
,2591467,apparent volume of distribution,"The apparent total body clearance (0.12 l/h/kg), apparent volume of distribution (0.98 l/kg), and volume of distribution at steady state (0.80 l/kg) were decreased by 47%, 35% and 30%.","Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[l] / [kg],0.98,121318,DB00328,Indomethacin
,2591467,volume of distribution at steady state,"The apparent total body clearance (0.12 l/h/kg), apparent volume of distribution (0.98 l/kg), and volume of distribution at steady state (0.80 l/kg) were decreased by 47%, 35% and 30%.","Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[l] / [kg],0.80,121319,DB00328,Indomethacin
,2591467,maximum plasma concentration,"The maximum plasma concentration (2.4 micrograms/ml) and total area under the curve (13.0 micrograms x h/ml) were increased by 40% and 119%, respectively.","Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[μg] / [ml],2.4,121320,DB00328,Indomethacin
,2591467,total area under the curve,"The maximum plasma concentration (2.4 micrograms/ml) and total area under the curve (13.0 micrograms x h/ml) were increased by 40% and 119%, respectively.","Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[h·μg] / [ml],13.0,121321,DB00328,Indomethacin
,2591467,terminal elimination half-life,The terminal elimination half-life (5.7 h) and mean residence time (6.7 h) were slightly prolonged (7.0 h and 8.8 h) in the presence of diflunisal.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),h,5.7,121322,DB00328,Indomethacin
,2591467,mean residence time,The terminal elimination half-life (5.7 h) and mean residence time (6.7 h) were slightly prolonged (7.0 h and 8.8 h) in the presence of diflunisal.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),h,6.7,121323,DB00328,Indomethacin
,2591467,mean residence time,The terminal elimination half-life (5.7 h) and mean residence time (6.7 h) were slightly prolonged (7.0 h and 8.8 h) in the presence of diflunisal.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),h,7.0,121324,DB00328,Indomethacin
,2591467,mean residence time,The terminal elimination half-life (5.7 h) and mean residence time (6.7 h) were slightly prolonged (7.0 h and 8.8 h) in the presence of diflunisal.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),h,8.8,121325,DB00328,Indomethacin
,17973935,clearance,"3. The systemic kinetics of indomethacin could be described by a two-compartment model, with small distribution volumes and a clearance of 0.68 L/min.",Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),[l] / [min],0.68,121513,DB00328,Indomethacin
,17973935,cerebral distribution volume,"The cerebral kinetics of indomethacin could be described using a model with a cerebral distribution volume between 5 and 8 mL and a loss term of 3.3 mL/min, the latter probably representing slow diffusion across the blood-brain barrier.",Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),ml,5 and 8,121514,DB00328,Indomethacin
,17973935,loss term,"The cerebral kinetics of indomethacin could be described using a model with a cerebral distribution volume between 5 and 8 mL and a loss term of 3.3 mL/min, the latter probably representing slow diffusion across the blood-brain barrier.",Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),[ml] / [min],3.3,121515,DB00328,Indomethacin
,17973935,turnover times,Indirect response models with turnover times of 1.70-4.08 min were generally better able to describe the effect of indomethacin on CBF than effect compartment models.,Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),min,1.70-4.08,121516,DB00328,Indomethacin
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],527.00,122561,DB00328,Indomethacin
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],269. 45,122562,DB00328,Indomethacin
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],258.65,122563,DB00328,Indomethacin
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],243.22,122564,DB00328,Indomethacin
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],88.09,122565,DB00328,Indomethacin
,10481615,bioavailability,Plasma concentrations barely rose to the lower therapeutic margin and mean bioavailability was 38.25 +/- 15.98%.,Pharmacokinetics of indomethacin after intraruminal administration to sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10481615/),%,38.25,123540,DB00328,Indomethacin
,10481615,beta,The elimination phase was slow (beta = 0.015 +/- 0.010 h-1) and the half-life was long (t1/2 beta = 56.52 +/- 31.21 h).,Pharmacokinetics of indomethacin after intraruminal administration to sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10481615/),1/[h],0.015,123541,DB00328,Indomethacin
,10481615,t1/2 beta,The elimination phase was slow (beta = 0.015 +/- 0.010 h-1) and the half-life was long (t1/2 beta = 56.52 +/- 31.21 h).,Pharmacokinetics of indomethacin after intraruminal administration to sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10481615/),h,56.52,123542,DB00328,Indomethacin
,10481615,mean residence time,The mean residence time was 20.01 +/- 6.92 h.,Pharmacokinetics of indomethacin after intraruminal administration to sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10481615/),h,20.01,123543,DB00328,Indomethacin
,3816544,total amount,The mean total amount of indomethacin removed by five hours of hemodialysis was 19.6 percent of the single dose of indomethacin 100 mg po.,Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816544/),%,19.6,124405,DB00328,Indomethacin
,3816544,Cpmax,"However, mean Cpmax, tmax, t1/2, and AUC0-infinity during and in the absence of hemodialysis were 5.4 and 5.4 micrograms/ml (not statistically significant [NS]), 1.9 and 2.0 h (NS), 6.1 and 5.3 h (NS), and 30.9 and 35.7 micrograms h ml-1 (NS), respectively.",Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816544/),[μg] / [ml],5.4,124406,DB00328,Indomethacin
,3816544,tmax,"However, mean Cpmax, tmax, t1/2, and AUC0-infinity during and in the absence of hemodialysis were 5.4 and 5.4 micrograms/ml (not statistically significant [NS]), 1.9 and 2.0 h (NS), 6.1 and 5.3 h (NS), and 30.9 and 35.7 micrograms h ml-1 (NS), respectively.",Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816544/),h,1.9,124407,DB00328,Indomethacin
,3816544,tmax,"However, mean Cpmax, tmax, t1/2, and AUC0-infinity during and in the absence of hemodialysis were 5.4 and 5.4 micrograms/ml (not statistically significant [NS]), 1.9 and 2.0 h (NS), 6.1 and 5.3 h (NS), and 30.9 and 35.7 micrograms h ml-1 (NS), respectively.",Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816544/),h,6.1,124408,DB00328,Indomethacin
,3816544,t1/2,"However, mean Cpmax, tmax, t1/2, and AUC0-infinity during and in the absence of hemodialysis were 5.4 and 5.4 micrograms/ml (not statistically significant [NS]), 1.9 and 2.0 h (NS), 6.1 and 5.3 h (NS), and 30.9 and 35.7 micrograms h ml-1 (NS), respectively.",Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816544/),h,1.9,124409,DB00328,Indomethacin
,3816544,t1/2,"However, mean Cpmax, tmax, t1/2, and AUC0-infinity during and in the absence of hemodialysis were 5.4 and 5.4 micrograms/ml (not statistically significant [NS]), 1.9 and 2.0 h (NS), 6.1 and 5.3 h (NS), and 30.9 and 35.7 micrograms h ml-1 (NS), respectively.",Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816544/),h,6.1,124410,DB00328,Indomethacin
,3816544,AUC0-infinity,"However, mean Cpmax, tmax, t1/2, and AUC0-infinity during and in the absence of hemodialysis were 5.4 and 5.4 micrograms/ml (not statistically significant [NS]), 1.9 and 2.0 h (NS), 6.1 and 5.3 h (NS), and 30.9 and 35.7 micrograms h ml-1 (NS), respectively.",Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816544/),h,5.3,124411,DB00328,Indomethacin
,3816544,AUC0-infinity,"However, mean Cpmax, tmax, t1/2, and AUC0-infinity during and in the absence of hemodialysis were 5.4 and 5.4 micrograms/ml (not statistically significant [NS]), 1.9 and 2.0 h (NS), 6.1 and 5.3 h (NS), and 30.9 and 35.7 micrograms h ml-1 (NS), respectively.",Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816544/),[h·μg] / [ml],30.9,124412,DB00328,Indomethacin
,3816544,AUC0-infinity,"However, mean Cpmax, tmax, t1/2, and AUC0-infinity during and in the absence of hemodialysis were 5.4 and 5.4 micrograms/ml (not statistically significant [NS]), 1.9 and 2.0 h (NS), 6.1 and 5.3 h (NS), and 30.9 and 35.7 micrograms h ml-1 (NS), respectively.",Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816544/),[h·μg] / [ml],35.7,124413,DB00328,Indomethacin
,17240100,recovery,The recovery of repaglinide was 92%+/-55.31.,Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),%,92,125550,DB00328,Indomethacin
,17240100,flow rate,The flow rate was 1 ml/min.,Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),[ml] / [min],1,125551,DB00328,Indomethacin
,17240100,retention time,"The retention time for repaglinide and indomethacin were approximately 6.2 and 5.3 min, respectively.",Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),min,6.2,125552,DB00328,Indomethacin
,17240100,retention time,"The retention time for repaglinide and indomethacin were approximately 6.2 and 5.3 min, respectively.",Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),min,5.3,125553,DB00328,Indomethacin
,17240100,limits of detection,"The limits of detection and quantification were 10 ng/ml and 20 ng/ml, respectively.",Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),[ng] / [ml],10,125554,DB00328,Indomethacin
,17240100,limits of detection,"The limits of detection and quantification were 10 ng/ml and 20 ng/ml, respectively.",Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),[ng] / [ml],20,125555,DB00328,Indomethacin
,14604305,peak plasma concentrations (Cmax,"Large interindividual variability was observed for peak plasma concentrations (Cmax; 137.9 +/- 14.0 ng/ml), elimination half-life (t1/2 el; 21.4 +/- 1.7 h) and area under the plasma concentrations time curve (AUC0-infinity;4172 +/- 303 ng.h/ml) in these infants.",A preliminary study on pharmacokinetics of oral indomethacin in premature infants in north India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14604305/),[ng] / [ml],137.9,126724,DB00328,Indomethacin
,14604305,elimination half-life (t1/2 el,"Large interindividual variability was observed for peak plasma concentrations (Cmax; 137.9 +/- 14.0 ng/ml), elimination half-life (t1/2 el; 21.4 +/- 1.7 h) and area under the plasma concentrations time curve (AUC0-infinity;4172 +/- 303 ng.h/ml) in these infants.",A preliminary study on pharmacokinetics of oral indomethacin in premature infants in north India. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14604305/),h,21.4,126725,DB00328,Indomethacin
,14604305,area under the plasma concentrations time curve (AUC0-infinity,"Large interindividual variability was observed for peak plasma concentrations (Cmax; 137.9 +/- 14.0 ng/ml), elimination half-life (t1/2 el; 21.4 +/- 1.7 h) and area under the plasma concentrations time curve (AUC0-infinity;4172 +/- 303 ng.h/ml) in these infants.",A preliminary study on pharmacokinetics of oral indomethacin in premature infants in north India. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14604305/),[h·ng] / [ml],4172,126726,DB00328,Indomethacin
,32238050,Ki,"In human CYP2C9 isoform, the Ki value of 21.93 μM (CYP2C9*1), 18.10 μM (CYP2C9*2), 13.12 μM (CYP2C9*3) indicate that there are individual differences in the inhibition of osthole on CYP2C9 activity.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),μM,21.93,127139,DB00328,Indomethacin
,32238050,Ki,"In human CYP2C9 isoform, the Ki value of 21.93 μM (CYP2C9*1), 18.10 μM (CYP2C9*2), 13.12 μM (CYP2C9*3) indicate that there are individual differences in the inhibition of osthole on CYP2C9 activity.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),μM,18.10,127140,DB00328,Indomethacin
,32238050,Ki,"In human CYP2C9 isoform, the Ki value of 21.93 μM (CYP2C9*1), 18.10 μM (CYP2C9*2), 13.12 μM (CYP2C9*3) indicate that there are individual differences in the inhibition of osthole on CYP2C9 activity.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),μM,13.12,127141,DB00328,Indomethacin
,32238050,AUC0-∞,"We found the value of PK on indomethacin, such as the AUC0-∞, was from 176.40 ± 17.29 to 173.74 ± 27.69 μg/ml h-1, Cmax from 9.02 ± 1.24 to 9.89 ± 0.82 μg/ml and CL/F from 0.11 ± 0.01 to 0.12 ± 0.04 mg/kg/h which were unsignificantly changed compared with the control groups.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),[μg] / [h·ml],176.40,127142,DB00328,Indomethacin
,32238050,AUC0-∞,"We found the value of PK on indomethacin, such as the AUC0-∞, was from 176.40 ± 17.29 to 173.74 ± 27.69 μg/ml h-1, Cmax from 9.02 ± 1.24 to 9.89 ± 0.82 μg/ml and CL/F from 0.11 ± 0.01 to 0.12 ± 0.04 mg/kg/h which were unsignificantly changed compared with the control groups.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),[μg] / [h·ml],173.74,127143,DB00328,Indomethacin
,32238050,Cmax,"We found the value of PK on indomethacin, such as the AUC0-∞, was from 176.40 ± 17.29 to 173.74 ± 27.69 μg/ml h-1, Cmax from 9.02 ± 1.24 to 9.89 ± 0.82 μg/ml and CL/F from 0.11 ± 0.01 to 0.12 ± 0.04 mg/kg/h which were unsignificantly changed compared with the control groups.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),[μg] / [ml],9.02,127144,DB00328,Indomethacin
,32238050,Cmax,"We found the value of PK on indomethacin, such as the AUC0-∞, was from 176.40 ± 17.29 to 173.74 ± 27.69 μg/ml h-1, Cmax from 9.02 ± 1.24 to 9.89 ± 0.82 μg/ml and CL/F from 0.11 ± 0.01 to 0.12 ± 0.04 mg/kg/h which were unsignificantly changed compared with the control groups.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),[μg] / [ml],9.89,127145,DB00328,Indomethacin
,32238050,CL/F,"We found the value of PK on indomethacin, such as the AUC0-∞, was from 176.40 ± 17.29 to 173.74 ± 27.69 μg/ml h-1, Cmax from 9.02 ± 1.24 to 9.89 ± 0.82 μg/ml and CL/F from 0.11 ± 0.01 to 0.12 ± 0.04 mg/kg/h which were unsignificantly changed compared with the control groups.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),[mg] / [h·kg],0.11,127146,DB00328,Indomethacin
,32238050,CL/F,"We found the value of PK on indomethacin, such as the AUC0-∞, was from 176.40 ± 17.29 to 173.74 ± 27.69 μg/ml h-1, Cmax from 9.02 ± 1.24 to 9.89 ± 0.82 μg/ml and CL/F from 0.11 ± 0.01 to 0.12 ± 0.04 mg/kg/h which were unsignificantly changed compared with the control groups.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),[mg] / [h·kg],0.12,127147,DB00328,Indomethacin
,32238050,Tmax,"However, the Tmax was prolonged from 2.00 ± 0.00 h to 7.33 ± 1.15 h, and T1/2 increased from 8.38 ± 2.30 h to 11.37 ± 2.11 h.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),h,2.00,127148,DB00328,Indomethacin
,32238050,Tmax,"However, the Tmax was prolonged from 2.00 ± 0.00 h to 7.33 ± 1.15 h, and T1/2 increased from 8.38 ± 2.30 h to 11.37 ± 2.11 h.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),h,7.33,127149,DB00328,Indomethacin
,32238050,T1/2,"However, the Tmax was prolonged from 2.00 ± 0.00 h to 7.33 ± 1.15 h, and T1/2 increased from 8.38 ± 2.30 h to 11.37 ± 2.11 h.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),h,8.38,127150,DB00328,Indomethacin
,32238050,T1/2,"However, the Tmax was prolonged from 2.00 ± 0.00 h to 7.33 ± 1.15 h, and T1/2 increased from 8.38 ± 2.30 h to 11.37 ± 2.11 h.",Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238050/),h,11.37,127151,DB00328,Indomethacin
greater,8135994,bioavailability,Ketorolac applied in this way had a bioavailability greater than 80%.,Nasal formulations of ketorolac tromethamine: technological evaluation--bioavailability and tolerability in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135994/),%,80,132170,DB00328,Indomethacin
,28579209,peak,"Gentamicin peak (5-12 µg/mL) and trough (<2 µg/mL) levels were compared to those in a historical control group of 39 infants who received traditional-interval dosing (TID) of 2.5 mg/kg of gentamicin with dosing intervals of 8, 12, or 24 hours.",Extended-interval Dosing of Gentamicin in Premature Neonates Born at <32 Weeks' Gestation and >7 Days of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28579209/),[μg] / [ml],5-12,132636,DB00328,Indomethacin
<,28579209,trough,"Gentamicin peak (5-12 µg/mL) and trough (<2 µg/mL) levels were compared to those in a historical control group of 39 infants who received traditional-interval dosing (TID) of 2.5 mg/kg of gentamicin with dosing intervals of 8, 12, or 24 hours.",Extended-interval Dosing of Gentamicin in Premature Neonates Born at <32 Weeks' Gestation and >7 Days of age. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28579209/),[μg] / [ml],2,132637,DB00328,Indomethacin
,28579209,peak level,"Compared with the TID group (n = 39), the EID group had a significantly higher peak level (median, 9.0 vs 4.7 µg/mL) and a significantly lower trough level (median, 0.7 vs 1.1 µg/mL) (both, P < 0.001).",Extended-interval Dosing of Gentamicin in Premature Neonates Born at <32 Weeks' Gestation and >7 Days of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28579209/),[μg] / [ml],9.0,132638,DB00328,Indomethacin
,28579209,peak level,"Compared with the TID group (n = 39), the EID group had a significantly higher peak level (median, 9.0 vs 4.7 µg/mL) and a significantly lower trough level (median, 0.7 vs 1.1 µg/mL) (both, P < 0.001).",Extended-interval Dosing of Gentamicin in Premature Neonates Born at <32 Weeks' Gestation and >7 Days of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28579209/),[μg] / [ml],4.7,132639,DB00328,Indomethacin
,28579209,trough level,"Compared with the TID group (n = 39), the EID group had a significantly higher peak level (median, 9.0 vs 4.7 µg/mL) and a significantly lower trough level (median, 0.7 vs 1.1 µg/mL) (both, P < 0.001).",Extended-interval Dosing of Gentamicin in Premature Neonates Born at <32 Weeks' Gestation and >7 Days of age. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28579209/),[μg] / [ml],0.7,132640,DB00328,Indomethacin
,28579209,trough level,"Compared with the TID group (n = 39), the EID group had a significantly higher peak level (median, 9.0 vs 4.7 µg/mL) and a significantly lower trough level (median, 0.7 vs 1.1 µg/mL) (both, P < 0.001).",Extended-interval Dosing of Gentamicin in Premature Neonates Born at <32 Weeks' Gestation and >7 Days of age. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28579209/),[μg] / [ml],1.1,132641,DB00328,Indomethacin
,2057990,volume of distribution,"Pre- and post-PDA closure, only INDO volume of distribution differed significantly (p less than 0.001) with mean values of 0.36 (+/- 0.06) L/kg and 0.26 (+/- 0.08) L/kg.",Indomethacin pharmacokinetics in neonates: the value of volume of distribution as a marker of permanent patent ductus arteriosus closure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057990/),[l] / [kg],0.36,134083,DB00328,Indomethacin
,2057990,volume of distribution,"Pre- and post-PDA closure, only INDO volume of distribution differed significantly (p less than 0.001) with mean values of 0.36 (+/- 0.06) L/kg and 0.26 (+/- 0.08) L/kg.",Indomethacin pharmacokinetics in neonates: the value of volume of distribution as a marker of permanent patent ductus arteriosus closure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057990/),[l] / [kg],0.26,134084,DB00328,Indomethacin
,11753268,Total body clearance,"Total body clearance, apparent volume of distribution, and plasma half-life of midazolam were (median [range]): 1.8 (0.7-6.7) ml/kg per min, 1.1 (0.4-4.2) L/kg, and 6.3 (2.6-17.7) h, respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),[ml] / [kg·min],1.8,134244,DB00328,Indomethacin
,11753268,apparent volume of distribution,"Total body clearance, apparent volume of distribution, and plasma half-life of midazolam were (median [range]): 1.8 (0.7-6.7) ml/kg per min, 1.1 (0.4-4.2) L/kg, and 6.3 (2.6-17.7) h, respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),[l] / [kg],1.1,134245,DB00328,Indomethacin
,11753268,plasma half-life,"Total body clearance, apparent volume of distribution, and plasma half-life of midazolam were (median [range]): 1.8 (0.7-6.7) ml/kg per min, 1.1 (0.4-4.2) L/kg, and 6.3 (2.6-17.7) h, respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),h,6.3,134246,DB00328,Indomethacin
,11753268,maximal concentration of drug in plasma (C(max)),"In 19 of 24 preterm infants, 1-OH-midazolam concentrations could be detected: 1-OH-midazolam (1-OH-M) maximal concentration of drug in plasma (C(max)), time to reach C(max) (T(max)), and 1-OH-M/M area under the concentration-time curve from time zero to the last sampling time point (AUC(0-t)) ratio were [median (range)]: 8.2 (<0.5-68.2) ng/ml, 6 (1-12) h, and 0.09 (<0.001-1), respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),[ng] / [ml],8.2,134247,DB00328,Indomethacin
,11753268,time to reach C(max) (T(max)),"In 19 of 24 preterm infants, 1-OH-midazolam concentrations could be detected: 1-OH-midazolam (1-OH-M) maximal concentration of drug in plasma (C(max)), time to reach C(max) (T(max)), and 1-OH-M/M area under the concentration-time curve from time zero to the last sampling time point (AUC(0-t)) ratio were [median (range)]: 8.2 (<0.5-68.2) ng/ml, 6 (1-12) h, and 0.09 (<0.001-1), respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),h,6,134248,DB00328,Indomethacin
,11753268,area under the concentration-time curve from time zero to the last sampling time point (AUC(0-t)),"In 19 of 24 preterm infants, 1-OH-midazolam concentrations could be detected: 1-OH-midazolam (1-OH-M) maximal concentration of drug in plasma (C(max)), time to reach C(max) (T(max)), and 1-OH-M/M area under the concentration-time curve from time zero to the last sampling time point (AUC(0-t)) ratio were [median (range)]: 8.2 (<0.5-68.2) ng/ml, 6 (1-12) h, and 0.09 (<0.001-1), respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),,0.09,134249,DB00328,Indomethacin
,7173304,tmax,"The slow-release tablet was absorbed more slowly than the capsule (tmax 3.7 h and less than 2 h, respectively) and produced more even serum drug levels in 10 subjects.",Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173304/),h,3.7,134984,DB00328,Indomethacin
,7173304,tmax,"The slow-release tablet was absorbed more slowly than the capsule (tmax 3.7 h and less than 2 h, respectively) and produced more even serum drug levels in 10 subjects.",Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173304/),h,less,134985,DB00328,Indomethacin
,7173304,tmax,"The slow-release tablet was absorbed more slowly than the capsule (tmax 3.7 h and less than 2 h, respectively) and produced more even serum drug levels in 10 subjects.",Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173304/),h,2,134986,DB00328,Indomethacin
,1807089,Minimal detectable concentration,Minimal detectable concentration of serum piroxicam by using HPLC reported in literature was mostly around 50 ng.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,50,135527,DB00328,Indomethacin
,1807089,detection limit,"A new HPLC method providing a detection limit of 0.75 ng, sensitive enough to quantify low concentrations of serum piroxicam down to 5 ng.",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,0.75,135528,DB00328,Indomethacin
,1807089,flow rate,A mixture of methanol and ammonium acetate 0.1 mol.L-1 (1:0.9 vol.vol-1) was selected as mobile phase with a flow rate of 1 ml.min-1. 0.025% tetramethyl ethylene diamine was added to ammonium acetate solution and adjusted to pH 4.5 with citric acid before mixing.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ml] / [min],1,135529,DB00328,Indomethacin
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),%,96.0-102.4,135530,DB00328,Indomethacin
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ng] / [ml],"10-5,000",135531,DB00328,Indomethacin
less,3552584,Volume of distribution,Volume of distribution is mostly low (less than 0.2 L/kg) and protein binding is high (usually 95 to 99%).,Non-steroidal anti-inflammatory analgesics other than salicylates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),[l] / [kg],0.2,136228,DB00328,Indomethacin
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,2 to 5,136229,DB00328,Indomethacin
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,20,136230,DB00328,Indomethacin
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,10,136231,DB00328,Indomethacin
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,12-15,136232,DB00328,Indomethacin
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,16,136233,DB00328,Indomethacin
,3552584,half-life,"Piroxicam has the longest half-life, averaging 45 hours.",Non-steroidal anti-inflammatory analgesics other than salicylates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,45,136234,DB00328,Indomethacin
,16326151,absolute recovery,The absolute recovery of IND over this range was 93.0-113.3%.,A rapid and sensitive microscale HPLC method for the determination of indomethacin in plasma of premature neonates with patent ductus arteriousus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326151/),%,93.0-113.3,138530,DB00328,Indomethacin
,3599650,Fractional chloride delivery,Fractional chloride delivery to early distal tubules was 10.8 +/- 0.4% in control but 6.2 +/- 0.3% in indomethacin rats (P less than 0.001).,Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,10.8,140138,DB00328,Indomethacin
,3599650,Fractional chloride delivery,Fractional chloride delivery to early distal tubules was 10.8 +/- 0.4% in control but 6.2 +/- 0.3% in indomethacin rats (P less than 0.001).,Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,6.2,140139,DB00328,Indomethacin
,3599650,reabsorption,Calculated loop chloride reabsorption was greater in indomethacin than control rats during hydrochlorothiazide administration (41.0 +/- 1.6% vs. 34.3 +/- 2.3%; P less than 0.05).,Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,41.0,140140,DB00328,Indomethacin
,3599650,reabsorption,Calculated loop chloride reabsorption was greater in indomethacin than control rats during hydrochlorothiazide administration (41.0 +/- 1.6% vs. 34.3 +/- 2.3%; P less than 0.05).,Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,34.3,140141,DB00328,Indomethacin
,3599650,Fractional chloride delivery,"Fractional chloride delivery to late distal tubules was 7.8 +/- 0.7% in control and 4.6 +/- 0.3% in indomethacin rats (P less than 0.005), but distal tubule chloride reabsorption was not different between groups.",Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,7.8,140142,DB00328,Indomethacin
,3599650,Fractional chloride delivery,"Fractional chloride delivery to late distal tubules was 7.8 +/- 0.7% in control and 4.6 +/- 0.3% in indomethacin rats (P less than 0.005), but distal tubule chloride reabsorption was not different between groups.",Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599650/),%,4.6,140143,DB00328,Indomethacin
,2303585,half-life,"The elimination of ketorolac was decreased slightly in the elderly following both doses, as evidenced by a prolongation in half-life (4.7 to 6.1 hours for PO and 4.5 to 7.0 hours for IM) and a reduced total plasma clearance compared to the young adult subjects.",Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303585/),h,4.7 to 6.1,141658,DB00328,Indomethacin
,2303585,half-life,"The elimination of ketorolac was decreased slightly in the elderly following both doses, as evidenced by a prolongation in half-life (4.7 to 6.1 hours for PO and 4.5 to 7.0 hours for IM) and a reduced total plasma clearance compared to the young adult subjects.",Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303585/),h,4.5 to 7.0,141659,DB00328,Indomethacin
,21945452,m/z,"The multi-reaction monitoring mode is selected and the ion selected channels are set at m/z: 283.1→238.9 for rhein ([M-H](-)→[M-CO(2)-H](-)) and m/z: 356.2→312.0 for indomethacin ([M-H](-)→[M-CO(2)-H](-)), respectively.",Quantitative determination of rhein in human plasma by liquid chromatography-negative electrospray ionization tandem mass/mass spectrometry and the application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21945452/),,283.1,141792,DB00328,Indomethacin
,21945452,m/z,"The multi-reaction monitoring mode is selected and the ion selected channels are set at m/z: 283.1→238.9 for rhein ([M-H](-)→[M-CO(2)-H](-)) and m/z: 356.2→312.0 for indomethacin ([M-H](-)→[M-CO(2)-H](-)), respectively.",Quantitative determination of rhein in human plasma by liquid chromatography-negative electrospray ionization tandem mass/mass spectrometry and the application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21945452/),,238.9,141793,DB00328,Indomethacin
,21945452,m/z,"The multi-reaction monitoring mode is selected and the ion selected channels are set at m/z: 283.1→238.9 for rhein ([M-H](-)→[M-CO(2)-H](-)) and m/z: 356.2→312.0 for indomethacin ([M-H](-)→[M-CO(2)-H](-)), respectively.",Quantitative determination of rhein in human plasma by liquid chromatography-negative electrospray ionization tandem mass/mass spectrometry and the application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21945452/),,356.2,141794,DB00328,Indomethacin
,21945452,m/z,"The multi-reaction monitoring mode is selected and the ion selected channels are set at m/z: 283.1→238.9 for rhein ([M-H](-)→[M-CO(2)-H](-)) and m/z: 356.2→312.0 for indomethacin ([M-H](-)→[M-CO(2)-H](-)), respectively.",Quantitative determination of rhein in human plasma by liquid chromatography-negative electrospray ionization tandem mass/mass spectrometry and the application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21945452/),,312.0,141795,DB00328,Indomethacin
,1498265,elimination half-life (t1/2 beta),The elimination half-life (t1/2 beta) calculated during the washout interval (mean +/- SD) was 47 x 4 +/- 21 x 5 min which is close to that calculated in a reference group of rabbits.,Effect of indomethacin on the pharmacokinetics of methotrexate in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1498265/),min,47 x 4,142272,DB00328,Indomethacin
,8998561,minimum quantifiable concentration,"The minimum quantifiable concentration of the assay was found to be 0.025 or 0.25 microgram/ml based on 1 ml of human or 0.1 ml of rat plasma samples, respectively.","Rapid, sensitive and direct chiral high-performance liquid chromatographic method for ketoprofen enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8998561/),[μg] / [ml],0.025,142501,DB00328,Indomethacin
,8998561,minimum quantifiable concentration,"The minimum quantifiable concentration of the assay was found to be 0.025 or 0.25 microgram/ml based on 1 ml of human or 0.1 ml of rat plasma samples, respectively.","Rapid, sensitive and direct chiral high-performance liquid chromatographic method for ketoprofen enantiomers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8998561/),[μg] / [ml],0.25,142502,DB00328,Indomethacin
,7952121,run time,Detection was at 325 nm and run time was 10 min.,Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,10,142547,DB00328,Indomethacin
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,3.3,142548,DB00328,Indomethacin
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,4.8,142549,DB00328,Indomethacin
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,6.4,142550,DB00328,Indomethacin
,7952121,retention time,The metabolite p-hydroxyketorolac was not resolved enantiomerically and had a retention time of 2.2 min.,Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,2.2,142551,DB00328,Indomethacin
,19161455,half-lives,"Following an i.v. dose, the plasma concentration profiles for the stereoisomers were similar with half-lives of 1.05 +/- 0.62 h for R-KT and 1.05 +/- 0.61 h for S-KT.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),h,1.05,144223,DB00328,Indomethacin
,19161455,half-lives,"Following an i.v. dose, the plasma concentration profiles for the stereoisomers were similar with half-lives of 1.05 +/- 0.62 h for R-KT and 1.05 +/- 0.61 h for S-KT.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),h,1.05,144224,DB00328,Indomethacin
,19161455,Clearance,"Clearance values for R- and S-KT after an i.v. dose were 0.53 +/- 0.23 and 0.54 +/- 0.23 L.h/kg, respectively.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),[h·l] / [kg],0.53,144225,DB00328,Indomethacin
,19161455,Clearance,"Clearance values for R- and S-KT after an i.v. dose were 0.53 +/- 0.23 and 0.54 +/- 0.23 L.h/kg, respectively.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),[h·l] / [kg],0.54,144226,DB00328,Indomethacin
,19161455,terminal half-lives,"Following an oral dose, the terminal half-lives were longer with values of 34.08 +/- 11.81 and 33.97 +/- 12.19 h for R-KT and S-KT, respectively.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),h,34.08,144227,DB00328,Indomethacin
,19161455,terminal half-lives,"Following an oral dose, the terminal half-lives were longer with values of 34.08 +/- 11.81 and 33.97 +/- 12.19 h for R-KT and S-KT, respectively.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),h,33.97,144228,DB00328,Indomethacin
,19161455,bioavailability,"The average bioavailability was 133 +/- 23% for R-KT and S-KT, respectively.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),%,133,144229,DB00328,Indomethacin
,7452492,plasma clearance,Indomethacin significantly decreased plasma clearance of furosemide from 1.84 +/- 0.36 to 1.10 +/- 0.08 ml/kg/min (P < 0.2) and renal clearance of furosemide from 1.05 +/- 0.23 to 0.60 +/- 0.06 ml/kg/min (P < 0.05).,Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],1.84,145403,DB00328,Indomethacin
,7452492,plasma clearance,Indomethacin significantly decreased plasma clearance of furosemide from 1.84 +/- 0.36 to 1.10 +/- 0.08 ml/kg/min (P < 0.2) and renal clearance of furosemide from 1.05 +/- 0.23 to 0.60 +/- 0.06 ml/kg/min (P < 0.05).,Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],1.10,145404,DB00328,Indomethacin
,7452492,renal clearance,Indomethacin significantly decreased plasma clearance of furosemide from 1.84 +/- 0.36 to 1.10 +/- 0.08 ml/kg/min (P < 0.2) and renal clearance of furosemide from 1.05 +/- 0.23 to 0.60 +/- 0.06 ml/kg/min (P < 0.05).,Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],1.05,145405,DB00328,Indomethacin
,7452492,renal clearance,Indomethacin significantly decreased plasma clearance of furosemide from 1.84 +/- 0.36 to 1.10 +/- 0.08 ml/kg/min (P < 0.2) and renal clearance of furosemide from 1.05 +/- 0.23 to 0.60 +/- 0.06 ml/kg/min (P < 0.05).,Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],0.60,145406,DB00328,Indomethacin
,7452492,nonrenal clearance,"The nonrenal clearance of furosemide decreased, but not significantly, from 0.80 +/- 0.17 to 0.50 +/- 0.10 ml/kg/min.",Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],0.80,145407,DB00328,Indomethacin
,7452492,nonrenal clearance,"The nonrenal clearance of furosemide decreased, but not significantly, from 0.80 +/- 0.17 to 0.50 +/- 0.10 ml/kg/min.",Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],0.50,145408,DB00328,Indomethacin
,22675252,clearance,"We documented a higher median paracetamol clearance at delivery when compared to 10-15 weeks postpartum (11.7 to 6.4 L/h·m², P < 0.01), even after correction for weight-related changes.",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],11.7 to 6.4,146695,DB00328,Indomethacin
,22675252,clearance,"Similar conclusions were drawn for ketorolac: median clearance was higher at delivery with a subsequent decrease (2.03 to 1.43 L/h·m², P < 0.05) in postpartum (17-23 weeks).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],2.,146696,DB00328,Indomethacin
,22675252,clearance,"Similar conclusions were drawn for ketorolac: median clearance was higher at delivery with a subsequent decrease (2.03 to 1.43 L/h·m², P < 0.05) in postpartum (17-23 weeks).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],1,146697,DB00328,Indomethacin
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],6.4,146698,DB00328,Indomethacin
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],9.6,146699,DB00328,Indomethacin
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],1.43,146700,DB00328,Indomethacin
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],1.48,146701,DB00328,Indomethacin
,12078996,steady-state fetal arterial plasma indometacin concentrations,The mean steady-state fetal arterial plasma indometacin concentrations were 68.6+/-16.5 ng mL(-1) in the LD infusion and 230.3+/-28.8 ng mL(-1) in the HD infusion.,Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078996/),[ng] / [ml],68.6,149233,DB00328,Indomethacin
,12078996,steady-state fetal arterial plasma indometacin concentrations,The mean steady-state fetal arterial plasma indometacin concentrations were 68.6+/-16.5 ng mL(-1) in the LD infusion and 230.3+/-28.8 ng mL(-1) in the HD infusion.,Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078996/),[ng] / [ml],230.3,149234,DB00328,Indomethacin
,12078996,Total body clearance (TBC),Total body clearance (TBC) in the LD and HD infusions were not different and the overall mean was 11.3+/-1.2 mL min(-1) kg(-1).,Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078996/),[ml] / [kg·min],11.3,149235,DB00328,Indomethacin
,12078996,extraction,"In the 11 experiments where paired fetal arterial and umbilical venous samples were collected, the extraction of indometacin across the placenta averaged only 5.2+/-1.1%, indicating low placental permeability to the drug in sheep.",Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078996/),%,5.2,149236,DB00328,Indomethacin
,12078996,placental clearance (CLpl),"However, fetal placental clearance (CLpl) of indometacin (10.0+/-2.5 mL min(-1) kg(-1), n = 10) averaged 115.1+/-41.2% of TBC in these animals and the calculated value for fetal non-placental clearance (0.6+/-2.8 mL min(-1) kg(-1)) was not significantly different from zero.",Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078996/),[ml] / [kg·min],10.0,149237,DB00328,Indomethacin
,12078996,non-placental clearance,"However, fetal placental clearance (CLpl) of indometacin (10.0+/-2.5 mL min(-1) kg(-1), n = 10) averaged 115.1+/-41.2% of TBC in these animals and the calculated value for fetal non-placental clearance (0.6+/-2.8 mL min(-1) kg(-1)) was not significantly different from zero.",Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078996/),[ml] / [kg·min],0.6,149238,DB00328,Indomethacin
,12078996,renal clearance,Fetal renal clearance of intact indometacin (3.8+/-1.1 microL min(-1) kg(-1); n = 12) was also very low.,Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078996/),[μl] / [kg·min],3.8,149239,DB00328,Indomethacin
,9853990,flow rate,A flow rate of 300 microL per minute was used with a 1-to-12 postcolumn split into the mass spectrometer.,Plasma indomethacin assay using high-performance liquid chromatography-electrospray-tandem mass spectrometry: application to therapeutic drug monitoring and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853990/),[μl] / [min],300,150066,DB00328,Indomethacin
,9853990,m/z,"Selected reaction monitoring with mass transitions m/z 357.9-->139.0 and m/z 242-->209.0 were used for IND and IS, respectively.",Plasma indomethacin assay using high-performance liquid chromatography-electrospray-tandem mass spectrometry: application to therapeutic drug monitoring and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853990/),,357.9,150067,DB00328,Indomethacin
,9853990,m/z,"Selected reaction monitoring with mass transitions m/z 357.9-->139.0 and m/z 242-->209.0 were used for IND and IS, respectively.",Plasma indomethacin assay using high-performance liquid chromatography-electrospray-tandem mass spectrometry: application to therapeutic drug monitoring and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853990/),,139.0,150068,DB00328,Indomethacin
,9853990,m/z,"Selected reaction monitoring with mass transitions m/z 357.9-->139.0 and m/z 242-->209.0 were used for IND and IS, respectively.",Plasma indomethacin assay using high-performance liquid chromatography-electrospray-tandem mass spectrometry: application to therapeutic drug monitoring and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853990/),,242,150069,DB00328,Indomethacin
,9853990,m/z,"Selected reaction monitoring with mass transitions m/z 357.9-->139.0 and m/z 242-->209.0 were used for IND and IS, respectively.",Plasma indomethacin assay using high-performance liquid chromatography-electrospray-tandem mass spectrometry: application to therapeutic drug monitoring and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853990/),,209.0,150070,DB00328,Indomethacin
,9853990,chromatographic analysis time,The chromatographic analysis time was 4 minutes.,Plasma indomethacin assay using high-performance liquid chromatography-electrospray-tandem mass spectrometry: application to therapeutic drug monitoring and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853990/),min,4,150071,DB00328,Indomethacin
,9853990,absolute recovery,"The absolute recovery of IND and IS was 74% (n=8) and 95% (n=24), respectively.",Plasma indomethacin assay using high-performance liquid chromatography-electrospray-tandem mass spectrometry: application to therapeutic drug monitoring and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853990/),%,74,150072,DB00328,Indomethacin
,9853990,absolute recovery,"The absolute recovery of IND and IS was 74% (n=8) and 95% (n=24), respectively.",Plasma indomethacin assay using high-performance liquid chromatography-electrospray-tandem mass spectrometry: application to therapeutic drug monitoring and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853990/),%,95,150073,DB00328,Indomethacin
,6469435,half life of elimination,There was considerable intersubject variability in the half life of elimination (63.1 +/- 38 h).,Pharmacokinetics and clinical efficacy of indomethacin in premature infants with patent ductus arteriosus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469435/),h,63.1,155655,DB00328,Indomethacin
,6469435,clearance,This variability was mainly due to clearance (0.0086 +/- 0.0069 l/h/kg) rather than to distribution volume variability (0.54 +/- 0.27 l/kg).,Pharmacokinetics and clinical efficacy of indomethacin in premature infants with patent ductus arteriosus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469435/),[l] / [h·kg],0.0086,155656,DB00328,Indomethacin
,6469435,distribution volume,This variability was mainly due to clearance (0.0086 +/- 0.0069 l/h/kg) rather than to distribution volume variability (0.54 +/- 0.27 l/kg).,Pharmacokinetics and clinical efficacy of indomethacin in premature infants with patent ductus arteriosus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469435/),[l] / [kg],0.54,155657,DB00328,Indomethacin
,8229782,ED50,"The arachidonic acid-induced mouse ear inflammation test allowed the evaluation of the antiedematous effects of BAY X1005 after topical (ED50, 18 micrograms/ear) and oral (ED50, 48.7 mg/kg) administration.","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),,18,155787,DB00328,Indomethacin
,8229782,ED50,"The arachidonic acid-induced mouse ear inflammation test allowed the evaluation of the antiedematous effects of BAY X1005 after topical (ED50, 18 micrograms/ear) and oral (ED50, 48.7 mg/kg) administration.","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),mg,48.7,155788,DB00328,Indomethacin
,8229782,ED50,"Profound inhibition of myeloperoxidase activity as a marker for phagocyte infiltration was seen (ED50, 3 micrograms/ear topically and 7.9 mg/kg p.o.) even 5 hr after application.","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),[μg] / [ear],3,155789,DB00328,Indomethacin
,8229782,ED50,"Profound inhibition of myeloperoxidase activity as a marker for phagocyte infiltration was seen (ED50, 3 micrograms/ear topically and 7.9 mg/kg p.o.) even 5 hr after application.","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),mg,7,155790,DB00328,Indomethacin
,8229782,ED50,"The rat whole blood ex vivo leukotriene B4 inhibition assay demonstrated that BAY X1005 was potent (ED50, 11.8 and 6.7 mg/kg p.o. at 1 and 5 hr, respectively) and had a long duration of action (16-hr ED40, 70 mg/kg p.o.).","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),[mg] / [kg],11.8,155791,DB00328,Indomethacin
,8229782,ED50,"The rat whole blood ex vivo leukotriene B4 inhibition assay demonstrated that BAY X1005 was potent (ED50, 11.8 and 6.7 mg/kg p.o. at 1 and 5 hr, respectively) and had a long duration of action (16-hr ED40, 70 mg/kg p.o.).","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),[mg] / [kg],6.7,155792,DB00328,Indomethacin
,8229782,ED50,"The rat whole blood ex vivo leukotriene B4 inhibition assay demonstrated that BAY X1005 was potent (ED50, 11.8 and 6.7 mg/kg p.o. at 1 and 5 hr, respectively) and had a long duration of action (16-hr ED40, 70 mg/kg p.o.).","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),,16,155793,DB00328,Indomethacin
,8229782,ED50,"Similarly, inhibition of the zymosan-induced exudate leukotrienes B4 and C4 inhibition confirmed these data (ED50, 8.3 and 10.5 mg/kg p.o., respectively).","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),[mg] / [kg],8.3,155794,DB00328,Indomethacin
,8229782,ED50,"Similarly, inhibition of the zymosan-induced exudate leukotrienes B4 and C4 inhibition confirmed these data (ED50, 8.3 and 10.5 mg/kg p.o., respectively).","BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229782/),[mg] / [kg],10.5,155795,DB00328,Indomethacin
,18678236,AUC(,"The AUC(IndOEt-NC)/AUC(IndOH) ratio after i.v. dosing was 0.68, accounting for dose and molecular weight differences, probably due to increased IndOH clearance after IndOEt-NC administration (alpha=0.05).",Pharmacokinetic evaluation of indomethacin ethyl ester-loaded nanoencapsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18678236/),,0.68,159511,DB00328,Indomethacin
,16025473,drug-loading efficiency,"When the feed weight ratio of indomethacin (IMC) to polymer was 1:1, the ML50 nanosphere having a relatively high drug-loading efficiency of about 33.0% could be obtained.","Indomethacin-loaded methoxy poly(ethylene glycol)/poly(D,L-lactide) amphiphilic diblock copolymeric nanospheres: pharmacokinetic and toxicity studies in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025473/),%,33.0,159923,DB00328,Indomethacin
,16025473,LD50,The LD50 of ML50 nanospheres determined by Litchfield-Wilcoxon method was about 1.54 g/kg.,"Indomethacin-loaded methoxy poly(ethylene glycol)/poly(D,L-lactide) amphiphilic diblock copolymeric nanospheres: pharmacokinetic and toxicity studies in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025473/),[g] / [kg],1.54,159924,DB00328,Indomethacin
,8889037,bioavailability,"The plasma levels of IM after the oral administration of IM-OE and IM-BE were comparatively low compared with those after IM, with a small bioavailability (2.1 and 15.0%, respectively).",Pharmacokinetics of indomethacin ester prodrugs: gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889037/),%,2.1,160878,DB00328,Indomethacin
,8889037,bioavailability,"The plasma levels of IM after the oral administration of IM-OE and IM-BE were comparatively low compared with those after IM, with a small bioavailability (2.1 and 15.0%, respectively).",Pharmacokinetics of indomethacin ester prodrugs: gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889037/),%,15.0,160879,DB00328,Indomethacin
,24435507,overall closure rate,"The overall closure rate of PDA was 60 and 65.7 % in the ibuprofen and indomethacin groups, respectively.",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),%,60,162314,DB00328,Indomethacin
,24435507,overall closure rate,"The overall closure rate of PDA was 60 and 65.7 % in the ibuprofen and indomethacin groups, respectively.",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),%,65.7,162315,DB00328,Indomethacin
,24435507,Closure rate,"Closure rate was significantly higher when the drugs were administered at an early postnatal age (<8 days) (83.3 % [p = 0.02] in the indomethacin group and 75 % [p = 0.03] in the ibuprofen group) in neonates >28 weeks (ibuprofen group 66.7 % [p = 0.02]; indomethacin group 65.5 % [p = 0.04]) and in babies with birth weight >1,000 g (ibuprofen group 62.2 %; indomethacin group 70 % [p = 0.04 in both groups]).",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),,83,162316,DB00328,Indomethacin
,24435507,Closure rate,"Closure rate was significantly higher when the drugs were administered at an early postnatal age (<8 days) (83.3 % [p = 0.02] in the indomethacin group and 75 % [p = 0.03] in the ibuprofen group) in neonates >28 weeks (ibuprofen group 66.7 % [p = 0.02]; indomethacin group 65.5 % [p = 0.04]) and in babies with birth weight >1,000 g (ibuprofen group 62.2 %; indomethacin group 70 % [p = 0.04 in both groups]).",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),,75,162317,DB00328,Indomethacin
,24435507,Closure rate,"Closure rate was significantly higher when the drugs were administered at an early postnatal age (<8 days) (83.3 % [p = 0.02] in the indomethacin group and 75 % [p = 0.03] in the ibuprofen group) in neonates >28 weeks (ibuprofen group 66.7 % [p = 0.02]; indomethacin group 65.5 % [p = 0.04]) and in babies with birth weight >1,000 g (ibuprofen group 62.2 %; indomethacin group 70 % [p = 0.04 in both groups]).",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),,66,162318,DB00328,Indomethacin
,24435507,Closure rate,"Closure rate was significantly higher when the drugs were administered at an early postnatal age (<8 days) (83.3 % [p = 0.02] in the indomethacin group and 75 % [p = 0.03] in the ibuprofen group) in neonates >28 weeks (ibuprofen group 66.7 % [p = 0.02]; indomethacin group 65.5 % [p = 0.04]) and in babies with birth weight >1,000 g (ibuprofen group 62.2 %; indomethacin group 70 % [p = 0.04 in both groups]).",Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435507/),,65,162319,DB00328,Indomethacin
,8765697,time to reach peak t(max),"The time to reach peak t(max) appeared slightly shorter for the test preparation (1.75 h) than for the reference formulation (2.67 h), but the difference was not statistically significant because of the high intersubject variability (non-parametric Wilcoxon matched pair test).","In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765697/),h,1.75,162414,DB00328,Indomethacin
,8765697,time to reach peak t(max),"The time to reach peak t(max) appeared slightly shorter for the test preparation (1.75 h) than for the reference formulation (2.67 h), but the difference was not statistically significant because of the high intersubject variability (non-parametric Wilcoxon matched pair test).","In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765697/),h,2.67,162415,DB00328,Indomethacin
,8765697,maximum plasma concentrations Cmax,"The mean maximum plasma concentrations Cmax were 3.35 and 2.82 micrograms/ml for the test and the reference formulation respectively, with the corresponding values of the area under the plasma concentration-time curve AUC amounting to 10.14 and 11.38 micrograms h/ml.","In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765697/),[μg] / [ml],3.35,162416,DB00328,Indomethacin
,8765697,maximum plasma concentrations Cmax,"The mean maximum plasma concentrations Cmax were 3.35 and 2.82 micrograms/ml for the test and the reference formulation respectively, with the corresponding values of the area under the plasma concentration-time curve AUC amounting to 10.14 and 11.38 micrograms h/ml.","In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765697/),[μg] / [ml],2.82,162417,DB00328,Indomethacin
,8765697,area under the plasma concentration-time curve AUC,"The mean maximum plasma concentrations Cmax were 3.35 and 2.82 micrograms/ml for the test and the reference formulation respectively, with the corresponding values of the area under the plasma concentration-time curve AUC amounting to 10.14 and 11.38 micrograms h/ml.","In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765697/),[h·μg] / [ml],10.14,162418,DB00328,Indomethacin
,8765697,area under the plasma concentration-time curve AUC,"The mean maximum plasma concentrations Cmax were 3.35 and 2.82 micrograms/ml for the test and the reference formulation respectively, with the corresponding values of the area under the plasma concentration-time curve AUC amounting to 10.14 and 11.38 micrograms h/ml.","In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765697/),[h·μg] / [ml],11.38,162419,DB00328,Indomethacin
,2082311,half-life for absorption,It is absorbed rapidly (half-life for absorption 3.8 min) after oral (fasting) and intramuscular administration; food delays but does not reduce its absorption.,"Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),min,3.8,162671,DB00328,Indomethacin
,2082311,plasma elimination half-life,"The mean plasma elimination half-life is 5-6 hours, and ketorolac is not extensively distributed outside the vascular compartment (Vd beta 15 L).","Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),h,5-6,162672,DB00328,Indomethacin
,2082311,Vd beta,"The mean plasma elimination half-life is 5-6 hours, and ketorolac is not extensively distributed outside the vascular compartment (Vd beta 15 L).","Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),l,15,162673,DB00328,Indomethacin
,23473380,minimal alveolar concentration,"During surgery, mean minimal alveolar concentration of isoflurane was 1.69 ± 0.11%, and normocapnia and spontaneous ventilation were maintained in all animals.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),%,1.69,163499,DB00328,Indomethacin
,23473380,elimination half-life (t½λz ),"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),h,10.95,163500,DB00328,Indomethacin
,23473380,ClB,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [h·kg],92.66,163501,DB00328,Indomethacin
,23473380,Vdss,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [kg],1030.09,163502,DB00328,Indomethacin
,23473380,Vz,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [kg],1512.25,163503,DB00328,Indomethacin
,23473380,AUC(0→last),"AUC(0→last) and MRT(0→last) were 6.08 ± 3.28 h × μg/mL and 5.59 ± 2.12 h, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[h·μg] / [ml],6.08,163504,DB00328,Indomethacin
,23473380,MRT(0→last),"AUC(0→last) and MRT(0→last) were 6.08 ± 3.28 h × μg/mL and 5.59 ± 2.12 h, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),h,5.59,163505,DB00328,Indomethacin
,16026004,clearance,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[ml] / [kg·min],26,164283,DB00328,Indomethacin
,16026004,clearance,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[ml] / [kg·min],12,164284,DB00328,Indomethacin
,16026004,hepatic extraction,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),,30,164285,DB00328,Indomethacin
,16026004,volume of distribution,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[l] / [kg],7.3,164286,DB00328,Indomethacin
,16026004,volume of distribution,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[l] / [kg],2.1,164287,DB00328,Indomethacin
>,16026004,permeability,The in vitro permeability for fluvastatin was high (>10 x 10(-6) cm/s).,Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[cm] / [s],10 x 10(-6),164288,DB00328,Indomethacin
,8573422,absolute bioavailability,An absolute bioavailability of approximately 6% has been reported with large inter- and intra-subject variability.,Human pharmacokinetics of tiludronate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),%,6,165181,DB00328,Indomethacin
,8573422,elimination half-life,"The elimination half-life in patients with normal renal function is approximately 40-60 h, but is significantly increased in subjects with severe renal impairment.",Human pharmacokinetics of tiludronate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),h,40-60,165182,DB00328,Indomethacin
,8573422,renal clearance,The renal clearance (0.7 L/h) is independent of dose and suggests that glomerular filtration is the mechanism responsible for elimination.,Human pharmacokinetics of tiludronate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),[l] / [h],0.7,165183,DB00328,Indomethacin
,23992042,Cmax,"The highest mean concentration of ketorolac was achieved in ISV-304 (0.4%) formulated in DuraSite 2 with a Cmax value of 1889 ± 884 ng/mL, compared to Cmax values for ISV-304 (0.4%) formulated in DuraSite (1212 ± 435 ng/mL) or Acular LS (275 ± 83 ng/mL).",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [ml],1889,165338,DB00328,Indomethacin
,23992042,Cmax,"The highest mean concentration of ketorolac was achieved in ISV-304 (0.4%) formulated in DuraSite 2 with a Cmax value of 1889 ± 884 ng/mL, compared to Cmax values for ISV-304 (0.4%) formulated in DuraSite (1212 ± 435 ng/mL) or Acular LS (275 ± 83 ng/mL).",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),%,0.4,165339,DB00328,Indomethacin
,23992042,Cmax,"The highest mean concentration of ketorolac was achieved in ISV-304 (0.4%) formulated in DuraSite 2 with a Cmax value of 1889 ± 884 ng/mL, compared to Cmax values for ISV-304 (0.4%) formulated in DuraSite (1212 ± 435 ng/mL) or Acular LS (275 ± 83 ng/mL).",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [ml],1212,165340,DB00328,Indomethacin
,23992042,Cmax,"The highest mean concentration of ketorolac was achieved in ISV-304 (0.4%) formulated in DuraSite 2 with a Cmax value of 1889 ± 884 ng/mL, compared to Cmax values for ISV-304 (0.4%) formulated in DuraSite (1212 ± 435 ng/mL) or Acular LS (275 ± 83 ng/mL).",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [ml],275,165341,DB00328,Indomethacin
,23992042,Cmax,ISV-304 (0.2%) formulations also achieved higher AH Cmax values (801 ± 205 ng/mL and 1077 ± 415 ng/mL) compared to Acular LS.,Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [ml],801,165342,DB00328,Indomethacin
,23992042,Cmax,ISV-304 (0.2%) formulations also achieved higher AH Cmax values (801 ± 205 ng/mL and 1077 ± 415 ng/mL) compared to Acular LS.,Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [ml],1077,165343,DB00328,Indomethacin
,23992042,AUC0.25-24h,"There was a significant increase in drug exposure in the ISV-304 (0.4%) formulated in DuraSite 2 or DuraSite formulations with AUC0.25-24h values 6836 ng/mL*h and 5684 ng/mL*h, respectively, compared to Acular LS with an AUC0.25-24h value of 1424 ng/mL*h.",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [h·ml],6836,165344,DB00328,Indomethacin
,23992042,AUC0.25-24h,"There was a significant increase in drug exposure in the ISV-304 (0.4%) formulated in DuraSite 2 or DuraSite formulations with AUC0.25-24h values 6836 ng/mL*h and 5684 ng/mL*h, respectively, compared to Acular LS with an AUC0.25-24h value of 1424 ng/mL*h.",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [h·ml],5684,165345,DB00328,Indomethacin
,23992042,AUC0.25-24h,"There was a significant increase in drug exposure in the ISV-304 (0.4%) formulated in DuraSite 2 or DuraSite formulations with AUC0.25-24h values 6836 ng/mL*h and 5684 ng/mL*h, respectively, compared to Acular LS with an AUC0.25-24h value of 1424 ng/mL*h.",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [h·ml],1424,165346,DB00328,Indomethacin
,23992042,AUC0.25-24h,"ISV-304 (0.2%) formulations also had high AUC0.25-24h values (3241 ng/mL*h and 4490 ng/mL*h), which were a 2.3-3.2-fold increase over the Acular LS AUC0.25-24h value.",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [h·ml],3241,165347,DB00328,Indomethacin
,23992042,AUC0.25-24h,"ISV-304 (0.2%) formulations also had high AUC0.25-24h values (3241 ng/mL*h and 4490 ng/mL*h), which were a 2.3-3.2-fold increase over the Acular LS AUC0.25-24h value.",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [h·ml],4490,165348,DB00328,Indomethacin
,25586152,time to reach maximum plasma concentration [t max],"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),min,22.50,165439,DB00328,Indomethacin
,25586152,elimination half-life [t ½],"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),min,21.70,165440,DB00328,Indomethacin
,25586152,maximum plasma concentration (C max),"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),[pg] / [ml],2.56,165441,DB00328,Indomethacin
,25586152,area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t),"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),[min·pg] / [ml],70.68,165442,DB00328,Indomethacin
,24029554,LLOQ,An LLOQ of 10pg/mL was achieved with 500μl plasma.,Determination of Prostaglandin E1 in dog plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24029554/),,10,166564,DB00328,Indomethacin
,24029554,half-life,The half-life was recovered at 7min.,Determination of Prostaglandin E1 in dog plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24029554/),min,7,166565,DB00328,Indomethacin
,2786553,MTD,The MTD was 5 x 10(6) U/m2 s.c. of IL-2 and 2 x 10(6) U/m2 i.v. of beta-IFN when given in combination.,Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786553/),[u] / [m2],5 x 10(6),167637,DB00328,Indomethacin
,2786553,MTD,The MTD was 5 x 10(6) U/m2 s.c. of IL-2 and 2 x 10(6) U/m2 i.v. of beta-IFN when given in combination.,Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2786553/),[u] / [m2],2 x 10(6),167638,DB00328,Indomethacin
,1920602,maximal concentration,The excretion rate peaked after 2-3 h while the maximal concentration ranged from 18.5 to 80.6 micrograms/ml.,Disposition of human drug preparations in the horse. I. Rectally administered indomethacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920602/),[μg] / [ml],18.5 to 80.6,169660,DB00328,Indomethacin
,8903001,EC50),"Using the sigmoidal Emax model the mean serum concentration (SD) of ketorolac, 4-methylaminoantipyrine and 4-aminoantipyrine inhibiting platelet TXB2 generation by 50% (EC50) in vitro was found to be 0.088 +/- 0.031, 1.2 +/- 0.3 and 10.2 +/- 3.4 micrograms ml-1, respectively.",The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903001/),[μg] / [ml],0.088,171050,DB00328,Indomethacin
,8903001,EC50),"Using the sigmoidal Emax model the mean serum concentration (SD) of ketorolac, 4-methylaminoantipyrine and 4-aminoantipyrine inhibiting platelet TXB2 generation by 50% (EC50) in vitro was found to be 0.088 +/- 0.031, 1.2 +/- 0.3 and 10.2 +/- 3.4 micrograms ml-1, respectively.",The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903001/),[μg] / [ml],1.2,171051,DB00328,Indomethacin
,8903001,EC50),"Using the sigmoidal Emax model the mean serum concentration (SD) of ketorolac, 4-methylaminoantipyrine and 4-aminoantipyrine inhibiting platelet TXB2 generation by 50% (EC50) in vitro was found to be 0.088 +/- 0.031, 1.2 +/- 0.3 and 10.2 +/- 3.4 micrograms ml-1, respectively.",The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903001/),[μg] / [ml],10.2,171052,DB00328,Indomethacin
,3067620,concentrations,Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001).,Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),μM,28.,171538,DB00328,Indomethacin
,3067620,concentrations,Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001).,Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),μ,1,171539,DB00328,Indomethacin
,3067620,area under the curve (AUC),"Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion.",Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),%·delta·min·t,5142,171540,DB00328,Indomethacin
,3067620,AUC,"Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion.",Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),bpm·min,1622,171541,DB00328,Indomethacin
,9084512,AD50s,"AD50s determined by the PPT in rabbits for morphine and nalbuphine were 3.1 and 8.4 mg/kg, respectively.",Paw pressure test in the rabbit: a new animal model for the study of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084512/),[mg] / [kg],3.1,171644,DB00328,Indomethacin
,9084512,AD50s,"AD50s determined by the PPT in rabbits for morphine and nalbuphine were 3.1 and 8.4 mg/kg, respectively.",Paw pressure test in the rabbit: a new animal model for the study of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084512/),[mg] / [kg],8.4,171645,DB00328,Indomethacin
,8863274,dose-corrected systemic availability,The dose-corrected systemic availability of the three oral rinses evaluated in the rinse study relative to the peroral capsule was about 15%.,Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,15,172454,DB00328,Indomethacin
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,59.2,172455,DB00328,Indomethacin
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,86.4,172456,DB00328,Indomethacin
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,1.0,172457,DB00328,Indomethacin
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,0.15,172458,DB00328,Indomethacin
,8863274,relative bioavailabilities,The relative bioavailabilities of ketorolac in the GCF after dosing with the dentifrice formulations with respect to the rinse were 89.1% for the 1.0% dentifrice and 19.7% for the 0.15% dentifrice.,Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,89.1,172459,DB00328,Indomethacin
,8863274,relative bioavailabilities,The relative bioavailabilities of ketorolac in the GCF after dosing with the dentifrice formulations with respect to the rinse were 89.1% for the 1.0% dentifrice and 19.7% for the 0.15% dentifrice.,Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,19.7,172460,DB00328,Indomethacin
,8863274,T1/2,"The T1/2 of ketorolac in the GCF was about 0.5 h for all three treatments, which is significantly less than the plasma half-life of about 5.3 h.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),h,0.5,172461,DB00328,Indomethacin
,8863274,plasma half-life,"The T1/2 of ketorolac in the GCF was about 0.5 h for all three treatments, which is significantly less than the plasma half-life of about 5.3 h.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),h,5.3,172462,DB00328,Indomethacin
,7249487,peak plasma concentrations,"In general, peak plasma concentrations of 2 to 3 microgram/ml are achieved with 1 to 2 hours, but concomitant ingestion of food reduces and delays the peak concentrations without reducing the amount absorbed.",Clinical Pharmacokinetics of indomethacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),[μg] / [ml],2 to 3,172594,DB00328,Indomethacin
,7249487,biological half-life,The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min.,Clinical Pharmacokinetics of indomethacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),h,5 to 10,172595,DB00328,Indomethacin
,7249487,plasma clearance,The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min.,Clinical Pharmacokinetics of indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),[ml] / [kg·min],1 to 2.5,172596,DB00328,Indomethacin
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],878.50,172791,DB00328,Indomethacin
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],"1,994.04",172792,DB00328,Indomethacin
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],314.82,172793,DB00328,Indomethacin
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],"1,314.12",172794,DB00328,Indomethacin
,10024078,plasma,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],786.04,172795,DB00328,Indomethacin
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],786.04,172796,DB00328,Indomethacin
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],960.04,172797,DB00328,Indomethacin
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],474.55,172798,DB00328,Indomethacin
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],490.82,172799,DB00328,Indomethacin
,27061415,flow rate,"After liquid-liquid extraction with dichloromethane, separation was achieved on a Syncronis HPLC C18 column (150 mm × 4.6 mm, 5 μm) using an isocratic mobile phase system consisting of acetonitrile-water (85:15, v/v) at a flow rate of 0.6 mL/min with a split ratio of 1:2.",Simultaneous determination of cucurbitacin IIa and cucurbitacin IIb of Hemsleya amabilis by HPLC-MS/MS and their pharmacokinetic study in normal and indomethacin-induced rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061415/),[ml] / [min],0.6,173209,DB00328,Indomethacin
>,27061415,extraction recoveries,The extraction recoveries of the analytes and IS from rat plasma were all >87.1%.,Simultaneous determination of cucurbitacin IIa and cucurbitacin IIb of Hemsleya amabilis by HPLC-MS/MS and their pharmacokinetic study in normal and indomethacin-induced rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061415/),%,87.1,173210,DB00328,Indomethacin
<,8749253,C.V.,The limit of quantitation (LOQ) is 1 ng/ml with a C.V. < 10% and signal-to-noise ratio > 10.,Sensitive fused-silica capillary gas chromatographic assay using electron-capture detection for indomethacin in ovine fetal fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8749253/),%,10,173830,DB00328,Indomethacin
>,8749253,signal-to-noise ratio,The limit of quantitation (LOQ) is 1 ng/ml with a C.V. < 10% and signal-to-noise ratio > 10.,Sensitive fused-silica capillary gas chromatographic assay using electron-capture detection for indomethacin in ovine fetal fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8749253/),,10,173831,DB00328,Indomethacin
greater,8749253,Recoveries,Recoveries from all fluids were greater than 80%.,Sensitive fused-silica capillary gas chromatographic assay using electron-capture detection for indomethacin in ovine fetal fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8749253/),%,80,173832,DB00328,Indomethacin
,18357738,excretion,"The excretion of 5-Fu in urine and feces amounted to 0.0065% and 0.063% of the dose, respectively.",[Tissue distribution and excretion of 5-fluorouracil from indomethacin 5-fluorouracil-1-ylmethylester in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18357738/),%,0.0065,175633,DB00328,Indomethacin
,18357738,excretion,"The excretion of 5-Fu in urine and feces amounted to 0.0065% and 0.063% of the dose, respectively.",[Tissue distribution and excretion of 5-fluorouracil from indomethacin 5-fluorouracil-1-ylmethylester in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18357738/),%,0.063,175634,DB00328,Indomethacin
,12631050,CBF,"In group 1, baseline CBF was 55 +/- 7 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],55,176357,DB00328,Indomethacin
,12631050,CBF,Indomethacin decreased CBF to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176358,DB00328,Indomethacin
,12631050,CBF,"In group 2, baseline CBF was 54 +/- 10 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],54,176359,DB00328,Indomethacin
,12631050,CBF,Placebo did not change CBF while indomethacin decreased CBF significantly to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176360,DB00328,Indomethacin
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],3.9,176361,DB00328,Indomethacin
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],1.4,176362,DB00328,Indomethacin
,8141297,clearance,Reduction in luminal pH from 7.4 to 6.0 in the presence of indomethacin (1.0 mg/ml) increased 51Cr-EDTA clearance from 2.0 +/- 0.1 to 6.5 +/- 0.3 microliter.min-1.g-1.,Role of leukocytes in indomethacin-induced small bowel injury in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141297/),[μl] / [g·min],2.0,178355,DB00328,Indomethacin
,8141297,clearance,Reduction in luminal pH from 7.4 to 6.0 in the presence of indomethacin (1.0 mg/ml) increased 51Cr-EDTA clearance from 2.0 +/- 0.1 to 6.5 +/- 0.3 microliter.min-1.g-1.,Role of leukocytes in indomethacin-induced small bowel injury in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141297/),[μl] / [g·min],6.5,178356,DB00328,Indomethacin
,17142563,plasma concentrations,"The corresponding plasma concentrations were 14.1, 4.1, and 4 microg/ml.",Mode of administration-dependent brain uptake of indomethacin: sustained systemic input increases brain influx. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17142563/),,4.1,178418,DB00328,Indomethacin
,17142563,plasma concentrations,"The corresponding plasma concentrations were 14.1, 4.1, and 4 microg/ml.",Mode of administration-dependent brain uptake of indomethacin: sustained systemic input increases brain influx. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17142563/),,4,178419,DB00328,Indomethacin
,7899229,synovial fluid exit rate constant,"The single dose mean +/- S.D. synovial fluid exit rate constant for diclofenac was 0.39 +/- 0.33 hr-1 (n = 6), which was not significantly different from that determined by method 2; which was 0.49 +/- 0.52 hr-1.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.39,178926,DB00328,Indomethacin
,7899229,synovial fluid exit rate constant,"The single dose mean +/- S.D. synovial fluid exit rate constant for diclofenac was 0.39 +/- 0.33 hr-1 (n = 6), which was not significantly different from that determined by method 2; which was 0.49 +/- 0.52 hr-1.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.49,178927,DB00328,Indomethacin
,7899229,steady state mean,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.43,178928,DB00328,Indomethacin
,7899229,steady state mean,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.54,178929,DB00328,Indomethacin
,7899229,s,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.43,178930,DB00328,Indomethacin
,7899229,s,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.54,178931,DB00328,Indomethacin
,7806600,lag time between dosing and first appearance,"The two products were not found to be statistically different with respect to the lag time between dosing and first appearance of the drug in the serum (1.0 +/- 0.1 and 0.9 +/- 0.1 h for A and B, respectively), or in the time needed to attain the peak concentrations (3.3 +/- 0.3 and 3.3 +/- 0.5 h for A and B, respectively).",A pharmacokinetic study on two sustained-release formulations of indomethacin in normal subjects following a single dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7806600/),h,1.0,178981,DB00328,Indomethacin
,7806600,lag time between dosing and first appearance,"The two products were not found to be statistically different with respect to the lag time between dosing and first appearance of the drug in the serum (1.0 +/- 0.1 and 0.9 +/- 0.1 h for A and B, respectively), or in the time needed to attain the peak concentrations (3.3 +/- 0.3 and 3.3 +/- 0.5 h for A and B, respectively).",A pharmacokinetic study on two sustained-release formulations of indomethacin in normal subjects following a single dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7806600/),h,0.9,178982,DB00328,Indomethacin
,7806600,time needed to attain the peak concentrations,"The two products were not found to be statistically different with respect to the lag time between dosing and first appearance of the drug in the serum (1.0 +/- 0.1 and 0.9 +/- 0.1 h for A and B, respectively), or in the time needed to attain the peak concentrations (3.3 +/- 0.3 and 3.3 +/- 0.5 h for A and B, respectively).",A pharmacokinetic study on two sustained-release formulations of indomethacin in normal subjects following a single dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7806600/),h,3.3,178983,DB00328,Indomethacin
,7806600,time needed to attain the peak concentrations,"The two products were not found to be statistically different with respect to the lag time between dosing and first appearance of the drug in the serum (1.0 +/- 0.1 and 0.9 +/- 0.1 h for A and B, respectively), or in the time needed to attain the peak concentrations (3.3 +/- 0.3 and 3.3 +/- 0.5 h for A and B, respectively).",A pharmacokinetic study on two sustained-release formulations of indomethacin in normal subjects following a single dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7806600/),h,3.3,178984,DB00328,Indomethacin
,7806600,peak serum concentrations,"The two products, however, varied significantly in the peak serum concentrations (2721 +/- 220 and 1797 +/- 129 ng/ml for A and B, respectively).",A pharmacokinetic study on two sustained-release formulations of indomethacin in normal subjects following a single dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7806600/),[ng] / [ml],2721,178985,DB00328,Indomethacin
,7806600,peak serum concentrations,"The two products, however, varied significantly in the peak serum concentrations (2721 +/- 220 and 1797 +/- 129 ng/ml for A and B, respectively).",A pharmacokinetic study on two sustained-release formulations of indomethacin in normal subjects following a single dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7806600/),[ng] / [ml],1797,178986,DB00328,Indomethacin
,7806600,area under the concentration-time curve over 24 h,"In terms of the extent of absorption, assessed by estimating the area under the concentration-time curve over 24 h, the two products were not found to be significantly different (11,575 +/- 630 and 10,212 +/- 556 ng . h/ml for A and B, respectively).",A pharmacokinetic study on two sustained-release formulations of indomethacin in normal subjects following a single dose administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7806600/),[h·ng] / [ml],"11,575",178987,DB00328,Indomethacin
,7806600,area under the concentration-time curve over 24 h,"In terms of the extent of absorption, assessed by estimating the area under the concentration-time curve over 24 h, the two products were not found to be significantly different (11,575 +/- 630 and 10,212 +/- 556 ng . h/ml for A and B, respectively).",A pharmacokinetic study on two sustained-release formulations of indomethacin in normal subjects following a single dose administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7806600/),[h·ng] / [ml],"10,212",178988,DB00328,Indomethacin
,26149245,limit of detection (LOD),"The method was linear for both analytes in the concentration range 0.05-30ng/mL with intra- and inter-day precisions (as relative standard deviation) of ≤6.75% and accuracy (as relative error) of ≤7.21% and limit of detection (LOD) values were 10 and 20pg/mL, respectively.",Simultaneous determination of carboprost methylate and its active metabolite carboprost in dog plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149245/),[pg] / [ml],10,181544,DB00328,Indomethacin
,26149245,limit of detection (LOD),"The method was linear for both analytes in the concentration range 0.05-30ng/mL with intra- and inter-day precisions (as relative standard deviation) of ≤6.75% and accuracy (as relative error) of ≤7.21% and limit of detection (LOD) values were 10 and 20pg/mL, respectively.",Simultaneous determination of carboprost methylate and its active metabolite carboprost in dog plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149245/),[pg] / [ml],20,181545,DB00328,Indomethacin
,10597535,elimination half-life (t1/2 beta),"Following i.v. administration mean (+/- SD) pharmacokinetic parameters were: elimination half-life (t1/2 beta) = 4.55 h, plasma clearance (Clp) = 1.25 (1.13) mL/kg/min, and volume of distribution at steady state (Vss) = 0.33 (0.10) L/kg.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),h,4.55,181697,DB00328,Indomethacin
,10597535,plasma clearance (Clp),"Following i.v. administration mean (+/- SD) pharmacokinetic parameters were: elimination half-life (t1/2 beta) = 4.55 h, plasma clearance (Clp) = 1.25 (1.13) mL/kg/min, and volume of distribution at steady state (Vss) = 0.33 (0.10) L/kg.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),[ml] / [kg·min],1.25,181698,DB00328,Indomethacin
,10597535,volume of distribution at steady state (Vss),"Following i.v. administration mean (+/- SD) pharmacokinetic parameters were: elimination half-life (t1/2 beta) = 4.55 h, plasma clearance (Clp) = 1.25 (1.13) mL/kg/min, and volume of distribution at steady state (Vss) = 0.33 (0.10) L/kg.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),[l] / [kg],0.33,181699,DB00328,Indomethacin
,10597535,t1/2 beta,"Mean (+/- SD) p.o. pharmacokinetic values were: t1/2 beta = 4.07 h, time to reach maximum concentration (tmax) = 51.2 (40.6) min, and p.o. bioavailability (F) = 100.9 (46.7)%.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),h,4.07,181700,DB00328,Indomethacin
,10597535,time to reach maximum concentration (tmax),"Mean (+/- SD) p.o. pharmacokinetic values were: t1/2 beta = 4.07 h, time to reach maximum concentration (tmax) = 51.2 (40.6) min, and p.o. bioavailability (F) = 100.9 (46.7)%.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),min,51.2,181701,DB00328,Indomethacin
,10597535,bioavailability (F),"Mean (+/- SD) p.o. pharmacokinetic values were: t1/2 beta = 4.07 h, time to reach maximum concentration (tmax) = 51.2 (40.6) min, and p.o. bioavailability (F) = 100.9 (46.7)%.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),%,100.9,181702,DB00328,Indomethacin
,6861873,steady-state plasma concentrations (Cssp),"Average steady-state plasma concentrations (Cssp) on Day 7 of the multiple dose regimens averaged 0.477 and 0.427 microgram/ml for the 75 mg CR once daily and the conventional 25 mg t.i.d. treatments, respectively.",Comparative multiple dose kinetics of two formulations of indomethacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861873/),[μg] / [ml],0.477,183025,DB00328,Indomethacin
,6861873,steady-state plasma concentrations (Cssp),"Average steady-state plasma concentrations (Cssp) on Day 7 of the multiple dose regimens averaged 0.477 and 0.427 microgram/ml for the 75 mg CR once daily and the conventional 25 mg t.i.d. treatments, respectively.",Comparative multiple dose kinetics of two formulations of indomethacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861873/),[μg] / [ml],0.427,183026,DB00328,Indomethacin
,32901947,concentration at half maximal effect,"Single dose simulations showed that a previously established analgesic concentration at half maximal effect in adults of 0.37 mg/L, had a mean S-ketorolac concentration of 0.057 mg/L, but a mean S-ketorolac concentration of 0.046 mg/L in infants.",Impact of enantiomer-specific changes in pharmacokinetics between infants and adults on the target concentration of racemic ketorolac: A pooled analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32901947/),[mg] / [l],0.37,184487,DB00328,Indomethacin
,32901947,S-ketorolac concentration,"Single dose simulations showed that a previously established analgesic concentration at half maximal effect in adults of 0.37 mg/L, had a mean S-ketorolac concentration of 0.057 mg/L, but a mean S-ketorolac concentration of 0.046 mg/L in infants.",Impact of enantiomer-specific changes in pharmacokinetics between infants and adults on the target concentration of racemic ketorolac: A pooled analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32901947/),,0.046,184488,DB00328,Indomethacin
,32901947,EC50,"To match the effective adult S-ketorolac-concentration (0.057 mg/L) in typical infants, the EC50-racemic should be increased to 0.41 mg/L.",Impact of enantiomer-specific changes in pharmacokinetics between infants and adults on the target concentration of racemic ketorolac: A pooled analysis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32901947/),[mg] / [l],0.41,184489,DB00328,Indomethacin
,3435597,initial plasma concentration (Co,When the animals were dosed at 2 h (physiological rest time for rats) the initial plasma concentration (Co = 4.2 +/- 0.08 micrograms/ml) and the area under the curve (AUC = 13.6 +/- 0.5 h micrograms/ml) was significantly lower while the distribution volume (Vd/b.w. = 120 +/- 2 ml/kg) and the total metabolic clearance (ClT/b.w. = 25 +/- 1.1 ml/h/kg) were higher than those observed in rats dosed at 20 h (period of activity).,Chronopharmacokinetics of indomethacin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435597/),[μg] / [ml],4.2,184492,DB00328,Indomethacin
,3435597,area under the curve (AUC,When the animals were dosed at 2 h (physiological rest time for rats) the initial plasma concentration (Co = 4.2 +/- 0.08 micrograms/ml) and the area under the curve (AUC = 13.6 +/- 0.5 h micrograms/ml) was significantly lower while the distribution volume (Vd/b.w. = 120 +/- 2 ml/kg) and the total metabolic clearance (ClT/b.w. = 25 +/- 1.1 ml/h/kg) were higher than those observed in rats dosed at 20 h (period of activity).,Chronopharmacokinetics of indomethacin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435597/),[h·μg] / [ml],13.6,184493,DB00328,Indomethacin
,3435597,distribution volume (Vd/b.w.,When the animals were dosed at 2 h (physiological rest time for rats) the initial plasma concentration (Co = 4.2 +/- 0.08 micrograms/ml) and the area under the curve (AUC = 13.6 +/- 0.5 h micrograms/ml) was significantly lower while the distribution volume (Vd/b.w. = 120 +/- 2 ml/kg) and the total metabolic clearance (ClT/b.w. = 25 +/- 1.1 ml/h/kg) were higher than those observed in rats dosed at 20 h (period of activity).,Chronopharmacokinetics of indomethacin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435597/),[ml] / [kg],120,184494,DB00328,Indomethacin
,3435597,total metabolic clearance (ClT/b.w.,When the animals were dosed at 2 h (physiological rest time for rats) the initial plasma concentration (Co = 4.2 +/- 0.08 micrograms/ml) and the area under the curve (AUC = 13.6 +/- 0.5 h micrograms/ml) was significantly lower while the distribution volume (Vd/b.w. = 120 +/- 2 ml/kg) and the total metabolic clearance (ClT/b.w. = 25 +/- 1.1 ml/h/kg) were higher than those observed in rats dosed at 20 h (period of activity).,Chronopharmacokinetics of indomethacin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435597/),[ml] / [h·kg],25,184495,DB00328,Indomethacin
,26416348,plasma clearance,Noncompartmental analysis of i.v. dosage indicated a mean plasma clearance of 8.4 (mL/min)/kg and an estimated mean volume of distribution at steady-state of 0.77 L/kg.,"Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),[ml] / [kg·min)],8.4,185580,DB00328,Indomethacin
,26416348,volume of distribution at steady-state,Noncompartmental analysis of i.v. dosage indicated a mean plasma clearance of 8.4 (mL/min)/kg and an estimated mean volume of distribution at steady-state of 0.77 L/kg.,"Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),[l] / [kg],0.77,185581,DB00328,Indomethacin
,26416348,mean residence times,"Noncompartmental analysis of i.v., i.m., and p.o. dosages indicated mean residence times of 2.0, 2.6, and 7.1 h, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),h,2.0,185582,DB00328,Indomethacin
,26416348,mean residence times,"Noncompartmental analysis of i.v., i.m., and p.o. dosages indicated mean residence times of 2.0, 2.6, and 7.1 h, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),h,2.6,185583,DB00328,Indomethacin
,26416348,mean residence times,"Noncompartmental analysis of i.v., i.m., and p.o. dosages indicated mean residence times of 2.0, 2.6, and 7.1 h, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),h,7.1,185584,DB00328,Indomethacin
,26416348,bioavailability,"The drug was rapidly absorbed after i.m. and p.o. administration, and mean bioavailability was 71% and 57% for i.m. and p.o. administration, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),%,71,185585,DB00328,Indomethacin
,26416348,bioavailability,"The drug was rapidly absorbed after i.m. and p.o. administration, and mean bioavailability was 71% and 57% for i.m. and p.o. administration, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),%,57,185586,DB00328,Indomethacin
,17081709,activation energy of thermal degradation,"The activation energy of thermal degradation for tablets A and B was calculated based on differential scanning calorimetry (DSC) to be 258.9 and 284.8 kcal/mol, respectively.","Sustained-release tablets of indomethacin-loaded microcapsules: preparation, in vitro and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081709/),[kcal] / [mol],258.9,186918,DB00328,Indomethacin
,17081709,activation energy of thermal degradation,"The activation energy of thermal degradation for tablets A and B was calculated based on differential scanning calorimetry (DSC) to be 258.9 and 284.8 kcal/mol, respectively.","Sustained-release tablets of indomethacin-loaded microcapsules: preparation, in vitro and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081709/),[kcal] / [mol],284.8,186919,DB00328,Indomethacin
,17081709,release t(1/2),"In vitro release profiles showed no burst effect and release t(1/2) of the two sustained-release tablets were found to be 41.30+/-1.86 and 33.25+/-2.84 min, respectively, while that of IDM plain tablets C was 6.30+/-0.39 min (P<0.01).","Sustained-release tablets of indomethacin-loaded microcapsules: preparation, in vitro and in vivo characterization. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081709/),min,41.30,186920,DB00328,Indomethacin
,17081709,release t(1/2),"In vitro release profiles showed no burst effect and release t(1/2) of the two sustained-release tablets were found to be 41.30+/-1.86 and 33.25+/-2.84 min, respectively, while that of IDM plain tablets C was 6.30+/-0.39 min (P<0.01).","Sustained-release tablets of indomethacin-loaded microcapsules: preparation, in vitro and in vivo characterization. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081709/),min,33.25,186921,DB00328,Indomethacin
,17081709,release t(1/2),"In vitro release profiles showed no burst effect and release t(1/2) of the two sustained-release tablets were found to be 41.30+/-1.86 and 33.25+/-2.84 min, respectively, while that of IDM plain tablets C was 6.30+/-0.39 min (P<0.01).","Sustained-release tablets of indomethacin-loaded microcapsules: preparation, in vitro and in vivo characterization. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081709/),min,6.30,186922,DB00328,Indomethacin
,2584317,limit of detection,The limit of detection of the two assays was also similar at 0.01 microM.,Comparison of high-performance liquid chromatography and the Abbott fluorescent polarization radioimmunoassay in the measurement of methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2584317/),μM,0.01,187584,DB00328,Indomethacin
,2584317,half-life,The 7-hydroxymethotrexate half-life was 15 h.,Comparison of high-performance liquid chromatography and the Abbott fluorescent polarization radioimmunoassay in the measurement of methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2584317/),h,15,187585,DB00328,Indomethacin
,8509997,renal clearance,"MTX renal clearance was nonlinear, increasing from 0.310 to 0.434 ml/min over the concentration range studied.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),[ml] / [min],0.310,187756,DB00328,Indomethacin
,8509997,renal clearance,"MTX renal clearance was nonlinear, increasing from 0.310 to 0.434 ml/min over the concentration range studied.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),[ml] / [min],0,187757,DB00328,Indomethacin
,8509997,excretion ratios,"Corresponding excretion ratios increased from 0.933 to 1.52, indicative of MTX renal elimination involving the processes of filtration, secretion and reabsorption.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),,0.933,187758,DB00328,Indomethacin
,8509997,excretion ratios,"Corresponding excretion ratios increased from 0.933 to 1.52, indicative of MTX renal elimination involving the processes of filtration, secretion and reabsorption.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),,1.52,187759,DB00328,Indomethacin
,1892273,Concentrations,"Concentrations were 350 ng/ml in primary AH and 1,305 ng/ml in secondary AH, 90 minutes after initial aqueocentesis.",Kinetics of uptake and effects of topical indomethacin application on protein concentration in the aqueous humor of dogs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1892273/),[ng] / [ml],350,188633,DB00328,Indomethacin
,1892273,Concentrations,"Concentrations were 350 ng/ml in primary AH and 1,305 ng/ml in secondary AH, 90 minutes after initial aqueocentesis.",Kinetics of uptake and effects of topical indomethacin application on protein concentration in the aqueous humor of dogs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1892273/),[ng] / [ml],"1,305",188634,DB00328,Indomethacin
,1892273,steady-state concentration,"Indomethacin administered topically is readily absorbed by the ocular adnexae, reaching a steady-state concentration of 25 ng/ml in blood plasma 18 hours after the start of treatment.",Kinetics of uptake and effects of topical indomethacin application on protein concentration in the aqueous humor of dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1892273/),[ng] / [ml],25,188635,DB00328,Indomethacin
,29440893,visco,The optimized AG-NE had a droplet size of 122±11 nm confirmed using transmission electron microscopy and a viscosity of 28 centipoise (cps).,Nanoemulsion as a strategy for improving the oral bioavailability and anti-inflammatory activity of andrographolide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29440893/),centipoise,28,190025,DB00328,Indomethacin
,29440893,relative bioavailability,"The pharmacokinetic results indicate that the absorption of AG from AG-NE was significantly enhanced in comparison with that from the AG suspension, with a relative bioavailability of 594.3%.",Nanoemulsion as a strategy for improving the oral bioavailability and anti-inflammatory activity of andrographolide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29440893/),%,594.3,190026,DB00328,Indomethacin
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.19-1.22,190047,DB00328,Indomethacin
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.39-1.63,190048,DB00328,Indomethacin
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.28-0.60,190049,DB00328,Indomethacin
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.48-0.88,190050,DB00328,Indomethacin
,31425209,clearance,"The clearance of the S (-) ketorolac enantiomer was higher than R (+) ketorolac (4.50 ± 2.27 vs 1.40 ± 0.694 L/h, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[l] / [h],4.50,190051,DB00328,Indomethacin
,31425209,clearance,"The clearance of the S (-) ketorolac enantiomer was higher than R (+) ketorolac (4.50 ± 2.27 vs 1.40 ± 0.694 L/h, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[l] / [h],1.40,190052,DB00328,Indomethacin
,18043480,CL,"Mean (range) conditional estimates from individual infants for CL, V, and elimination half-life were 18.9 (4.7-45.5) mL/h/kg, 509 (191-1120) mL/kg, and 20.0 (12.0-37.3) hours, respectively.","Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043480/),[ml] / [h·kg],18.9,190559,DB00328,Indomethacin
,18043480,V,"Mean (range) conditional estimates from individual infants for CL, V, and elimination half-life were 18.9 (4.7-45.5) mL/h/kg, 509 (191-1120) mL/kg, and 20.0 (12.0-37.3) hours, respectively.","Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043480/),[ml] / [kg],509,190560,DB00328,Indomethacin
,18043480,elimination half-life,"Mean (range) conditional estimates from individual infants for CL, V, and elimination half-life were 18.9 (4.7-45.5) mL/h/kg, 509 (191-1120) mL/kg, and 20.0 (12.0-37.3) hours, respectively.","Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043480/),h,20.0,190561,DB00328,Indomethacin
,7191306,bioavailability,"100%, whereas after a single dose bioavailability of acemetcin is found to be smaller (66% from blood level, 64% from urine).",[Metabolism and pharmacokinetics of acemetacin in man (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191306/),%,66,190935,DB00328,Indomethacin
,7191306,bioavailability,"100%, whereas after a single dose bioavailability of acemetcin is found to be smaller (66% from blood level, 64% from urine).",[Metabolism and pharmacokinetics of acemetacin in man (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191306/),%,64,190936,DB00328,Indomethacin
,7191306,half-life of elimination,"After a steady-state has been reached half-life of elimination is 4.5 +/- 2.8 h, which is longer than for indometacin (2.2 +/- 0.5 h).",[Metabolism and pharmacokinetics of acemetacin in man (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191306/),h,4.5,190937,DB00328,Indomethacin
,7191306,half-life of elimination,"After a steady-state has been reached half-life of elimination is 4.5 +/- 2.8 h, which is longer than for indometacin (2.2 +/- 0.5 h).",[Metabolism and pharmacokinetics of acemetacin in man (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191306/),h,2.2,190938,DB00328,Indomethacin
,6927544,terminal plasma half-lives,"The elimination of I appeared to follow two compartment open model kinetics, with terminal plasma half-lives ranging from 30 to 90 h.",Pharmacokinetics of indomethacin in the premature infant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6927544/),h,30 to 90,191274,DB00328,Indomethacin
,6927544,Apparent plasma clearance,Apparent plasma clearance values were between 0.076 and 0.335 ml/min/kg.,Pharmacokinetics of indomethacin in the premature infant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6927544/),[ml] / [kg·min],0.076 and 0.335,191275,DB00328,Indomethacin
,2720707,serum half-life (t1/2),Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,11,195730,DB00328,Indomethacin
,2720707,serum half-life (t1/2),Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,17,195731,DB00328,Indomethacin
,2720707,clearance with,Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,54,195732,DB00328,Indomethacin
,2720707,clearance with,Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,70,195733,DB00328,Indomethacin
,2720707,t1/2,Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,54,195734,DB00328,Indomethacin
,2720707,t1/2,Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,70,195735,DB00328,Indomethacin
,33049584,bioavailability,The bioavailability was 8.676 %.,Studies on pharmacokinetic properties and absorption mechanism of phloretin: In vivo and in vitro. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33049584/),%,8.676,198449,DB00328,Indomethacin
,33598961,elimination half-life (βT1/2,"With these methods, we identified a long elimination half-life (βT1/2 = 11.867 hr) but a low maximum concentration (CMAX = 0.508 µg/mL) and concentrations were below the level proposed to be therapeutic in humans (EC50 = 0.1-0.3 μg/mL) for most of the collection period.",Pharmacokinetics of ketorolac in juvenile loggerhead sea turtles (Caretta caretta) after a single intramuscular injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33598961/),h,11.867,199100,DB00328,Indomethacin
,33598961,maximum concentration (CMAX,"With these methods, we identified a long elimination half-life (βT1/2 = 11.867 hr) but a low maximum concentration (CMAX = 0.508 µg/mL) and concentrations were below the level proposed to be therapeutic in humans (EC50 = 0.1-0.3 μg/mL) for most of the collection period.",Pharmacokinetics of ketorolac in juvenile loggerhead sea turtles (Caretta caretta) after a single intramuscular injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33598961/),[μg] / [ml],0.508,199101,DB00328,Indomethacin
,33598961,EC50,"With these methods, we identified a long elimination half-life (βT1/2 = 11.867 hr) but a low maximum concentration (CMAX = 0.508 µg/mL) and concentrations were below the level proposed to be therapeutic in humans (EC50 = 0.1-0.3 μg/mL) for most of the collection period.",Pharmacokinetics of ketorolac in juvenile loggerhead sea turtles (Caretta caretta) after a single intramuscular injection. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33598961/),[μg] / [ml],0.1-0.3,199102,DB00328,Indomethacin
,19277848,T (max),"The T (max), C (max), AUC(O-24) and T (1/2) values of MicrocidSR and optimized formulation were 3.0 h, 2038 +/- 51.31 ng/ml, 9528 +/- 129.65 ng/ml h(-1), and 2.59 +/- 0.02 h(-1); and 3.2 h, 1940 +/- 22.61 ng/ml, 8751 +/- 41.32 ng/ml h(-1), and 2.68 +/- 0.02 h(-1), respectively.","Preparation, evaluation and bioavailability studies of indomethacin-bees wax microspheres. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277848/),h,3.0,199602,DB00328,Indomethacin
,19277848,C (max),"The T (max), C (max), AUC(O-24) and T (1/2) values of MicrocidSR and optimized formulation were 3.0 h, 2038 +/- 51.31 ng/ml, 9528 +/- 129.65 ng/ml h(-1), and 2.59 +/- 0.02 h(-1); and 3.2 h, 1940 +/- 22.61 ng/ml, 8751 +/- 41.32 ng/ml h(-1), and 2.68 +/- 0.02 h(-1), respectively.","Preparation, evaluation and bioavailability studies of indomethacin-bees wax microspheres. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277848/),[ng] / [ml],2038,199603,DB00328,Indomethacin
,19277848,AUC(O-24),"The T (max), C (max), AUC(O-24) and T (1/2) values of MicrocidSR and optimized formulation were 3.0 h, 2038 +/- 51.31 ng/ml, 9528 +/- 129.65 ng/ml h(-1), and 2.59 +/- 0.02 h(-1); and 3.2 h, 1940 +/- 22.61 ng/ml, 8751 +/- 41.32 ng/ml h(-1), and 2.68 +/- 0.02 h(-1), respectively.","Preparation, evaluation and bioavailability studies of indomethacin-bees wax microspheres. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277848/),[ng] / [ml],2038,199604,DB00328,Indomethacin
,19277848,T (1/2),"The T (max), C (max), AUC(O-24) and T (1/2) values of MicrocidSR and optimized formulation were 3.0 h, 2038 +/- 51.31 ng/ml, 9528 +/- 129.65 ng/ml h(-1), and 2.59 +/- 0.02 h(-1); and 3.2 h, 1940 +/- 22.61 ng/ml, 8751 +/- 41.32 ng/ml h(-1), and 2.68 +/- 0.02 h(-1), respectively.","Preparation, evaluation and bioavailability studies of indomethacin-bees wax microspheres. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277848/),1/[h],2.59,199605,DB00328,Indomethacin
,19277848,T (1/2),"The T (max), C (max), AUC(O-24) and T (1/2) values of MicrocidSR and optimized formulation were 3.0 h, 2038 +/- 51.31 ng/ml, 9528 +/- 129.65 ng/ml h(-1), and 2.59 +/- 0.02 h(-1); and 3.2 h, 1940 +/- 22.61 ng/ml, 8751 +/- 41.32 ng/ml h(-1), and 2.68 +/- 0.02 h(-1), respectively.","Preparation, evaluation and bioavailability studies of indomethacin-bees wax microspheres. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277848/),1/[h],2.68,199606,DB00328,Indomethacin
,7174829,terminal t1/2,There is a wide variation in the terminal t1/2 (2.5-10.3 h) and the AUC (5264-12693 ng/ml h) of indomethacin after a standard oral dose (50 mg) under 'normal' urinary condition.,The influence of urinary pH on the disposition of indomethacin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174829/),h,2.5-10.3,200335,DB00328,Indomethacin
,7174829,AUC,There is a wide variation in the terminal t1/2 (2.5-10.3 h) and the AUC (5264-12693 ng/ml h) of indomethacin after a standard oral dose (50 mg) under 'normal' urinary condition.,The influence of urinary pH on the disposition of indomethacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174829/),[ng] / [h·ml],5264-12693,200336,DB00328,Indomethacin
,7174829,urinary recovery,"The urinary recovery of unchanged indomethacin is highest at alkaline pH (15.7 +/- 5.3%), lowest at acidic pH (3.5 +/- 2.0%) and the 'normal' value is 7.1 +/- 1.6%.",The influence of urinary pH on the disposition of indomethacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174829/),%,15.7,200337,DB00328,Indomethacin
,7174829,urinary recovery,"The urinary recovery of unchanged indomethacin is highest at alkaline pH (15.7 +/- 5.3%), lowest at acidic pH (3.5 +/- 2.0%) and the 'normal' value is 7.1 +/- 1.6%.",The influence of urinary pH on the disposition of indomethacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174829/),%,3.5,200338,DB00328,Indomethacin
,7174829,urinary recovery,"The urinary recovery of unchanged indomethacin is highest at alkaline pH (15.7 +/- 5.3%), lowest at acidic pH (3.5 +/- 2.0%) and the 'normal' value is 7.1 +/- 1.6%.",The influence of urinary pH on the disposition of indomethacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174829/),%,7.1,200339,DB00328,Indomethacin
,2787750,maximum potential amount,"The maximum potential amount of ketorolac that an infant may be exposed to daily could range from 3.16 mg to 7.9 mg, assuming a consumption of between 400 ml and 1 l of breast milk.",The excretion of ketorolac tromethamine into breast milk after multiple oral dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2787750/),,3,200410,DB00328,Indomethacin
,12971028,elimination half-life (t1/2),"There was a large interindividual variability observed for plasma concentrations, elimination half-life (t1/2) (15.72 +/- 3.76 h), and area under the plasma concentration-time curve (AUC0-infinity) (402.60 +/- 79.67 micrograms.h/mL) in these babies.",Pharmacokinetics of oral ibuprofen in premature infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12971028/),h,15.72,200922,DB00328,Indomethacin
,12971028,area under the plasma concentration-time curve (AUC0-infinity),"There was a large interindividual variability observed for plasma concentrations, elimination half-life (t1/2) (15.72 +/- 3.76 h), and area under the plasma concentration-time curve (AUC0-infinity) (402.60 +/- 79.67 micrograms.h/mL) in these babies.",Pharmacokinetics of oral ibuprofen in premature infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12971028/),[h·μg] / [ml],402.60,200923,DB00328,Indomethacin
,29266539,EC50,An effect site EC50 for analgesia of 0.37 mg.,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),mg,0.37,202737,DB00328,Indomethacin
,29266539,Clearance,Clearance was 2.53 (CV 45.9%) L. h-1. 70 kg-1 and intercompartment clearance was 4.43 (CV 95.6%) L. h-1. 70 kg-1 .,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),[l] / [70·h·kg],2.53,202738,DB00328,Indomethacin
,29266539,intercompartment clearance,Clearance was 2.53 (CV 45.9%) L. h-1. 70 kg-1 and intercompartment clearance was 4.43 (CV 95.6%) L. h-1. 70 kg-1 .,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),[l] / [70·h·kg],4.43,202739,DB00328,Indomethacin
,29266539,V1,Both central (V1) and peripheral (V2) volumes of distribution decreased with age over the first few years of postnatal life to reach V1 6.89 (CV 30.3%) L. 70 kg-1 and V2 5.53 (CV 47.6%) L. 70 kg-1 .,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),[l] / [70·kg],6.89,202740,DB00328,Indomethacin
,29266539,V2,Both central (V1) and peripheral (V2) volumes of distribution decreased with age over the first few years of postnatal life to reach V1 6.89 (CV 30.3%) L. 70 kg-1 and V2 5.53 (CV 47.6%) L. 70 kg-1 .,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),,5.53,202741,DB00328,Indomethacin
larger,29266539,trough concentration,kg-1 every 6 hours maintains a trough concentration larger than 0.37 mg.,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),mg,0.37,202742,DB00328,Indomethacin
,8988064,drug concentration at half-maximal effect (EC50),The drug concentration at half-maximal effect (EC50) and the first-order rate constant (keo) half-life for pain relief were 0.37 mg/L and 24 minutes.,Population pharmacodynamic model for ketorolac analgesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988064/),[mg] / [l],0.37,203579,DB00328,Indomethacin
,8988064,first-order rate constant (keo) half-life,The drug concentration at half-maximal effect (EC50) and the first-order rate constant (keo) half-life for pain relief were 0.37 mg/L and 24 minutes.,Population pharmacodynamic model for ketorolac analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988064/),min,24,203580,DB00328,Indomethacin
,25138250,absolute bioavailability,"Pharmacokinetic study of intranasal CPH containing 15% ketorolac tromethamine in rats demonstrated enhanced absolute bioavailability (68.8 ± 23.3%) and prolonged mean residence time (8.8 ± 3.5h) in comparison with the intranasal solution group (24.8 ± 13.8%, 3.9 ± 0.6h).",Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138250/),%,68.8,204939,DB00328,Indomethacin
,25138250,mean residence time,"Pharmacokinetic study of intranasal CPH containing 15% ketorolac tromethamine in rats demonstrated enhanced absolute bioavailability (68.8 ± 23.3%) and prolonged mean residence time (8.8 ± 3.5h) in comparison with the intranasal solution group (24.8 ± 13.8%, 3.9 ± 0.6h).",Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138250/),h,8.8,204940,DB00328,Indomethacin
,25138250,mean residence time,"Pharmacokinetic study of intranasal CPH containing 15% ketorolac tromethamine in rats demonstrated enhanced absolute bioavailability (68.8 ± 23.3%) and prolonged mean residence time (8.8 ± 3.5h) in comparison with the intranasal solution group (24.8 ± 13.8%, 3.9 ± 0.6h).",Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138250/),%,24.8,204941,DB00328,Indomethacin
,25138250,mean residence time,"Pharmacokinetic study of intranasal CPH containing 15% ketorolac tromethamine in rats demonstrated enhanced absolute bioavailability (68.8 ± 23.3%) and prolonged mean residence time (8.8 ± 3.5h) in comparison with the intranasal solution group (24.8 ± 13.8%, 3.9 ± 0.6h).",Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138250/),h,3.9,204942,DB00328,Indomethacin
>,22818944,extraction recovery,Matrix effect was assessed by post-column analyte infusion and the extraction recovery was >95.0% across four quality control levels for both the analytes.,Challenges in the simultaneous quantitation of sumatriptan and naproxen in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22818944/),%,95.0,205117,DB00328,Indomethacin
,7915309,clearance,"The clearance and apparent volume of distribution of prednisolone in the control and indomethacin-treated animals were similar, averaging 4.71 versus 4.05 L/h/kg and 1.37 versus 1.33 L/kg, respectively.",Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915309/),[l] / [h·kg],4.71,205750,DB00328,Indomethacin
,7915309,clearance,"The clearance and apparent volume of distribution of prednisolone in the control and indomethacin-treated animals were similar, averaging 4.71 versus 4.05 L/h/kg and 1.37 versus 1.33 L/kg, respectively.",Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915309/),[l] / [h·kg],4.05,205751,DB00328,Indomethacin
,7915309,apparent volume of distribution,"The clearance and apparent volume of distribution of prednisolone in the control and indomethacin-treated animals were similar, averaging 4.71 versus 4.05 L/h/kg and 1.37 versus 1.33 L/kg, respectively.",Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915309/),[l] / [kg],1.37,205752,DB00328,Indomethacin
,7915309,apparent volume of distribution,"The clearance and apparent volume of distribution of prednisolone in the control and indomethacin-treated animals were similar, averaging 4.71 versus 4.05 L/h/kg and 1.37 versus 1.33 L/kg, respectively.",Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915309/),[l] / [kg],1.33,205753,DB00328,Indomethacin
,7915309,elimination half-life,The elimination half-life was 0.48 h in both groups.,Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915309/),h,0.48,205754,DB00328,Indomethacin
,15324530,oral bioavailability,"Oxaprozin has a high oral bioavailability (95%), with peak plasma concentrations at 3 to 5 hours after dosing.",Oxaprozin: kinetic and dynamic profile in the treatment of pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15324530/),%,95,215232,DB00328,Indomethacin
,2813287,alpha half-life,Calculated pharmacokinetic parameters were (mean +/- SD); alpha half-life 25.2 +/- 11.3 min; beta half-life 366 +/- 295 min; steady-state volume of distribution 0.74 +/- 0.75 l/kg; volume during elimination phase 1.53 +/- 1.27 l/kg; total body clearance 3.2 +/- 1.7 ml/min./kg.,Pharmacokinetics of postoperative intravenous indomethacin in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813287/),min,25.2,218822,DB00328,Indomethacin
,2813287,beta half-life,Calculated pharmacokinetic parameters were (mean +/- SD); alpha half-life 25.2 +/- 11.3 min; beta half-life 366 +/- 295 min; steady-state volume of distribution 0.74 +/- 0.75 l/kg; volume during elimination phase 1.53 +/- 1.27 l/kg; total body clearance 3.2 +/- 1.7 ml/min./kg.,Pharmacokinetics of postoperative intravenous indomethacin in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813287/),min,366,218823,DB00328,Indomethacin
,2813287,steady-state volume of distribution,Calculated pharmacokinetic parameters were (mean +/- SD); alpha half-life 25.2 +/- 11.3 min; beta half-life 366 +/- 295 min; steady-state volume of distribution 0.74 +/- 0.75 l/kg; volume during elimination phase 1.53 +/- 1.27 l/kg; total body clearance 3.2 +/- 1.7 ml/min./kg.,Pharmacokinetics of postoperative intravenous indomethacin in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813287/),[l] / [kg],0.74,218824,DB00328,Indomethacin
,2813287,volume during elimination phase,Calculated pharmacokinetic parameters were (mean +/- SD); alpha half-life 25.2 +/- 11.3 min; beta half-life 366 +/- 295 min; steady-state volume of distribution 0.74 +/- 0.75 l/kg; volume during elimination phase 1.53 +/- 1.27 l/kg; total body clearance 3.2 +/- 1.7 ml/min./kg.,Pharmacokinetics of postoperative intravenous indomethacin in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813287/),[l] / [kg],1.53,218825,DB00328,Indomethacin
,2813287,total body clearance,Calculated pharmacokinetic parameters were (mean +/- SD); alpha half-life 25.2 +/- 11.3 min; beta half-life 366 +/- 295 min; steady-state volume of distribution 0.74 +/- 0.75 l/kg; volume during elimination phase 1.53 +/- 1.27 l/kg; total body clearance 3.2 +/- 1.7 ml/min./kg.,Pharmacokinetics of postoperative intravenous indomethacin in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813287/),[ml] / [·kg·min],3.2,218826,DB00328,Indomethacin
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,22,218927,DB00328,Indomethacin
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,93,218928,DB00328,Indomethacin
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,10,218929,DB00328,Indomethacin
,16763096,half-life,"After DP-155 oral administration, indomethacin's half-life in the serum and the brain was 22 and 93 h, respectively, compared with 10 and 24 h following indomethacin oral administration.","A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763096/),h,24,218930,DB00328,Indomethacin
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [ml],0.378,219021,DB00328,Indomethacin
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [g],3.15,219022,DB00328,Indomethacin
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [ml],156.2,219023,DB00328,Indomethacin
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [g],208.0,219024,DB00328,Indomethacin
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [ml],0.873,219025,DB00328,Indomethacin
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [g],56.71,219026,DB00328,Indomethacin
,23099451,area under the curve (AUC0-t),"In the RC, the area under the curve (AUC0-t) in group B (866.1 ± 52.67 μg/g·h) was higher (P < 0.01) than that in group C (77.10 ± 25.90 μg/g·h).","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [g·h],866.1,219027,DB00328,Indomethacin
,23099451,area under the curve (AUC0-t),"In the RC, the area under the curve (AUC0-t) in group B (866.1 ± 52.67 μg/g·h) was higher (P < 0.01) than that in group C (77.10 ± 25.90 μg/g·h).","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [g·h],77.10,219028,DB00328,Indomethacin
,23099451,elimination half-life (t1/2),The elimination half-life (t1/2) in group B (3.09 hours) was longer (P < 0.01) than that in group C (1.19 hours).,"Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),h,3.09,219029,DB00328,Indomethacin
,23099451,elimination half-life (t1/2),The elimination half-life (t1/2) in group B (3.09 hours) was longer (P < 0.01) than that in group C (1.19 hours).,"Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),h,1.19,219030,DB00328,Indomethacin
,8199745,cumulative M excretion,"Though cumulative M excretion 750 +/- 247 [mucg/36 h] [M]; 749 +/- 239 [M+I]; 848 +/- 443 [M+S] was comparable between treatment groups, total sodium [Na+] excretion was significantly depressed in the presence of S or I, 685 +/- 114 [mEq/36 h] [M]; 454 +/- 90 [M+I] (p < or = 0.05); 553 +/- 123 [M+S] (p < or = 0.05).",The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8199745/),[mucg] / [36·h],750,220548,DB00328,Indomethacin
,8199745,cumulative M excretion,"Though cumulative M excretion 750 +/- 247 [mucg/36 h] [M]; 749 +/- 239 [M+I]; 848 +/- 443 [M+S] was comparable between treatment groups, total sodium [Na+] excretion was significantly depressed in the presence of S or I, 685 +/- 114 [mEq/36 h] [M]; 454 +/- 90 [M+I] (p < or = 0.05); 553 +/- 123 [M+S] (p < or = 0.05).",The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8199745/),[mucg] / [36·h],749,220549,DB00328,Indomethacin
,8199745,cumulative M excretion,"Though cumulative M excretion 750 +/- 247 [mucg/36 h] [M]; 749 +/- 239 [M+I]; 848 +/- 443 [M+S] was comparable between treatment groups, total sodium [Na+] excretion was significantly depressed in the presence of S or I, 685 +/- 114 [mEq/36 h] [M]; 454 +/- 90 [M+I] (p < or = 0.05); 553 +/- 123 [M+S] (p < or = 0.05).",The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8199745/),[mucg] / [36·h],848,220550,DB00328,Indomethacin
,8199745,total sodium [Na+] excretion,"Though cumulative M excretion 750 +/- 247 [mucg/36 h] [M]; 749 +/- 239 [M+I]; 848 +/- 443 [M+S] was comparable between treatment groups, total sodium [Na+] excretion was significantly depressed in the presence of S or I, 685 +/- 114 [mEq/36 h] [M]; 454 +/- 90 [M+I] (p < or = 0.05); 553 +/- 123 [M+S] (p < or = 0.05).",The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8199745/),[meq] / [36·h],685,220551,DB00328,Indomethacin
,8199745,total sodium [Na+] excretion,"Though cumulative M excretion 750 +/- 247 [mucg/36 h] [M]; 749 +/- 239 [M+I]; 848 +/- 443 [M+S] was comparable between treatment groups, total sodium [Na+] excretion was significantly depressed in the presence of S or I, 685 +/- 114 [mEq/36 h] [M]; 454 +/- 90 [M+I] (p < or = 0.05); 553 +/- 123 [M+S] (p < or = 0.05).",The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8199745/),,454,220552,DB00328,Indomethacin
,8199745,total sodium [Na+] excretion,"Though cumulative M excretion 750 +/- 247 [mucg/36 h] [M]; 749 +/- 239 [M+I]; 848 +/- 443 [M+S] was comparable between treatment groups, total sodium [Na+] excretion was significantly depressed in the presence of S or I, 685 +/- 114 [mEq/36 h] [M]; 454 +/- 90 [M+I] (p < or = 0.05); 553 +/- 123 [M+S] (p < or = 0.05).",The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8199745/),,553,220553,DB00328,Indomethacin
,8199745,excretion,Total potassium [K+] excretion 160 +/- 39 [mEq/36 h] [M]; 111 +/- 53 [M+I] (p < or = 0.05); 135 +/- 31 [M+S] significantly decreased with I.,The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8199745/),[meq] / [36·h],160,220554,DB00328,Indomethacin
,8199745,excretion,Total potassium [K+] excretion 160 +/- 39 [mEq/36 h] [M]; 111 +/- 53 [M+I] (p < or = 0.05); 135 +/- 31 [M+S] significantly decreased with I.,The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8199745/),,111,220555,DB00328,Indomethacin
,8199745,excretion,Total potassium [K+] excretion 160 +/- 39 [mEq/36 h] [M]; 111 +/- 53 [M+I] (p < or = 0.05); 135 +/- 31 [M+S] significantly decreased with I.,The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8199745/),,135,220556,DB00328,Indomethacin
,6511132,peak drug concentrations,"When a capsule containing 75 mg indomethacin was administered after a 12 h fast, the mean peak drug concentrations in plasma of 2.7 micrograms/ml +/- 0.8 SD occurred at a mean time of 4.2 h (range 2-6 h).",The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511132/),[μg] / [ml],2.7,222740,DB00328,Indomethacin
,6511132,peak plasma concentration,"When this dose was administered with a substantial breakfast, the mean of the peak plasma concentration of 2.2 micrograms/ml +/- 1.0 SD occurred at 6.4 h (range 5-12 h).",The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511132/),[μg] / [ml],2.2,222741,DB00328,Indomethacin
,6511132,bioavailability,Drug bioavailability after co-administration with food was 91% of that following administration after fasting.,The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511132/),%,91,222742,DB00328,Indomethacin
,6511132,drug bioavailability,"When the controlled-release capsule was administered during 3 days in a b.i.d. dosage regimen, drug bioavailability was 103% of that from a standard capsule administered q.i.d.",The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511132/),%,103,222743,DB00328,Indomethacin
,6511132,peak level,"The mean peak level after administration of the last dose of 50 mg as controlled-release capsules was 2.5 micrograms/ml +/- 1.1 SD and the means of peak levels after the penultimate and last doses of 25 mg as standard capsules were 2.0 micrograms/ml +/- 0.3 SD and 2.1 micrograms/ml +/- 0.7 SD, respectively.",The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511132/),[μg] / [ml],2.5,222744,DB00328,Indomethacin
,6511132,peak levels,"The mean peak level after administration of the last dose of 50 mg as controlled-release capsules was 2.5 micrograms/ml +/- 1.1 SD and the means of peak levels after the penultimate and last doses of 25 mg as standard capsules were 2.0 micrograms/ml +/- 0.3 SD and 2.1 micrograms/ml +/- 0.7 SD, respectively.",The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511132/),[μg] / [ml],2.0,222745,DB00328,Indomethacin
,6511132,peak levels,"The mean peak level after administration of the last dose of 50 mg as controlled-release capsules was 2.5 micrograms/ml +/- 1.1 SD and the means of peak levels after the penultimate and last doses of 25 mg as standard capsules were 2.0 micrograms/ml +/- 0.3 SD and 2.1 micrograms/ml +/- 0.7 SD, respectively.",The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511132/),[μg] / [ml],2.1,222746,DB00328,Indomethacin
less,17192507,CSF to plasma concentration ratio,The CSF to plasma concentration ratio remained less than 0.01.,Plasma and cerebrospinal fluid concentrations of indomethacin in children after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192507/),,0.01,224057,DB00328,Indomethacin
,26056929,peak plasma concentration (Cmax,"From the pharmacokinetic evaluation, the immediate release core mini-tablets reached peak plasma concentration (Cmax of 4532.68 ± 28.14 ng/ml) at 2h Tmax and colon targeted tablets showed Cmax=3782.29 ± 17.83 ng/ml at 12h Tmax.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),[ng] / [ml],4532.68,225477,DB00328,Indomethacin
,26056929,Cmax,"From the pharmacokinetic evaluation, the immediate release core mini-tablets reached peak plasma concentration (Cmax of 4532.68 ± 28.14 ng/ml) at 2h Tmax and colon targeted tablets showed Cmax=3782.29 ± 17.83 ng/ml at 12h Tmax.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),[ng] / [ml],3782.29,225478,DB00328,Indomethacin
,26056929,area under the curve,"The area under the curve and mean resident time of core mini-tablets were found to be 11,278.26 ± 132.67 ng-h/ml and 3.68 h respectively while 17,324.48 ± 56.32 ng-h/ml and 10.39 h for compression coated tablets.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),[ng-h] / [ml],"11,278.26",225479,DB00328,Indomethacin
,26056929,area under the curve,"The area under the curve and mean resident time of core mini-tablets were found to be 11,278.26 ± 132.67 ng-h/ml and 3.68 h respectively while 17,324.48 ± 56.32 ng-h/ml and 10.39 h for compression coated tablets.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),[ng-h] / [ml],"17,324.48",225480,DB00328,Indomethacin
,26056929,resident time,"The area under the curve and mean resident time of core mini-tablets were found to be 11,278.26 ± 132.67 ng-h/ml and 3.68 h respectively while 17,324.48 ± 56.32 ng-h/ml and 10.39 h for compression coated tablets.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),h,3.68,225481,DB00328,Indomethacin
,26056929,resident time,"The area under the curve and mean resident time of core mini-tablets were found to be 11,278.26 ± 132.67 ng-h/ml and 3.68 h respectively while 17,324.48 ± 56.32 ng-h/ml and 10.39 h for compression coated tablets.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),h,10.39,225482,DB00328,Indomethacin
,19222906,elimination half-life,A two-compartment model with a fast distribution and an elimination half-life of 5.9 +/- 3.8 h described the PG15 plasma profile after intravenous dosing.,Preclinical pharmacokinetic and pharmacodynamic evaluation of thiazolidinone PG15: an anti-inflammatory candidate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19222906/),h,5.9,226544,DB00328,Indomethacin
,22913908,Tmax,"There was a more rapid mean (± standard deviation) Tmax for nano-formulated indomethacin 20 mg (1.11 ± 0.55 h) and 40 mg (1.25 ± 0.60 h) compared with indomethacin 50 mg (1.97 ± 0.81 h) under fasting conditions, demonstrating faster absorption for the nano-formulated indomethacin.","A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913908/),h,1.11,227447,DB00328,Indomethacin
,22913908,Tmax,"There was a more rapid mean (± standard deviation) Tmax for nano-formulated indomethacin 20 mg (1.11 ± 0.55 h) and 40 mg (1.25 ± 0.60 h) compared with indomethacin 50 mg (1.97 ± 0.81 h) under fasting conditions, demonstrating faster absorption for the nano-formulated indomethacin.","A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913908/),h,1.25,227448,DB00328,Indomethacin
,22913908,Tmax,"There was a more rapid mean (± standard deviation) Tmax for nano-formulated indomethacin 20 mg (1.11 ± 0.55 h) and 40 mg (1.25 ± 0.60 h) compared with indomethacin 50 mg (1.97 ± 0.81 h) under fasting conditions, demonstrating faster absorption for the nano-formulated indomethacin.","A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913908/),h,1.97,227449,DB00328,Indomethacin
,22913908,C(max),"The C(max) for nano-formulated indomethacin 40 mg was higher compared with indomethacin 50 mg in fasted subjects (3115 ± 900 ng/mL vs 2759 ± 936 ng/mL, respectively), and slightly lower in fed subjects (1360 ± 424 ng/mL vs 1408 ± 469 ng/mL, respectively).","A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913908/),[ng] / [ml],3115,227450,DB00328,Indomethacin
,22913908,C(max),"The C(max) for nano-formulated indomethacin 40 mg was higher compared with indomethacin 50 mg in fasted subjects (3115 ± 900 ng/mL vs 2759 ± 936 ng/mL, respectively), and slightly lower in fed subjects (1360 ± 424 ng/mL vs 1408 ± 469 ng/mL, respectively).","A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913908/),[ng] / [ml],2759,227451,DB00328,Indomethacin
,22913908,C(max),"The C(max) for nano-formulated indomethacin 40 mg was higher compared with indomethacin 50 mg in fasted subjects (3115 ± 900 ng/mL vs 2759 ± 936 ng/mL, respectively), and slightly lower in fed subjects (1360 ± 424 ng/mL vs 1408 ± 469 ng/mL, respectively).","A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913908/),[ng] / [ml],1360,227452,DB00328,Indomethacin
,22913908,C(max),"The C(max) for nano-formulated indomethacin 40 mg was higher compared with indomethacin 50 mg in fasted subjects (3115 ± 900 ng/mL vs 2759 ± 936 ng/mL, respectively), and slightly lower in fed subjects (1360 ± 424 ng/mL vs 1408 ± 469 ng/mL, respectively).","A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913908/),[ng] / [ml],1408,227453,DB00328,Indomethacin
,22913908,AUC(0-∞)),"There was a 26% reduction in drug exposure (AUC(0-∞)) when subjects received nano-formulated indomethacin 40 mg compared with indomethacin 50 mg under fasting conditions (6861 ± 1585 h*ng/mL vs 9306 ± 2234 h*ng/mL, respectively).","A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913908/),[h·ng] / [ml],6861,227454,DB00328,Indomethacin
,22913908,AUC(0-∞)),"There was a 26% reduction in drug exposure (AUC(0-∞)) when subjects received nano-formulated indomethacin 40 mg compared with indomethacin 50 mg under fasting conditions (6861 ± 1585 h*ng/mL vs 9306 ± 2234 h*ng/mL, respectively).","A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913908/),[h·ng] / [ml],9306,227455,DB00328,Indomethacin
,24512312,Cmax,"After F3 administration to rats, the Cmax (2.2 ± 0.3 µg/ml) was achieved at ∼2 h and the decline in KT concentration was slower.",Pharmacokinetics and analgesic effect of ketorolac floating delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512312/),[μg] / [ml],2.2,230072,DB00328,Indomethacin
,24251328,LLOQs,"The LLOQs of the method were 0.15 ng on column and 0.31 ng on column for R (+) and S (-) ketorolac, respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),ng,0.15,231458,DB00328,Indomethacin
,24251328,LLOQs,"The LLOQs of the method were 0.15 ng on column and 0.31 ng on column for R (+) and S (-) ketorolac, respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),ng,0.31,231459,DB00328,Indomethacin
,24251328,VD,"The median (range) VD and CL of R (+) and S (-) ketorolac were 0.12 l/kg (0.07–0.17), 0.017 l/h/kg (0.12–0.29) and 0.17 (0.09–0.31) l/kg, 0.049 (0.02–0.1) l/h/kg, p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),[l] / [kg],0.12,231460,DB00328,Indomethacin
,24251328,VD,"The median (range) VD and CL of R (+) and S (-) ketorolac were 0.12 l/kg (0.07–0.17), 0.017 l/h/kg (0.12–0.29) and 0.17 (0.09–0.31) l/kg, 0.049 (0.02–0.1) l/h/kg, p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),[l] / [kg],0.17,231461,DB00328,Indomethacin
,24251328,CL,"The median (range) VD and CL of R (+) and S (-) ketorolac were 0.12 l/kg (0.07–0.17), 0.017 l/h/kg (0.12–0.29) and 0.17 (0.09–0.31) l/kg, 0.049 (0.02–0.1) l/h/kg, p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),[l] / [h·kg],0.017,231462,DB00328,Indomethacin
,24251328,CL,"The median (range) VD and CL of R (+) and S (-) ketorolac were 0.12 l/kg (0.07–0.17), 0.017 l/h/kg (0.12–0.29) and 0.17 (0.09–0.31) l/kg, 0.049 (0.02–0.1) l/h/kg, p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),[l] / [h·kg],0.049,231463,DB00328,Indomethacin
,24251328,elimination half-life (t1/2),"The median (range) elimination half-life (t1/2) of the R (+) and S (-) ketorolac was 5.0 h (2.5–5.8) and 3.1 h (1.8–4.4), p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),h,5.0,231464,DB00328,Indomethacin
,24251328,elimination half-life (t1/2),"The median (range) elimination half-life (t1/2) of the R (+) and S (-) ketorolac was 5.0 h (2.5–5.8) and 3.1 h (1.8–4.4), p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),h,3.1,231465,DB00328,Indomethacin
,7848629,Detection limit,Detection limit of the method was 3 ng/ml using 1 ml of plasma and 10 ng/ml using 0.2 ml of blood.,Determination of ketorolac in blood and plasma samples by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848629/),[ng] / [ml],3,232476,DB00328,Indomethacin
,7848629,Detection limit,Detection limit of the method was 3 ng/ml using 1 ml of plasma and 10 ng/ml using 0.2 ml of blood.,Determination of ketorolac in blood and plasma samples by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848629/),[ng] / [ml],10,232477,DB00328,Indomethacin
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],180,234456,DB00328,Indomethacin
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],177,234457,DB00328,Indomethacin
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],14,234458,DB00328,Indomethacin
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],1.265,234459,DB00328,Indomethacin
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],0.696,234460,DB00328,Indomethacin
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],0.092,234461,DB00328,Indomethacin
,20600724,Cmax,"After NPs administration the mean Cmax, 5.0+/-1.3 mg/l, was attained at 1 h.",Pharmacokinetics of ketorolac loaded to polyethylcyanoacrylate nanoparticles using UPLC MS/MS for its determination in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600724/),[mg] / [l],5.0,235436,DB00328,Indomethacin
,17951119,m/z,"The mass transitions m/z 397>269 and m/z 356>312 were used to measure beraprost and internal standard, respectively.",Determination of beraprost in human plasma by a high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17951119/),,39,238947,DB00328,Indomethacin
,17951119,m/z,"The mass transitions m/z 397>269 and m/z 356>312 were used to measure beraprost and internal standard, respectively.",Determination of beraprost in human plasma by a high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17951119/),,269,238948,DB00328,Indomethacin
,17951119,m/z,"The mass transitions m/z 397>269 and m/z 356>312 were used to measure beraprost and internal standard, respectively.",Determination of beraprost in human plasma by a high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17951119/),,312,238949,DB00328,Indomethacin
,7161339,initial half-life,"An initial half-life of 1.32 +/- 0.44 h-1 was found which is in good agreement with other findings, but the terminal phase was much longer (13.6 +/- 6.9 h-1) than previously reported.",Sensitive high-performance liquid chromatographic determination of indomethacin in human plasma. Pharmacokinetic studies after single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161339/),1/[h],1.32,239915,DB00328,Indomethacin
,7161339,terminal phase,"An initial half-life of 1.32 +/- 0.44 h-1 was found which is in good agreement with other findings, but the terminal phase was much longer (13.6 +/- 6.9 h-1) than previously reported.",Sensitive high-performance liquid chromatographic determination of indomethacin in human plasma. Pharmacokinetic studies after single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161339/),1/[h],13.6,239916,DB00328,Indomethacin
,9743814,absolute bio-availability,The absolute bio-availability is 15 and 12% for rats and humans respectively.,Anti-inflammatory activity of chondroitin sulfate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743814/),%,15,240564,DB00328,Indomethacin
,9743814,absolute bio-availability,The absolute bio-availability is 15 and 12% for rats and humans respectively.,Anti-inflammatory activity of chondroitin sulfate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743814/),%,12,240565,DB00328,Indomethacin
,9578191,Cmax,"There were no significant differences in peak plasma concentration, time to peak plasma concentration or area under the plasma concentration-time curve between bleeders or controls for any of the NSAIDs studied, apart from piroxicam Cmax being lower in bleeders at 2.07 mg l(-1) than in controls at 3.21 mg l(-1), mean difference (95% CI) -1.14 (-1.83 - -0.48), P<0.005.",Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578191/),[mg] / [l],2.07,241166,DB00328,Indomethacin
,9578191,Cmax,"There were no significant differences in peak plasma concentration, time to peak plasma concentration or area under the plasma concentration-time curve between bleeders or controls for any of the NSAIDs studied, apart from piroxicam Cmax being lower in bleeders at 2.07 mg l(-1) than in controls at 3.21 mg l(-1), mean difference (95% CI) -1.14 (-1.83 - -0.48), P<0.005.",Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578191/),[mg] / [l],3.21,241167,DB00328,Indomethacin
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.24,241866,DB00328,Indomethacin
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0. 29,241867,DB00328,Indomethacin
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.08,241868,DB00328,Indomethacin
,7671245,peak absolute monocyte count,"rhM-CSF therapy was associated with peripheral monocytosis (peak absolute monocyte count, 1444 +/- 394/mm3) and thrombocytopenia (nadir count, 78 +/- 10/mm3).",Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7671245/),1/[mm3],1444,243740,DB00328,Indomethacin
,7671245,nadir count,"rhM-CSF therapy was associated with peripheral monocytosis (peak absolute monocyte count, 1444 +/- 394/mm3) and thrombocytopenia (nadir count, 78 +/- 10/mm3).",Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7671245/),1/[mm3],78,243741,DB00328,Indomethacin
,7671245,half-life,There was a significant difference in the half-life of the first and last dose of D612 (35.8 +/- 2 versus 27 +/- 2.9 h; P < 0.05).,Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7671245/),h,35.8,243742,DB00328,Indomethacin
,7671245,half-life,There was a significant difference in the half-life of the first and last dose of D612 (35.8 +/- 2 versus 27 +/- 2.9 h; P < 0.05).,Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7671245/),h,27,243743,DB00328,Indomethacin
,3443952,clearance,A maximal effect was induced by a dose of 30 pmol h-1 100 g body weight-1 which decreased inulin clearance from 3.23 +/- 0.76 (mean +/- S.E. of mean) to 1.60 +/- 0.37 ml/min (P less than 0.02).,Renal haemodynamic actions of pressor doses of lysine vasopressin in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443952/),[ml] / [min],3.23,244575,DB00328,Indomethacin
,3443952,clearance,A maximal effect was induced by a dose of 30 pmol h-1 100 g body weight-1 which decreased inulin clearance from 3.23 +/- 0.76 (mean +/- S.E. of mean) to 1.60 +/- 0.37 ml/min (P less than 0.02).,Renal haemodynamic actions of pressor doses of lysine vasopressin in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443952/),[ml] / [min],1.60,244576,DB00328,Indomethacin
,3443952,clearance,"A change in inulin clearance (from 3.42 +/- 0.46 to 2.17 +/- 0.33 ml/min, P less than 0.01) was also observed in rats pre-treated with indomethacin and infused with vasopressin at the same dose.",Renal haemodynamic actions of pressor doses of lysine vasopressin in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443952/),[ml] / [min],3.42,244577,DB00328,Indomethacin
,3443952,clearance,"A change in inulin clearance (from 3.42 +/- 0.46 to 2.17 +/- 0.33 ml/min, P less than 0.01) was also observed in rats pre-treated with indomethacin and infused with vasopressin at the same dose.",Renal haemodynamic actions of pressor doses of lysine vasopressin in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443952/),[ml] / [min],2.17,244578,DB00328,Indomethacin
less,1576392,trough,Measured trough concentrations differed significantly between the two groups with 35 percent of patients in group I and 90 percent of patients in group II having trough values less than 2 mg/L (p less than 0.001).,Effectiveness of a gentamicin dosing protocol based on postconceptional age: comparison to published neonatal guidelines. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576392/),[mg] / [l],2,244741,DB00328,Indomethacin
,19628498,peak vitreous concentration,"Ketorolac and diclofenac achieved a peak vitreous concentration of 234 and 73 microg/ml, respectively.",Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [ml],234,245012,DB00328,Indomethacin
,19628498,peak vitreous concentration,"Ketorolac and diclofenac achieved a peak vitreous concentration of 234 and 73 microg/ml, respectively.",Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [ml],73,245013,DB00328,Indomethacin
,19628498,peak concentration,The peak concentration of each drug in the retina/choroid was 201 microg/g for ketorolac and 4.1 microg/g for diclofenac.,Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [g],201,245014,DB00328,Indomethacin
,19628498,peak concentration,The peak concentration of each drug in the retina/choroid was 201 microg/g for ketorolac and 4.1 microg/g for diclofenac.,Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [g],4.1,245015,DB00328,Indomethacin
,1505614,AUC,"AUC values (micrograms.ml-1.h), for example, for the two formulations in the young subjects were 5.85 and 6.85 while the values for the elderly subjects were 6.55 and 6.50 respectively.",Steady state pharmacokinetic profile of indomethacin in elderly patients and young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505614/),[h·μg] / [ml],5.85,247146,DB00328,Indomethacin
,1505614,AUC,"AUC values (micrograms.ml-1.h), for example, for the two formulations in the young subjects were 5.85 and 6.85 while the values for the elderly subjects were 6.55 and 6.50 respectively.",Steady state pharmacokinetic profile of indomethacin in elderly patients and young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505614/),[h·μg] / [ml],6.85,247147,DB00328,Indomethacin
,1505614,AUC,"AUC values (micrograms.ml-1.h), for example, for the two formulations in the young subjects were 5.85 and 6.85 while the values for the elderly subjects were 6.55 and 6.50 respectively.",Steady state pharmacokinetic profile of indomethacin in elderly patients and young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505614/),[h·μg] / [ml],6.55,247148,DB00328,Indomethacin
,1505614,AUC,"AUC values (micrograms.ml-1.h), for example, for the two formulations in the young subjects were 5.85 and 6.85 while the values for the elderly subjects were 6.55 and 6.50 respectively.",Steady state pharmacokinetic profile of indomethacin in elderly patients and young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505614/),[h·μg] / [ml],6.50,247149,DB00328,Indomethacin
less,2891477,Tmax,KT was absorbed rapidly (Tmax less than 1.0 hr) and efficiently (greater than 87%) following po and im doses in all species.,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),h,1.0,247960,DB00328,Indomethacin
,2891477,plasma half-life,The plasma half-life of ketorolac (K) ranged from 1.1 hr (rabbits) to 6.0 hr (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),h,1.1,247961,DB00328,Indomethacin
,2891477,plasma half-life,The plasma half-life of ketorolac (K) ranged from 1.1 hr (rabbits) to 6.0 hr (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),h,6.0,247962,DB00328,Indomethacin
,2891477,protein binding,The protein binding of K ranged from 72.0% (mouse) to 99.2% (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),%,72.0,247963,DB00328,Indomethacin
,2891477,protein binding,The protein binding of K ranged from 72.0% (mouse) to 99.2% (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),%,99.2,247964,DB00328,Indomethacin
,17497352,drug entrapment,"The high drug entrapment values of 2.38 +/- 0.16 microg/mg and 2.48 +/- 0.12 microg/mg for liposomes-encapsulated IMC/ beta-CD and IMC/HP-beta-CD inclusion complexes were achieved, as only 1.60 +/- 0.09 microg/mg for conventional liposomes.","Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17497352/),[μg] / [mg],2.38,248426,DB00328,Indomethacin
,17497352,drug entrapment,"The high drug entrapment values of 2.38 +/- 0.16 microg/mg and 2.48 +/- 0.12 microg/mg for liposomes-encapsulated IMC/ beta-CD and IMC/HP-beta-CD inclusion complexes were achieved, as only 1.60 +/- 0.09 microg/mg for conventional liposomes.","Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17497352/),[μg] / [mg],2.48,248427,DB00328,Indomethacin
,17497352,drug entrapment,"The high drug entrapment values of 2.38 +/- 0.16 microg/mg and 2.48 +/- 0.12 microg/mg for liposomes-encapsulated IMC/ beta-CD and IMC/HP-beta-CD inclusion complexes were achieved, as only 1.60 +/- 0.09 microg/mg for conventional liposomes.","Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17497352/),[μg] / [mg],1.60,248428,DB00328,Indomethacin
,17497352,C(max),"After intramuscular administration, C(max) has been increased to 5.21 +/- 1.14 microg x ml(-1) and 6.02 +/- 1.22 microg x ml(- 1) for liposomes-encapsulated IMC/ beta -CD and IMC/HP-beta -CD inclusion complexes, respectively, whereas only 2.43 +/- 0.69 microg x ml(- 1) for liposomes-encapsulated free drug (p < 0.01).","Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17497352/),[μg] / [ml],5.21,248429,DB00328,Indomethacin
,17497352,C(max),"After intramuscular administration, C(max) has been increased to 5.21 +/- 1.14 microg x ml(-1) and 6.02 +/- 1.22 microg x ml(- 1) for liposomes-encapsulated IMC/ beta -CD and IMC/HP-beta -CD inclusion complexes, respectively, whereas only 2.43 +/- 0.69 microg x ml(- 1) for liposomes-encapsulated free drug (p < 0.01).","Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17497352/),1)·ml(-·μg,6.02,248430,DB00328,Indomethacin
,17497352,C(max),"After intramuscular administration, C(max) has been increased to 5.21 +/- 1.14 microg x ml(-1) and 6.02 +/- 1.22 microg x ml(- 1) for liposomes-encapsulated IMC/ beta -CD and IMC/HP-beta -CD inclusion complexes, respectively, whereas only 2.43 +/- 0.69 microg x ml(- 1) for liposomes-encapsulated free drug (p < 0.01).","Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17497352/),1)·ml(-·μg,2.43,248431,DB00328,Indomethacin
,19358600,fasted state absolute bioavailability (F),"Specifically, the fasted state absolute bioavailability (F) was statistically higher (93.07 +/- 5.09%) (p < 0.05) than for aqueous suspension (53.54 +/- 2.91%) and o/w submicron emulsion (64.57 +/- 2.11%).",Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358600/),%,93.07,248529,DB00328,Indomethacin
,19358600,fasted state absolute bioavailability (F),"Specifically, the fasted state absolute bioavailability (F) was statistically higher (93.07 +/- 5.09%) (p < 0.05) than for aqueous suspension (53.54 +/- 2.91%) and o/w submicron emulsion (64.57 +/- 2.11%).",Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358600/),%,53.54,248530,DB00328,Indomethacin
,19358600,fasted state absolute bioavailability (F),"Specifically, the fasted state absolute bioavailability (F) was statistically higher (93.07 +/- 5.09%) (p < 0.05) than for aqueous suspension (53.54 +/- 2.91%) and o/w submicron emulsion (64.57 +/- 2.11%).",Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358600/),%,64.57,248531,DB00328,Indomethacin
,8703647,total body clearance,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),[ml] / [h],34.7,249379,DB00328,Indomethacin
,8703647,total body clearance,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),[ml] / [h],50.6,249380,DB00328,Indomethacin
,8703647,total body clearance,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),[ml] / [h·kg],30.7,249381,DB00328,Indomethacin
,8703647,total body clearance,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),[ml] / [h·kg],41.6,249382,DB00328,Indomethacin
,8703647,total body clearance,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),[ml] / [min],0.72,249383,DB00328,Indomethacin
,8703647,total body clearance,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),[ml] / [min],0.91,249384,DB00328,Indomethacin
,8703647,apparent volume of distribution,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),ml,425,249385,DB00328,Indomethacin
,8703647,apparent volume of distribution,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),ml,352,249386,DB00328,Indomethacin
,8703647,apparent volume of distribution,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),[ml] / [kg],363,249387,DB00328,Indomethacin
,8703647,apparent volume of distribution,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),[ml] / [kg],292,249388,DB00328,Indomethacin
,8703647,elimination half-life,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),h,8.7,249389,DB00328,Indomethacin
,8703647,elimination half-life,"4. The total body clearance of CAZ (34.7 +/- 9.2 vs 50.6 +/- 19.6 ml h-1, P < 0.05; 30.7 +/- 5.9 vs 41.6 +/- 9.0 ml h-1 kg-1, P < 0.05) and GFR (0.72 +/- 0.11 vs 0.91 +/- 0.15 ml min-1, P < 0.05) increased, whereas the apparent volume of distribution (425 +/- 147 vs 352 +/- 108 ml, P < 0.05; 363 +/- 59 vs 292 +/- 44 ml kg-1, P < 0.005) and the elimination half-life (8.7 +/- 2.8 vs 5.0 +/- 0.9 h, P < 0.005) decreased significantly between day 3 and day 10 after birth.",Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703647/),h,5.0,249390,DB00328,Indomethacin
,2591407,Plasma levels,"Plasma levels of indomethacin were 1.18 +/- 0.74; 1.8 +/- 1.0; 1.51 +/- 0.93 and 1.25 +/- 0.98 micrograms/ml (mean +/- SD) at 12, 24, 48 and 72 h after initial dose administration.",Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591407/),[μg] / [ml],1.18,249970,DB00328,Indomethacin
,2591407,Plasma levels,"Plasma levels of indomethacin were 1.18 +/- 0.74; 1.8 +/- 1.0; 1.51 +/- 0.93 and 1.25 +/- 0.98 micrograms/ml (mean +/- SD) at 12, 24, 48 and 72 h after initial dose administration.",Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591407/),[μg] / [ml],1.8,249971,DB00328,Indomethacin
,2591407,Plasma levels,"Plasma levels of indomethacin were 1.18 +/- 0.74; 1.8 +/- 1.0; 1.51 +/- 0.93 and 1.25 +/- 0.98 micrograms/ml (mean +/- SD) at 12, 24, 48 and 72 h after initial dose administration.",Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591407/),[μg] / [ml],1.51,249972,DB00328,Indomethacin
,2591407,Plasma levels,"Plasma levels of indomethacin were 1.18 +/- 0.74; 1.8 +/- 1.0; 1.51 +/- 0.93 and 1.25 +/- 0.98 micrograms/ml (mean +/- SD) at 12, 24, 48 and 72 h after initial dose administration.",Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591407/),[μg] / [ml],1.25,249973,DB00328,Indomethacin
,2591407,Volume of drug distribution,"Volume of drug distribution was 0.23 +/- 0.18 l/kg, total clearance 0.1 +/- 0.11 ml/min and elimination constant 0.06 +/- 0.05 h-1 (mean +/- SD).",Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591407/),[l] / [kg],0.23,249974,DB00328,Indomethacin
,2591407,total clearance,"Volume of drug distribution was 0.23 +/- 0.18 l/kg, total clearance 0.1 +/- 0.11 ml/min and elimination constant 0.06 +/- 0.05 h-1 (mean +/- SD).",Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591407/),[ml] / [min],0.1,249975,DB00328,Indomethacin
,2591407,elimination constant,"Volume of drug distribution was 0.23 +/- 0.18 l/kg, total clearance 0.1 +/- 0.11 ml/min and elimination constant 0.06 +/- 0.05 h-1 (mean +/- SD).",Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591407/),1/[h],0.06,249976,DB00328,Indomethacin
,3675676,t1/2,"Afterwards the radioactivity is eliminated from plasma according to a bi-exponential equation, with an initial elimination rate having a t1/2 of 4.5 h and a terminal elimination rate having a t1/2 of 16 h.",Pharmacokinetics and metabolism of [14C]-proglumetacin after oral administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675676/),h,4.5,251891,DB00328,Indomethacin
,3675676,t1/2,"Afterwards the radioactivity is eliminated from plasma according to a bi-exponential equation, with an initial elimination rate having a t1/2 of 4.5 h and a terminal elimination rate having a t1/2 of 16 h.",Pharmacokinetics and metabolism of [14C]-proglumetacin after oral administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675676/),h,16,251892,DB00328,Indomethacin
,7283656,elimination half life of indomethacin (t 1/2 beta),"The elimination half life of indomethacin (t 1/2 beta), of 40.3 +/- 12.2 hours in group I and 33.9 +/- 11.7 hours in group II, is increased as compared with adults.",[Patent ductus arteriosus in premature newborns. Treatment with indomethacin (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283656/),h,40.3,252395,DB00328,Indomethacin
,7283656,elimination half life of indomethacin (t 1/2 beta),"The elimination half life of indomethacin (t 1/2 beta), of 40.3 +/- 12.2 hours in group I and 33.9 +/- 11.7 hours in group II, is increased as compared with adults.",[Patent ductus arteriosus in premature newborns. Treatment with indomethacin (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283656/),h,33.9,252396,DB00328,Indomethacin
,7283656,surface under the curve (AUC O leads,"The difference of the surface under the curve (AUC O leads to 24 h, ng.ml-1.h-1) between the infants who presented complete or transient closure, suggests a relationship between the biodisponibility of the drug and the effect on patent ductus arteriosus.",[Patent ductus arteriosus in premature newborns. Treatment with indomethacin (author's transl)]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283656/),[ng] / [h·ml],24,252397,DB00328,Indomethacin
,2670397,elimination half-life,"Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid.",Diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670397/),h,1.5,252500,DB00328,Indomethacin
,2275236,apparent volume of distribution,Ketorolac is more than 99 percent bound to plasma proteins and has a mean apparent volume of distribution of 0.11-0.25 L/kg.,Ketorolac: a parenteral nonsteroidal antiinflammatory drug. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2275236/),[l] / [kg],0.11-0.25,255157,DB00328,Indomethacin
,11555181,AUC(infinity),The following parameters adjusted to circadian rhythms: C(0) (acrophase: 13.9788 h); AUC(infinity) (acrophase: 13.4377 h); V(d) (acrophase: 0.8245 h) and Cl (acrophase: 1.4965 h).,Chronobiological variations of indomethacin pharmacokinetic parameters in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555181/),h,13.4377,257001,DB00328,Indomethacin
,11555181,V(d),The following parameters adjusted to circadian rhythms: C(0) (acrophase: 13.9788 h); AUC(infinity) (acrophase: 13.4377 h); V(d) (acrophase: 0.8245 h) and Cl (acrophase: 1.4965 h).,Chronobiological variations of indomethacin pharmacokinetic parameters in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555181/),h,0.8245,257002,DB00328,Indomethacin
,11555181,Cl,The following parameters adjusted to circadian rhythms: C(0) (acrophase: 13.9788 h); AUC(infinity) (acrophase: 13.4377 h); V(d) (acrophase: 0.8245 h) and Cl (acrophase: 1.4965 h).,Chronobiological variations of indomethacin pharmacokinetic parameters in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555181/),h,1.4965,257003,DB00328,Indomethacin
,11555181,acrophase,The following parameters adjusted to circadian rhythms: C(0) (acrophase: 13.9788 h); AUC(infinity) (acrophase: 13.4377 h); V(d) (acrophase: 0.8245 h) and Cl (acrophase: 1.4965 h).,Chronobiological variations of indomethacin pharmacokinetic parameters in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555181/),h,1.4965,257004,DB00328,Indomethacin
,7391154,recovery of,"The recovery of the extraction was found to be 88% and 77% for indomethacin and salicylic acid, respectively.",Rapid determination of indomethacin and salicylic acid in serum by means of reversed-phase liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391154/),%,88,257472,DB00328,Indomethacin
,7391154,recovery of,"The recovery of the extraction was found to be 88% and 77% for indomethacin and salicylic acid, respectively.",Rapid determination of indomethacin and salicylic acid in serum by means of reversed-phase liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391154/),%,77,257473,DB00328,Indomethacin
,7391154,detection limits,The detection limits for indomethacin and salicylic acid were 2 ng.,Rapid determination of indomethacin and salicylic acid in serum by means of reversed-phase liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391154/),ng,2,257474,DB00328,Indomethacin
,17803736,half-lives,"Following an i.v. dose, the plasma concentration profiles of the stereoisomers were similar with half-lives of 5.9 +/- 5.1 h for R-KT and 6.0 +/- 4.9 h for S-KT.",Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),h,5.9,257623,DB00328,Indomethacin
,17803736,half-lives,"Following an i.v. dose, the plasma concentration profiles of the stereoisomers were similar with half-lives of 5.9 +/- 5.1 h for R-KT and 6.0 +/- 4.9 h for S-KT.",Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),h,6.0,257624,DB00328,Indomethacin
,17803736,Clearance,Clearance values for R- and S-KT after an i.v. dose were 0.0470 +/- 0.0370 and 0.0480 +/- 0.0370 L/h/kg respectively.,Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),[l] / [h·kg],0.0470,257625,DB00328,Indomethacin
,17803736,Clearance,Clearance values for R- and S-KT after an i.v. dose were 0.0470 +/- 0.0370 and 0.0480 +/- 0.0370 L/h/kg respectively.,Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),[l] / [h·kg],0.0480,257626,DB00328,Indomethacin
,17803736,terminal half-lives,"After an oral dose, the terminal half-lives were longer than following i.v. administration with values of 14.77 +/- 3.08 and 14.55 +/- 2.95 h for R-KT and S-KT respectively.",Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),h,14.77,257627,DB00328,Indomethacin
,17803736,terminal half-lives,"After an oral dose, the terminal half-lives were longer than following i.v. administration with values of 14.77 +/- 3.08 and 14.55 +/- 2.95 h for R-KT and S-KT respectively.",Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),h,14.55,257628,DB00328,Indomethacin
,17803736,oral bioavailability,The average oral bioavailability was 86.5 +/- 20.6% for R-KT and 86.7 +/- 20.3% for S-KT.,Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),%,86.5,257629,DB00328,Indomethacin
,17803736,oral bioavailability,The average oral bioavailability was 86.5 +/- 20.6% for R-KT and 86.7 +/- 20.3% for S-KT.,Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),%,86.7,257630,DB00328,Indomethacin
,6254359,maximal urinary osmolality,Indomethacin was associated with a significant increase in maximal urinary osmolality from 826 +/- 47 mosmol/kg H2) to 920 +/- 32 mosmol/kg H2O (P < 0.01).,The role of the prostaglandin system in the regulation of renal function in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[mosmol] / [h2·kg],826,257963,DB00328,Indomethacin
,6254359,maximal urinary osmolality,Indomethacin was associated with a significant increase in maximal urinary osmolality from 826 +/- 47 mosmol/kg H2) to 920 +/- 32 mosmol/kg H2O (P < 0.01).,The role of the prostaglandin system in the regulation of renal function in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[mosmol] / [h2o·kg],920,257964,DB00328,Indomethacin
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],-1.40,257965,DB00328,Indomethacin
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],-,257966,DB00328,Indomethacin
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],1.63,257967,DB00328,Indomethacin
,6851625,constant rate,"'Osmosin' is an osmotically-controlled oral drug delivery system which presents a saturated solution of sodium indomethacin trihydrate (105.4 mg), equivalent to 85 mg indomethacin, to the gastro-intestinal tract at a constant rate of 7 mg per hour, with a release time of 10 to 12 hours.",Biopharmaceutical evaluation of 'Osmosin'. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851625/),[mg] / [h],7,258205,DB00328,Indomethacin
,6851625,release time,"'Osmosin' is an osmotically-controlled oral drug delivery system which presents a saturated solution of sodium indomethacin trihydrate (105.4 mg), equivalent to 85 mg indomethacin, to the gastro-intestinal tract at a constant rate of 7 mg per hour, with a release time of 10 to 12 hours.",Biopharmaceutical evaluation of 'Osmosin'. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851625/),h,10 to 12,258206,DB00328,Indomethacin
,6851625,bioavailable,This comparability was verified by the fact that indomethacin is 85% bioavailable from 'Osmosin' compared to intravenous or oral regimens (75 mg given as one dose of 3 X 25 mg capsules or 25 mg 3-times).,Biopharmaceutical evaluation of 'Osmosin'. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851625/),%,85,258207,DB00328,Indomethacin
,1100305,half-life of the beta-phase,The half-life of the beta-phase varied between 2.6 and 11.2 hr.,Pharmacokinetics of indomethacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1100305/),h,2.6 and 11.2,258905,DB00328,Indomethacin
,1100305,volume of distribution,The volume of distribution ranged from 0.34 to 1.57 L/kg and the plasma clearance from 0.044 to 0.109 L/kg/hr.,Pharmacokinetics of indomethacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1100305/),[l] / [kg],0.34 to 1.57,258906,DB00328,Indomethacin
,1100305,plasma clearance,The volume of distribution ranged from 0.34 to 1.57 L/kg and the plasma clearance from 0.044 to 0.109 L/kg/hr.,Pharmacokinetics of indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1100305/),[l] / [h·kg],0.044 to 0.109,258907,DB00328,Indomethacin
,16454200,flow rate,The mobile phase consisted of acetonitrile:0.1 mol/L ammonium acetate buffer (pH 4.0) (65:35% v/v) at a flow rate of 1.0 ml/min.,HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454200/),[ml] / [min],1.0,258959,DB00328,Indomethacin
,16454200,injection volume,The injection volume was 25 microl.,HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454200/),μl,25,258960,DB00328,Indomethacin
,16454200,limit of detection,"The limit of quantification was 25 ng/mL, the limit of detection was 8 ng/ml.",HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454200/),[ng] / [ml],8,258961,DB00328,Indomethacin
,16454200,total chromatographic analysis time,The total chromatographic analysis time was within 9 min.,HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454200/),min,9,258962,DB00328,Indomethacin
<,21830472,polydispersity index,Submicron polymeric particles with size < 800 nm were produced possessing narrow polydispersity index (< 0.5).,In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21830472/),,0.5,259861,DB00328,Indomethacin
,21830472,Entrapment efficiency,Entrapment efficiency varied from 27-38% depending upon particle size.,In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21830472/),%,27-38,259862,DB00328,Indomethacin
,21830472,t(max),The observed t(max) value was 3 h for IGNP compared to 1 h for IDM.,In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21830472/),h,3,259863,DB00328,Indomethacin
,21830472,t(max),The observed t(max) value was 3 h for IGNP compared to 1 h for IDM.,In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21830472/),h,1,259864,DB00328,Indomethacin
,21830472,Cmax,Cmax of IGNP had higher value (110.81 +/- 8.53 microg/mL) compared to that of IDM (51.66 +/- 7.5 microg/mL).,In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21830472/),[μg] / [ml],110.81,259865,DB00328,Indomethacin
,21830472,Cmax,Cmax of IGNP had higher value (110.81 +/- 8.53 microg/mL) compared to that of IDM (51.66 +/- 7.5 microg/mL).,In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21830472/),[μg] / [ml],51.66,259866,DB00328,Indomethacin
,21830472,AUC0-12,AUC0-12 was 1009.78 +/- 80.24 and 194.33 +/- 46.76/microg x h/mL in IGNP and IDM respectively (relative bioavailability 500%).,In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21830472/),1/[h·ml·μg],1009.78,259867,DB00328,Indomethacin
,21830472,AUC0-12,AUC0-12 was 1009.78 +/- 80.24 and 194.33 +/- 46.76/microg x h/mL in IGNP and IDM respectively (relative bioavailability 500%).,In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21830472/),1/[h·ml·μg],194.33,259868,DB00328,Indomethacin
,21830472,relative bioavailability,AUC0-12 was 1009.78 +/- 80.24 and 194.33 +/- 46.76/microg x h/mL in IGNP and IDM respectively (relative bioavailability 500%).,In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21830472/),%,500,259869,DB00328,Indomethacin
,6668541,absolute bioavailability,"The absolute bioavailability calculated was 63.7% for IND, 83.2% for IND-Mg and 96.8% for IND-Ca.","Bioavailability of indomethacin calcium and magnesium, and effect of the salts on drug metabolizing enzyme activities in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668541/),%,63.7,262234,DB00328,Indomethacin
,6668541,absolute bioavailability,"The absolute bioavailability calculated was 63.7% for IND, 83.2% for IND-Mg and 96.8% for IND-Ca.","Bioavailability of indomethacin calcium and magnesium, and effect of the salts on drug metabolizing enzyme activities in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668541/),%,83.2,262235,DB00328,Indomethacin
,6668541,absolute bioavailability,"The absolute bioavailability calculated was 63.7% for IND, 83.2% for IND-Mg and 96.8% for IND-Ca.","Bioavailability of indomethacin calcium and magnesium, and effect of the salts on drug metabolizing enzyme activities in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668541/),%,96.8,262236,DB00328,Indomethacin
,2955324,permanent closure rate,For all infants the permanent closure rate was 68% (56% with 0.1 mg/kg and 75% with 0.2 mg/kg - n.s.) and the positive response rate (i.e. permanent and transient closure) 84%.,[Treatment of patent ductus arteriosus in premature infants by indomethacin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2955324/),%,68,262374,DB00328,Indomethacin
,2955324,permanent closure rate,For all infants the permanent closure rate was 68% (56% with 0.1 mg/kg and 75% with 0.2 mg/kg - n.s.) and the positive response rate (i.e. permanent and transient closure) 84%.,[Treatment of patent ductus arteriosus in premature infants by indomethacin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2955324/),%,56,262375,DB00328,Indomethacin
,2955324,positive response rate,For all infants the permanent closure rate was 68% (56% with 0.1 mg/kg and 75% with 0.2 mg/kg - n.s.) and the positive response rate (i.e. permanent and transient closure) 84%.,[Treatment of patent ductus arteriosus in premature infants by indomethacin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2955324/),%,84,262376,DB00328,Indomethacin
,9117035,clearance half-time,"Balloon occlusion of a localized arterial territory caused significant acceleration of technetium-99m diethylenetriamine pentaacetic acid (Tc-99m DTPA) clearance in the zone immediately distal to the occlusion (baseline clearance half-time 23.1 +/- 0/7 min versus 19.3 +/- 0.4 min, mean +/- SEM, p < 0.05).",Thromboxane-mediated alveolar responses to acute obstruction of the pulmonary vasculature. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9117035/),min,23.1,262958,DB00328,Indomethacin
,9117035,clearance half-time,"Balloon occlusion of a localized arterial territory caused significant acceleration of technetium-99m diethylenetriamine pentaacetic acid (Tc-99m DTPA) clearance in the zone immediately distal to the occlusion (baseline clearance half-time 23.1 +/- 0/7 min versus 19.3 +/- 0.4 min, mean +/- SEM, p < 0.05).",Thromboxane-mediated alveolar responses to acute obstruction of the pulmonary vasculature. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9117035/),min,19.3,262959,DB00328,Indomethacin
,9117035,normal,"However, significant (p < 0.05) normalization did occur in the presence of indomethacin (21.9 +/- 0.4 min) and meclofenamic acid (20.4 +/- 0.5 min).",Thromboxane-mediated alveolar responses to acute obstruction of the pulmonary vasculature. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9117035/),,21,262960,DB00328,Indomethacin
,9117035,normal,"However, significant (p < 0.05) normalization did occur in the presence of indomethacin (21.9 +/- 0.4 min) and meclofenamic acid (20.4 +/- 0.5 min).",Thromboxane-mediated alveolar responses to acute obstruction of the pulmonary vasculature. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9117035/),,20,262961,DB00328,Indomethacin
,9117035,peak pulmonary thromboxane B2 [TXB2] concentration,"Plasma values of thromboxane rose dramatically (pulmonary blood baseline 119 pg/ml to > 40,000 pg/ml) and transiently immediately after pulmonary vascular occlusion, and this rise was blunted significantly (peak pulmonary thromboxane B2 [TXB2] concentration = 668 pg/ml, p < 0.05) by meclofenamic acid.",Thromboxane-mediated alveolar responses to acute obstruction of the pulmonary vasculature. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9117035/),[pg] / [ml],668,262962,DB00328,Indomethacin
,6533086,half-lives,"Mean half-lives (+/- s.d.) of capsules (100 and 200 mg) and solution were respectively 3.5 +/- 2.33, 2.8 +/- 1.22, 4.4 +/- 2.96 h.",Zidometacin: pharmacokinetic study on oral absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533086/),h,3.5,263324,DB00328,Indomethacin
,6533086,half-lives,"Mean half-lives (+/- s.d.) of capsules (100 and 200 mg) and solution were respectively 3.5 +/- 2.33, 2.8 +/- 1.22, 4.4 +/- 2.96 h.",Zidometacin: pharmacokinetic study on oral absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533086/),h,2.8,263325,DB00328,Indomethacin
,6533086,half-lives,"Mean half-lives (+/- s.d.) of capsules (100 and 200 mg) and solution were respectively 3.5 +/- 2.33, 2.8 +/- 1.22, 4.4 +/- 2.96 h.",Zidometacin: pharmacokinetic study on oral absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533086/),h,4.4,263326,DB00328,Indomethacin
,6533086,0-48 h,"The 0-48 h recovery of total zidometacin (free + conjugated) was 27.4% (100 mg capsule), 20.7% (200 mg capsule) and 24.6% (solution).",Zidometacin: pharmacokinetic study on oral absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533086/),%,27.4,263327,DB00328,Indomethacin
,6533086,0-48 h,"The 0-48 h recovery of total zidometacin (free + conjugated) was 27.4% (100 mg capsule), 20.7% (200 mg capsule) and 24.6% (solution).",Zidometacin: pharmacokinetic study on oral absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533086/),%,20.7,263328,DB00328,Indomethacin
,6533086,0-48 h,"The 0-48 h recovery of total zidometacin (free + conjugated) was 27.4% (100 mg capsule), 20.7% (200 mg capsule) and 24.6% (solution).",Zidometacin: pharmacokinetic study on oral absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533086/),%,24.6,263329,DB00328,Indomethacin
,6533086,recovery,"The 0-48 h recovery of total zidometacin (free + conjugated) was 27.4% (100 mg capsule), 20.7% (200 mg capsule) and 24.6% (solution).",Zidometacin: pharmacokinetic study on oral absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533086/),%,27.4,263330,DB00328,Indomethacin
,6533086,recovery,"The 0-48 h recovery of total zidometacin (free + conjugated) was 27.4% (100 mg capsule), 20.7% (200 mg capsule) and 24.6% (solution).",Zidometacin: pharmacokinetic study on oral absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533086/),%,20.7,263331,DB00328,Indomethacin
,6533086,recovery,"The 0-48 h recovery of total zidometacin (free + conjugated) was 27.4% (100 mg capsule), 20.7% (200 mg capsule) and 24.6% (solution).",Zidometacin: pharmacokinetic study on oral absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533086/),%,24.6,263332,DB00328,Indomethacin
,10737665,elimination half-life,"The elimination half-life and mean residence time (MRT) obtained were 1.0 hr and 0.8 hr, respectively.",Pharmacokinetics of indomethacin in poultry. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737665/),h,1.0,263347,DB00328,Indomethacin
,10737665,mean residence time (MRT),"The elimination half-life and mean residence time (MRT) obtained were 1.0 hr and 0.8 hr, respectively.",Pharmacokinetics of indomethacin in poultry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737665/),h,0.8,263348,DB00328,Indomethacin
,23189208,serum half-life,"The serum half-life of GLP2-2G-XTEN in mice, rats and monkeys was 34, 38 and 120 hours, respectively.",GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23189208/),h,34,264314,DB00328,Indomethacin
,23189208,serum half-life,"The serum half-life of GLP2-2G-XTEN in mice, rats and monkeys was 34, 38 and 120 hours, respectively.",GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23189208/),h,38,264315,DB00328,Indomethacin
,23189208,serum half-life,"The serum half-life of GLP2-2G-XTEN in mice, rats and monkeys was 34, 38 and 120 hours, respectively.",GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23189208/),h,120,264316,DB00328,Indomethacin
,23189208,half-life,"Allometric scaling based on pharmacokinetics from mouse, rat and monkey projects a human half-life of 240 hours.",GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23189208/),h,240,264317,DB00328,Indomethacin
less,19281996,total run-time,The total run-time was less than 18 min.,Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),min,18,268619,DB00328,Indomethacin
,19281996,extraction recoveries,"The mean extraction recoveries were 60%, 72% and 76% for paracetamol, R-ketorolac and S-ketorolac, respectively.",Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),%,60,268620,DB00328,Indomethacin
,19281996,extraction recoveries,"The mean extraction recoveries were 60%, 72% and 76% for paracetamol, R-ketorolac and S-ketorolac, respectively.",Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),%,72,268621,DB00328,Indomethacin
,19281996,extraction recoveries,"The mean extraction recoveries were 60%, 72% and 76% for paracetamol, R-ketorolac and S-ketorolac, respectively.",Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),%,76,268622,DB00328,Indomethacin
,25639879,peak plasma levels,Comparable fasting peak plasma levels (mean ± standard deviation) were demonstrated for submicron indomethacin 40 mg (2368.79 ± 631.38 ng/ml) and indomethacin 50 mg (2369.40 ± 969.06 ng/ml).,Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25639879/),[ng] / [ml],2368.79,268769,DB00328,Indomethacin
,25639879,peak plasma levels,Comparable fasting peak plasma levels (mean ± standard deviation) were demonstrated for submicron indomethacin 40 mg (2368.79 ± 631.38 ng/ml) and indomethacin 50 mg (2369.40 ± 969.06 ng/ml).,Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25639879/),[ng] / [ml],2369.40,268770,DB00328,Indomethacin
,25639879,overall systemic exposure,The overall systemic exposure (geometric least squares mean; 95% CI) was > 21% lower for submicron indomethacin 40 mg (6007.71 ng·h/mL; 5585.73-6461.58) compared with indomethacin 50 mg (7646.23 ng·h/ml; 7110.44-8222.40) under fasting conditions.,Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25639879/),[h·ng] / [ml],6007.71,268771,DB00328,Indomethacin
,25639879,overall systemic exposure,The overall systemic exposure (geometric least squares mean; 95% CI) was > 21% lower for submicron indomethacin 40 mg (6007.71 ng·h/mL; 5585.73-6461.58) compared with indomethacin 50 mg (7646.23 ng·h/ml; 7110.44-8222.40) under fasting conditions.,Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25639879/),[h·ng] / [ml],7646.23,268772,DB00328,Indomethacin
,25639879,time to peak plasma levels,Submicron indomethacin 40 mg administration resulted in earlier time to peak plasma levels (median 1.67; min-max 0.5-3.5 hours) under fasting conditions compared with indomethacin 50 mg (2.02; 0.5-5.0 hours).,Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25639879/),h,1.67,268773,DB00328,Indomethacin
,25639879,time to peak plasma levels,Submicron indomethacin 40 mg administration resulted in earlier time to peak plasma levels (median 1.67; min-max 0.5-3.5 hours) under fasting conditions compared with indomethacin 50 mg (2.02; 0.5-5.0 hours).,Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25639879/),h,2.02,268774,DB00328,Indomethacin
,10963905,mechanical thresholds,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),g,124,269313,DB00328,Indomethacin
,10963905,mechanical thresholds,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),g,63,269314,DB00328,Indomethacin
,10963905,thermal latencies,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),s,19,269315,DB00328,Indomethacin
,10963905,thermal latencies,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),s,4.7,269316,DB00328,Indomethacin
,10963905,D(30),"The D(30) values for RPR100893 and SR140333 were estimated to be 17 and >100 mg kg(-1), respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],17,269317,DB00328,Indomethacin
,10963905,D(30),"The D(30) values for RPR100893 and SR140333 were estimated to be 17 and >100 mg kg(-1), respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],>,269318,DB00328,Indomethacin
,10963905,D(30),"The D(30) values for RPR100893 and SR140333 were estimated to be 17 and >100 mg kg(-1), respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],100,269319,DB00328,Indomethacin
,10963905,D(30),The D(30) value for SDZ NKT 343 was 3.89 mg kg(-1).,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],3.89,269320,DB00328,Indomethacin
,10963905,ED(50),"For comparison, morphine inhibited the carrageenan-induced mechanical and thermal hyperalgesia with an ED(50) of 1.85 and 2.51 mg kg(-1) s.c., respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],1.85,269321,DB00328,Indomethacin
,10963905,ED(50),"For comparison, morphine inhibited the carrageenan-induced mechanical and thermal hyperalgesia with an ED(50) of 1.85 and 2.51 mg kg(-1) s.c., respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],2.51,269322,DB00328,Indomethacin
,10963905,maximum reversal,RPR100893 was significantly less effective with a maximum reversal of 30% at 100 mg kg(-1).,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),%,30,269323,DB00328,Indomethacin
,33810564,particle size (d50),"The median particle size (d50) categories of the experimental suspensions were 0.37-1.33 and 3.12-3.50 µm and their viscosity levels were 1.3, 7.0, and 15 mPa·s.",Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33810564/),µm,0.37-1.33,270949,DB00328,Indomethacin
,33810564,particle size (d50),"The median particle size (d50) categories of the experimental suspensions were 0.37-1.33 and 3.12-3.50 µm and their viscosity levels were 1.3, 7.0, and 15 mPa·s.",Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33810564/),µm,3.12-3.50,270950,DB00328,Indomethacin
,33810564,viscosity,"The median particle size (d50) categories of the experimental suspensions were 0.37-1.33 and 3.12-3.50 µm and their viscosity levels were 1.3, 7.0, and 15 mPa·s.",Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33810564/),mpa·s,1.3,270951,DB00328,Indomethacin
,33810564,viscosity,"The median particle size (d50) categories of the experimental suspensions were 0.37-1.33 and 3.12-3.50 µm and their viscosity levels were 1.3, 7.0, and 15 mPa·s.",Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33810564/),mpa·s,7.0,270952,DB00328,Indomethacin
,33810564,viscosity,"The median particle size (d50) categories of the experimental suspensions were 0.37-1.33 and 3.12-3.50 µm and their viscosity levels were 1.3, 7.0, and 15 mPa·s.",Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33810564/),mpa·s,15,270953,DB00328,Indomethacin
,16245284,polydispersities,"The molecular weights and the polydispersities of synthesized copolymers were in the range of 15,000-31,000 g/mol and 1.7-2.7, respectively.",Characterization of pegylated copolymeric micelles and in vivo pharmacokinetics and biodistribution studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16245284/),,1.7-2.7,272749,DB00328,Indomethacin
,16245284,CMC,All of the pegylated amphiphilic copolymers were micelles formed with low CMC values in the range of 10(-7)-10(-8)M.,Characterization of pegylated copolymeric micelles and in vivo pharmacokinetics and biodistribution studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16245284/),M,10(-7)-10(-8),272750,DB00328,Indomethacin
,6547611,maximum plasma indometacin concentration,"The maximum plasma indometacin concentration after administration of the product A 50 mg suppository was found after 62 +/- 18 min (mean +/- S.D.), and measured 2.0 +/- 0.5 mg X l-1.",Clinical pharmacokinetic comparison of two indometacin containing suppositories with different vehicula. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6547611/),[mg] / [l],2.0,272827,DB00328,Indomethacin
,6547611,area under the plasma indometacin concentration-time curve,The area under the plasma indometacin concentration-time curve was found to be 384 +/- 130 mg X l-1 X min for product A 50 mg suppositories and 372 +/- 62 mg X l-1 X min for the reference product.,Clinical pharmacokinetic comparison of two indometacin containing suppositories with different vehicula. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6547611/),[mg·min] / [l],384,272828,DB00328,Indomethacin
,6547611,area under the plasma indometacin concentration-time curve,The area under the plasma indometacin concentration-time curve was found to be 384 +/- 130 mg X l-1 X min for product A 50 mg suppositories and 372 +/- 62 mg X l-1 X min for the reference product.,Clinical pharmacokinetic comparison of two indometacin containing suppositories with different vehicula. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6547611/),[mg·min] / [l],372,272829,DB00328,Indomethacin
,6547611,relative bioavailability,"This results in a relative bioavailability of the product A 50 mg suppositories of 1.02, after correction for actual amount of indometacin in each dosage form.",Clinical pharmacokinetic comparison of two indometacin containing suppositories with different vehicula. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6547611/),,1.02,272830,DB00328,Indomethacin
,23829165,absolute bioavailability (F),3. Pharmacokinetic analysis of Inh-1 revealed an absolute bioavailability (F) of 21% and a short t1/2 of <1 h.,"Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23829165/),%,21,273116,DB00328,Indomethacin
<,23829165,t1/2,3. Pharmacokinetic analysis of Inh-1 revealed an absolute bioavailability (F) of 21% and a short t1/2 of <1 h.,"Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23829165/),h,1,273117,DB00328,Indomethacin
,17456651,central volume of distribution,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),ml,1200,274021,DB00328,Indomethacin
,17456651,peripheral volume of distribution,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),ml,828,274022,DB00328,Indomethacin
,17456651,clearance from the central compartment,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),[ml] / [min],7.52,274023,DB00328,Indomethacin
,17456651,elimination half-life,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),min,238,274024,DB00328,Indomethacin
